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This Special Issue enqueues a series of publications dealing with arteriogenesis, which is the
growth of a natural bypass from pre-existing arteriolar connections, as defined by Wolfgang Schaper,
Werner Risau and Ramon Munoz-Chapuli in the late nineties of the last century. In times of increasing
numbers of patients with cardiovascular occlusive diseases not only in highly industrialized but in
almost all countries of the world, it is of major importance to understand the molecular mechanisms of
this tissue- and life-saving process, which was given to us by mother nature to compensate for the
function of a stenosed coronary or peripheral artery non-invasively. Since our first investigations on
collateral artery growth more than 20 years ago, a lot of progress has been made, which we try to give
access to in this issue on arteriogenesis.
In the current special issue, entitled “Arteriogenesis – Molecular Regulation, Pathophysiology
and Therapeutics II“ in the International Journal of Molecular Sciences, Zeen Aref and Margreet de Vries,
from the group around Paul Quax, give an overview of the currently available variations of murine
hind limb models for the study of angiogenesis and arteriogenesis, and highlight their advantages and
disadvantages [1]. Huan Zhang and Don Chalothron, from Jim Fabers´ group, describe the features of
collateral vessels and supply insights into the unique phenotypes and features of collateral endothelial
and smooth muscle cells [2].
The trigger for arteriogenesis is increased fluid shear stress, which is exerted on the endothelial
cells of pre-existing collateral arteries by blood flow being redirected around stenosed vessels. For a
long time, it was completely unknown how this increased mechanical stress results in local leukocyte
recruitment promoting collateral artery growth. Co-workers of the group of Elisabeth Deindl describe
the functional role of extracellular RNA in that process and highlight the role of this nucleic acid during
ongoing arteriogenesis [3]. Moreover, the same group presents a simple flow cytometry-based method to
identify and quantify tissue infiltrated leukocyte subpopulations [4]. Macrophages, which accumulate
in the perivascular tissue of growing collateral arteries, are well described for their pro-arteriogenic
feature. Co-workers of Kerstin and Christian Troidl delineate the relevance of alternatively and
classically activated macrophages, and explain the function of IL10 in that context [5].
Arterial occlusion results in reduced perfusion, and hence ischemia, in distally located tissue.
As a consequence of the thereto related hypoxia, angiogenesis is induced. In contrast to other ischemic
conditions, where capillaries are required to supply tissue locally with oxygen and nutrients, capillaries
in regions distal to occluded arteries are necessary for the removal of cell debris. Yvonn Heun and the
group around Hanna Mannel show that the tyrosine phosphatase SHP-2 inhibits 26S proteasome and
thereby activates hypoxia-induced HIF-1α (hypoxia inducible factor 1α). This mechanism, which was
identified in wounds, seems to be generally applicable, and results in pro-angiogenic gene expression
under hypoxic conditions in ischemic tissue [6].
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The process of collateral artery growth is often severely compromised in patients with diabetes
mellitus. Srinivasan Vedantham and Elisabeth Deindl investigated the role of insulin for arteriogenesis
in diabetic mice. They were able to attribute to this peptide hormone a function in the expression of
Egr-1 (early growth response-1), a transcription factor relevant for collateral outward remodeling [7].
Cathrine Gorick, John Chappell and Richard Price explain the technical possibilities of ultrasound
together with microbubbles as a non-invasive and spatially targeted option to therapeutically stimulate
revascularization and point to perspectives of such approaches [8].
Thomas-Schmitz-Rixen, Kerstin Troidl and co-workers have developed an exercise training
protocol in mice allowing the investigation of the effect of this physical force on collateral artery growth
in mice [9], and, together with co-workers of Winfried Banzer, they show the effect of resistance training
with and without blood flow restriction on the expression of circulating micro RNAs, which are relevant
for collateral artery growth, in healthy volunteers [10].
Last but not least, the interventional cardiologists and specialists in the field of arteriogenesis,
Bigler Marius Reto and Christian Seiler, provide an overview of human coronary collateral circulation
and introduce the different clinical therapeutic approaches for the promotion of arteriogenesis in
patients. They explain the problematic nature of biochemical concepts involving, for example, G-CSF
(granulocyte-colony stimulating factor) and GM-CSF (granulocyte-macrophage colony stimulating
factor), review the feasibility of biophysical concepts such as physical exercise and ECP (external
counterpulsation), and focus on the promising approach of permanent occlusion of the internal
mammary arteries in promoting natural bypass growth in patients [11].
With all our investigations and efforts, we think that we have come much closer to the goal of all
of us to understand the mechanisms of collateral artery growth, finally enabling clinicians to promote
arteriogenesis effectively in patients with vascular occlusive diseases.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Mouse hind limb ischemia is the most common used preclinical model for peripheral
arterial disease and critical limb ischemia. This model is used to investigate the mechanisms of
neovascularization and to develop new therapeutic agents. The literature shows many variations in
the model, including the method of occlusion, the number of occlusions, and the position at which
the occlusions are made to induce hind limb ischemia. Furthermore, predefined end points and
the histopathological and radiological analysis vary. These differences hamper the correlation of
results between different studies. In this review, variations in surgical methods of inducing hind limb
ischemia in mice are described, and the consequences of these variations on perfusion restoration and
vascular remodeling are discussed. This study aims at providing the reader with a comprehensive
overview of the methods so far described, and proposing uniformity in research of hind limb ischemia
in a mouse model.
Keywords: arteriogenesis; angiogenesis; hind limb ischemia; animal model; mouse
1. Introduction
Peripheral arterial disease (PAD) is a major cause of morbidity and mortality [1]. PAD is caused
by atherosclerotic plaque progression which leads to the occlusion of peripheral arteries and results
in claudication intermittens, or in more severe cases, in critical limb ischemia. The prevalence of
PAD increases with age to 20% in people over 70 years [1]. Furthermore, type II diabetes, obesity,
and hypertension are known risk factors for atherosclerosis [2]. As increased life expectancy is leading
to an increased number of elderly patients suffering from these comorbidities [2], the number of patients
with PAD is expected to grow the coming years. Therefore, there is a need for developing new therapies
to treat peripheral arterial disease. As a consequence, there is a need for representative models to study
and validate these potential new therapies. Therapeutic neovascularization is an alternative therapeutic
strategy aimed at improving blood flow to the lower extremities and promoting blood vessel growth.
Neovascularization consists of the processes of arteriogenesis, angiogenesis, and vasculogenesis. These
processes differ from each other. Arteriogenesis is initiated by shear stress and is the formation of
collateral arteries from the pre-existing arteriolar network [3], and will mainly be found in the upper
limb of the mice after ligation of the arteries in the limb. The molecular mechanism for arteriogenesis
is based on shear stress regulated inflammatory responses, accompanied by the influx of inflammatory
cells in the perivascular compartment around the collateral that are being formed.
Angiogenesis is the process of sprouting new capillaries from pre-existing microvasculature.
Angiogenesis is mainly driven by ischemia and the upregulation of ischemia-induced transcription
factors like HIF1a, and the genes that are responsive to these transcription factors, such as VEGFa
and SDF1. In the mouse hind limb model, angiogenesis will mostly occur in the distal parts of the
Int. J. Mol. Sci. 2019, 20, 3704; doi:10.3390/ijms20153704 www.mdpi.com/journal/ijms4
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limbs, the gastrocnemius muscle, and the soleus muscle. Vasculogenesis describes the incorporation of
circulating (progenitor) cells into the regenerating microvasculature [4], and will only be of relevance
in the mouse hind limb ischemia model in cases of cell therapy related studies.
For the purpose of elucidating the cellular and molecular mechanisms underlying the
process of neovascularization, and for developing and testing the new therapeutic approaches
for neovascularization, a reliable and reproducible animal model is needed.
Animal models of hind limb ischemia have been developed in rabbits, pigs, rats, and mice.
A mouse model is preferable over larger animal models because of practical circumstances, and over
a rat model because of the wide range of transgenic mice that are available. These are not only mice
lacking angiogenic factors like eNOS [5], but also mice deficient in various factors of inflammatory
or immune pathways that can subsequently be related to the molecular mechanisms involved in
angiogenesis and arteriogenesis [6–9]. Therefore, the mouse model of hind limb ischemia is the main
model used in the preclinical studies. It has to be noted that the mouse model can be performed using
different strains of mice, each having a specific pattern of blood flow recovery [10–14]. Applying
to all local and governmental regulatory and ethical aspects regarding animal experimentation is,
of course, essential.
In this model, limb ischemia is induced by ligation, electrocoagulation, or by applying an ameroid
constrictor to occlude the femoral artery. The occlusion of the femoral artery results in arteriogenesis
in the thigh and angiogenesis in the distal part of the limb to recover perfusion. Different positions of
ligation trigger different pathways of neovascularization. Therefore, the position at which the ligation
of the femoral artery should be performed in order to provide a proper model for investigating the
perfusion recovery, arteriogenesis, and or angiogenesis remains a topic of research and debate [10].
This illustrates that variations in the model for inducing hind limb ischemia in mice may lead to
differences in blood flow recovery and vascular repair or neovascularisation, and may also have
consequences for the interpretation of the data obtained in relation to the underlying pathophysiological
mechanisms. In the literature, the tourniquet-induced hindlimb ischemia-reperfusion method is also
described to induce acute ischemia [15–17]. For the current review, this method is less relevant, since
the induced ischemia is for such a short period that no effects on neovascularization are observed.
Moreover, as will be discussed below, it is essential to consider which mouse strain to use, because
genetic background influences the outcome. Several studies have shown that different mouse strains
display a high variability in the degree of neovascularization [13,14]. Many studies have shown fast
recovery of limb perfusion in C57BL/6 after inducing hind limb ischemia in comparison to the slow
recovering Balb/C mice. Furthermore, it is important to realize that immune-compromised mice such
as nude mice or non-obese diabetic-severe combined immunodeficiency (NOD-SCID) mice that are
frequently used for cell therapy studies [18] have an increased number of pre-existing collaterals and
require a more fierce induction of ischemia, including the removal of arterial branches [18].
The aim of this paper is to review the techniques of inducing hind limb ischemia in a mouse
model, providing a rationale with which to identify the optimal mouse model. To this end, we describe
variations in anatomical nomenclature, variation in surgical methods, and histopathological and
radiological techniques for the quantification of the end-points.
2. Mouse Model for Hind Limb Ischemia
The mouse model of hind limb ischemia was first described by Couffinhal et al. [19] based on the
rabbit model for hind ischemia, as developed in the group of Wolfgang Schaper. They induced acute
hind limb ischemia by ligating the proximal end of the femoral artery, and the distal portion of the
saphenous artery, and subsequently excised the femoral artery and all side-branches. The recovery of
the blood flow in the limbs was monitored for 5 weeks postoperatively by Laser Doppler Perfusion
Imaging (LDPI). The blood flow was reduced postoperatively and the reduction maintained for 7 days;
then, the flow was increased over the course of 14 days, reaching a plateau between days 21 and 28 [19].
Thereafter, many groups used the model and also developed new adapted approaches.
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2.1. Vascular Anatomy of the Mouse
The mouse hind limb is perfused by the external iliac artery (EIA), which changes in the common
femoral artery after it passes the inguinal ligament. The femoral artery gives rise to branches that
further divide into collateral vessels that penetrate the muscles.
Kochi et al. described in detail the arterial anatomy of the mouse hind limb, the distribution of
collaterals, and also three collateral arterial routes [20]. They indicated that there are collateral artery
routes through the quadriceps femoris, the biceps femoris muscles, and medial thigh muscles [20].
The medial thigh muscles include the adductor muscles, and are perfused by the proximal caudal
femoral artery, as named by Kochi et al.; however, the same artery is termed the deep femoral artery by
Limbourg et al. [20,21]. It is the same artery which gives rise to collateral arteries that pervade the
adductor muscle group and are the most evaluated muscle groups for arteriogenesis in the tissue after
inducing hind limb ischemia.
Kochi et al. highlighted the confusion in the literature about the arterial anatomy due the
embedding of the arteries in the musculature and the fact that some of the small arteries are only
visualized after dilating and fixing the arteries and, if needed, dissecting the vein to better expose the
artery. In order to compare the different approaches used to induce hind limb ischemia, it is important
to name the structures identically, and it is more important to describe the procedure and, if possible,
to add images of the ligation site to make comparisons possible between the studies and a correct
interpretation of the results.
2.2. Technical Aspects of Inducing Mouse Limb Ischemia
For the induction of hind limb ischemia in mice, the blood flow in vessels supplying the limb
needs to be interrupted by surgical intervention. The general steps of the procedure are described
below, whereas the details on the variations in the procedure will be described in the following sections.
After anesthetizing a mouse, it is positioned in dorsal decubitus with the hind limbs externally rotated.
In one limb, ischemia was operatively induced by ligation or coagulation, with the other limb serving
as an internal control. Ligation and coagulation are considered equal in inducing hind limb ischemia,
even though coagulation may induce recoil of the femoral artery. For anesthesia two types are commonly
used: inhalation, using isoflurane [22], and injectable, using different combinations. The most used
combination is midazolam (5 mg·kg−1) and medetomidine (0.5 mg·kg−1) [10] or a combination of
100 mg/kg of ketamine (100 mg·kg−1) and xylazine (10 mg·kg−1) [23]. However, alpha-agonists induce
early peripheral vasoconstriction and may disturb the results of the experiment [24]. Therefore,
ketamine and alpha-agonist combinations are not suitable for studies of vascular smooth muscle cell
rich vasculature [23]. For analgesics, fentanyl (0.05 mg·kg−1) is most commonly used. For anesthesia
reversal, atipamezole (1 mg·kg−1) is used. After surgery, the skin can be closed with 6-0 (Ethilon) sutures.
2.3. Variants of Surgical Procedure
To induce hind limb ischemia, different surgical approaches have been used (Figure 1, Table 1),
ranging from a single ligation of the femoral artery or iliac artery [11,25] to a complete excision of the
femoral artery and its side-branches [19], sometimes even in combination with dissection of the vein
and the nerve [26]. Also, there is a variation in the level of inducing the arterial occlusion ranging from
proximal ligation of the iliac artery to distal ligation just proximal to the bifurcation of the saphenous
artery and the popliteal artery.
6
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Figure 1. Schematic diagram illustrating the hind limb ischemia and different surgical methods to
induce hind limb ischemia. (A) Hind limb vasculature. (B) Single electrocoagulation of the iliac artery.
(C) Single electrocoagulation of the femoral artery. (D) Double electrocoagulation of the iliac and
femoral artery. Alternatively, the electrocoagulation of the iliac artery can be replaced by a second
electrocoagulation of the femoral artery just above the bifurcation of the saphenous and popliteal artery.
(E) Total excision of the femoral artery. Round circles are muscle groups: (Ad) adductor muscle group.
(QF) Quadriceps femoris. (BF) Biceps femoris. Dotted line is the inguinal ligament. Black beam is the
occlusion site.
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Table 1. Surgical methods used to induce hind limb ischemia, time course of blood reperfusion recovery,
whether the method is suitable to assess arteriogenesis and angiogenesis, and if arteriogenesis takes
place, where it will take place.
Surgical Method
Used to Induce HLI




















distal from origin of
deep branch









7–14 days mild Yes Quadriceps femorisBiceps femoris
Total excision of the
femoral artery 28 days severe No Yes
Double
electrocoagulation of
iliac and femoral artery







Ameriod constrictors mild Unclear No
2.3.1. Single Electrocoagulation or Ligation of Femoral Artery
This surgical method is the most used method to induce hind limb ischemia. Through an incision
in the inguinal region, the femoral artery is exposed. Thereafter, the subcutaneous inguinal fat pad is
pulled aside and the artery is dissected from the vein and the nerve. Then the femoral artery is ligated
or coagulated. The anatomical level at which the occlusion of femoral artery is induced differs among
studies. Limbourg et al. ligated the femoral artery distally to the origin of the deep branch [21], which
leads to increase of blood flow and shear stress in the collaterals where remodeling occurs. The deep
branch of the femoral artery gives rise to collaterals in the adductor muscles, and after ligation of
femoral artery distally from it, remodeling will take place and collaterals will develop, as is the case in
neovascularization in human PAD. In some studies, the electrocoagulation level is more proximal in
the femoral artery. The most important consideration for the site of ligation is that collaterals need to
form from proximal side branches of the femoral artery; thus, the ideal site of ligation should be distal
of side branches of the artery.
Furthermore, ligation of the femoral artery also induces ischemia and triggers angiogenesis in the
distal part of the limb, in the calf muscles, especially in the gastrocnemicus muscle.
2.3.2. Single Electrocoagulation of Iliac Artery
For the exposure of the iliac artery, two approaches are used; Westvik et al. performed a midline
incision in the abdomen exposing the common iliac artery and vein and then ligated both, proximally
from the origin of the internal iliac artery [26]. Hellingman et al. used the approach of making an incision
in the inguinal region and retroperitoneally moving the peritoneum proximally with a cotton swab.
Thereafter, the artery is prepared from the vein and the common iliac artery is electrocoagulated
proximally from the origin of the internal iliac artery [10,18,27]. In this method arteriogenesis in the
upper thigh muscles in all the three collateral compartments can be evaluated. Also, angiogenesis in
the distal calf muscle can be evaluated. The recovery of blood perfusion in C57Bl6 mice analyzed by
Laser Doppler Perfusion Imaging (LDPI) was complete in 7–14 days. This was the same as the blood
reperfusion period in single electrocoagulation of the femoral artery [10].
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2.3.3. Double Electrocoagulation of Both Femoral Artery and Iliac Artery
An incision in the inguinal region is made, and through the retroperitoneal approach,
the peritoneum is moved proximally with a cotton swab. In this model, both the common iliac
artery and femoral artery were electrocoagulated. The common iliac artery is ligated proximally of the
internal iliac artery and the femoral artery is electro-coagulated proximal to the superficial epigastric
artery [10]. Alternatively, a double electrocoagulation may be performed in the femoral artery, one just
distally to the origin of the deep branch and the second one just above the bifurcation of the saphenous
and popliteal artery. These double occlusion models are suitable for assessing both arteriogenesis and
angiogenesis. The double electrocoagulation leads to severe ischemia and prolonged time course of
blood flow recovery in C57Bl6 mice up to 21 days for reaching the plateau in flow recovery. This makes
the method suitable for studying new therapeutic approaches, as it offers, due to a higher degree of
tissue damage as well as ischemia, a therapeutic window in which improvements can be evaluated.
2.3.4. Total Excision of the Femoral Artery
Total excision of the femoral artery was the first described method by Couffinhal, Isner and
colleagues [19]. An incision is made in the skin overlying the middle portion of the hind limb.
The common femoral artery is exposed and dissected from the vein and nerve in the distal direction.
All side branches of the artery were dissected free and coagulated. The distal ligation level was at the
popliteal artery level, just distal from the bifurcation of the saphenous artery and the popliteal artery.
After cutting the artery between the two ligatures proximal and distal, the whole artery was removed
from the surrounding tissue. The advantage of this method is that a severe ischemia is induced in the
calf muscle, and angiogenesis can be assessed. The disadvantage is that the collateral artery formation
is impeded due to the disturbance of the pre-existing arterial bed and connections. Therefore, this
method is not suitable for assessing arteriogenesis, but is very adequate for assessing angiogenesis in
ischemic distal tissue.
2.3.5. Ameroid Constrictors
One of the shortcomings of all the aforementioned models is the fact that all are for acute induction
of ischemia in the hind limb, whereas PAD patients mostly suffer from a gradual occlusion of the
blood vessels in the legs. Yang et al. and Padgett et al. used ameroid constrictors to induce hind
limb ischemia [6,28]. Ameroid constrictors are devices that occlude the artery over 1–3 days through
gradually absorption of moisture from the surrounding tissues. By using this method, the blood
flow fell to its lowest in 3 days instead of directly after surgery in the traditional hind limb ischemia
model. The aim of this method was to develop a more subacute ischemia instead of an acute one.
However, Yang et al. showed that this method leads to different responses in the thigh than the
traditional ligation model. In the thigh, where the remodeling of collaterals occurs, was a lack of
upregulation of shear stress responsive genes and inflammatory genes, which are essential for the
process of arteriogenesis, despite the formation of collaterals. There are also technical challenges,
namely that commercially-available ameroid constrictors are variable in depth and shape. Furthermore,
the severity of the induced ischemia is influenced by the vessel size which depends on age, and age
differences of only a few weeks can lead to vessel size differences.
This model has potential. However, for studying the effects of flow recovery, it is hampered by the
fact that gradual occlusion leads to a gradual induction of collateral formation to compensate for the
occlusions. Consequently, distal ischemia, and thus angiogenesis, is hardly observed. Although this
model has to potential to better mimic the situation in patients with chronic ischemia, more research is
needed to optimize the method.
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3. Analysis of Blood Flow Perfusion and Neovascularization/End-Points
Different approaches are used to visualize the blood flow recovery and evaluate the arteriogenic
effects and the angiogenic effects.
3.1. Laser Doppler Perfusion Imaging
The essential readout of the model is the time course and extent of the blood flow recovery in
the ischemic limb. The blood reperfusion in the ischemic limb and control limb is mainly analyzed
by Laser Doppler Perfusion Imaging (LDPI). LDPI is based on the principle whereby the Doppler
effect caused by the interaction between the laser light and red blood cells is depicted on a color scale.
The blood perfusion values are measured per pixel and the region of interest can be indicated on
the images by manually drawing these regions of interest. The mean of perfusion in this region is
calculated. The ratio of blood flow in the ischemic to the control limb is the general method to express
the blood flow reperfusion.
Laser Doppler Perfusion Imaging is a non-invasive method and is reproducible and repeatable
under the same experimental conditions at different time points. The perfusion signal is influenced by
various experimental conditions including the presence of hair, the type of anesthesia that mice are
subjected to and body temperature [23]; it is also associated with movement. Therefore, standardization
of the analysis conditions including the environmental temperature is essential. Keeping the animals at
physiological temperatures ~37 ◦C during the Laser Doppler measurements is strongly recommended
using e.g., a body temperature control pad or a 37 ◦C double glass water bowl.
For measuring the recovery of the blood flow, different regions of interest can be used. These
regions vary from whole limb with or without the inguinal region, or the footpad. A critical point in
whole limb analysis is that increased angiogenesis due to wound healing at the site of the incision
should be taken into account. The footpad is the most reliable region, since it is hairless, and shaving is
not required. Shaving can irritate the skin, and therefore, influences the flow signal. The hair absorbs
laser light and prevents it from interacting with red blood cells. Other methods for removing the hair
such as the use of hair removal creams can be considered, but usually require that the mouse be under
anesthesia for a longer period, and can irritate the skin too.
The LPDI analysis is generally performed at predetermined time points; before the surgery,
directly after the surgery, after 3 and 7 days, and thereafter weekly over a period of 2 or 4 weeks.
3.2. Immunohistochemical Analysis
Next to evaluating the blood flow restoration, usually a histological analysis is performed to
study arteriogenic and angiogenic responses in the tissue. Immunohistochemical analysis can be used
to detect neovessels, as well as inflammatory cells that infiltrate the tissue. In addition, histological
analysis can also be used for analysis of skeletal muscle remodeling, damage, and necrosis.
Arteriogenesis is studied in the proximal part of the limb, in the adductor muscle group.
The collateral formation is determined by immunohistochemical staining using antibodies against
alpha-Smooth Muscle Actin (a-SMA) to demonstrate the arterial nature of the newly formed vessels in
the adductor muscle [7].
For assessing angiogenic capillary density in the distal part of the limb, the ischemic calf muscle,
is most commonly used. The angiogenic capillaries are detected by using immunohistochemical
techniques to identify endothelial cells (e.g., CD31 or von Willebrand factor) [29,30].
3.3. Other Methods for Assessment of Collateral Formation and Limb Perfusion
For assessments of vascular remodeling, both the evaluation of the anatomic dimensions and the
functionality of the newly formed vessels are of interest. Methods for evaluations will be discussed in
the following section and are summarized in Table 2.
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Table 2. Methods of assessment of collateral formation and limb perfusion.
Techniques Results Obtained Advantages Disadvantages
Micro-CT
- Anatomical visualization of
vasculature circulation





- Challenging to discriminate
arteries from veins
- Ionizing radiation
Ex vivo Micro-CT of
polymer casted
vasculature
- Extent of vasculature formation







X-ray microangiography - Gross anatomical view ofthe circulation




- Only 2D projection images
Post-mortem X-ray
microangiography
- Gross anatomical view of
the circulation





- Detecting arterial blood flow






- Invasive (vascular access
for injecting contrast)
- Long scan times
MRI TOF
- Visualizing flow within vessels
- Quantitative evaluation of
arterial blood flow





- Long scan times
SPECT -Analyzing perfusion recovery -Non-invasive-Accurate -Special facility is needed
The traditionally-used X-ray microangiography after administration of an iodinated contrast
agent can provide a gross anatomical view of the circulation visualizing the vessels in the range of 25
to 50 μm in diameter. This method is invasive and provides only 2-D projection images. Furthermore,
the need for anesthesia and vascular access makes this technique technically challenging.
A different method is to inject the aorta with polyacrylamide-bismuth contrast inducing
vasodilation followed by post-mortem angiographic images to study the collateral vessel growth [31].
Although technically less demanding, the obvious disadvantage of this method is that it is acquired
post-mortem, and therefore, repeated measurements are not possible.
For the anatomical visualization of the arterial circulation, high-resolution micro-computed
tomography (Micro-CT) is the best method, which is reproducible, and the 2D images can be
reconstructed as 3D images [32]. Also, for the quantification of the extent of arteriogenesis, micro-CT
can be used by analyzing the obtained images for the number, volume and length of the newly-formed
collateral arteries [33]. Using Micro-CT in combination with the administration of intra-arterial contrast
medium makes it possible to visualize vessels of 8 μm in diameter [34]. The challenge of this technique
is discriminating arteries from veins after administration of the contrast agent. Also, underfilling the
arteries with the contrast agent, or conversely, overfilling leading to extravasation of the contrast agent,
are possible problems impairing comparisons between different measurements.
Another method is casting the vasculature with a silicone radiopaque casting agent (Microfill)
and post-mortem imaging using Micro-CT to quantify changes in the microvasculature [35].
For the functional assessment of blood flow recovery and tissue perfusion, magnetic resonance
imaging (MRI) is a promising technique to detect arterial blood flow and to follow the collateral arterial
formation after occlusion of the femoral artery in the hind limb ischemia model. There are two MR
imaging techniques, namely contrast-enhanced MRA with a gadolinium-based contrast agent and the
time-of-flight (TOF) sequence technique. TOF is an MRI technique to visualize flow within vessels,
and is based on flow-related increase of spins entering into a single image slice; as a result of being
unsaturated, these spins of the blood give more signal than the stationary spins of the surrounding
tissue [36,37]. Wagner et al. showed that the use of MRI angiograms is an effective technique for
determining the collateral formation, and whether the collateral arteries in the quadriceps muscles
are better developed than those in the adductor muscle group [38]. In another study, Wagner et al.
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showed that TOF MRI imaging without using a contrast agent is effective in mice, and can be used for
quantitative evaluations of arterial blood flow. The advantage of this method is that it does not require
a contrast agent, and therefore, no vascular access for injection of contrast is needed; furthermore,
repetitive analyses on one animal is feasible, without considering the residue of the used contrast
agent [37]. Using a non-invasive MRI technique to follow the development of collateral arteries is
a promising technique, now even more so as the images can be combined using a reconstruction
technique of maximum intensity projection (MIP) to acquire a 3D image of the vessels, similarly to
conventional angiography.
Hendrikx et al. showed that single photon emission computed tomography (SPECT) perfusion
imaging using radioisotope-based tracers can be used to analyze perfusion recovery and muscular
damage in the mouse hind limb model [39]. This nuclear perfusion imaging and myocyte damage
imaging are non-invasive and have high resolution. The results of the study demonstrated that LDPI
analysis underestimates the revascularization processes in the hind limb ischemia model. When
interpreting the results of LDPI, researchers should take into account that the main blood flow recovery
occurs in the first 7 days. The disadvantage of this method is that it needs special facilities to work
with the radioisotope-based tracers.
Microsphere injection and contrast enhanced ultrasounds are two further techniques currently in
early experimental phases of research.
3.4. Methods to Further Differentiate the Results of HLI and Neovascularisation
3.4.1. Matrigel Plug Assay
Studies using the mouse hind limb ischemia model are often directed at the discovery of factors
that improve or impair blood flow recovery. As mentioned, the blood flow recovery is dependent on
the processes of arteriogenesis, angiogenesis, or both. A method to further differentiate whether the
blood recovery is due arteriogenesis or angiogenesis is performing an in vivo Matrigel plug assay.
The in vivo Matrigel plug assay is an assay solely intended to assess angiogenesis; it is performed
by injecting Matrigel into the subcutaneous space on the dorsal side of the mice on both the left and
right flank [7]. Post-implantation, after 7 to 14 days, the mice are sacrificed and the Matrigel plugs
are excised and processed for immunohistological analysis. Paraffin sections could be stained with
a general staining such as Hematoxylin, Eosin or Hematoxylin, Phloxine and Saffron, and anti-CD31.
The CD31 staining affirms the endothelial nature of the infiltrating capillary structures. The extent of
the angiogenesis is determined by assessing the vascular ingrowth in the Matrigel plug. The vascular
ingrowth is scored by measuring the depth of ingrowth and the length of the capillary structures,
and provides information on the angiogenic potential of the condition or compound being studied.
3.4.2. Pre-existing Collateral Density
The dominant mechanism responsible for the restoration of the blood flow after arterial occlusion
is the remodeling of the pre-existing collateral arterioles into mature functioning collateral arteries.
There are pre-existing interarterial collateral connections in the peripheral circulation. The amount
of these pre-existing arterioles varies between different strains, and different factors can influence the
pre-existing vascular bed. Pre-existing collateral density can be determined in pial circulation of the
pia mater [40]. The pre-existing collateral density in the cerebral pial circulation gives an indication of
collateral density in skeletal muscle [8].
To determine the pial circulation in mice, after anesthesia, the thoracic aorta is cannulated
retrograde, and the circulation is maximally dilated by infusion of sodium-nitroprusside and papaverine
in PBS at approximately 100 mmHg prior to vascular casting. After craniotomy, Microfil is infused
under a stereomicroscope. The dorsal cerebral circulation is then fixed by the topical application of
4% paraformaldehyde (PFA) to prevent any degradation in vessel dimensions after Microfil injection.
The brains are fixed overnight in 4% PFA, and subsequently incubated for several days to improve
12
Int. J. Mol. Sci. 2019, 20, 3704
the contrast of the visualization of the vasculature. The number of pre-existing collaterals in the
semi-hemispheres of the pia mater is subsequently quantified, and can be used as a general degree for
pre-existing arterioles in the particular strain of mice [14,41].
4. Discussion
The mouse hind limb ischemia model is the most used model for basic research and for
pre-clinical studies investigating therapeutic neovascularization. It is considered a proper model, as it
is reproducible, and strongly mimics the specific features of human peripheral arterial disease.
To perform this model, occlusions at different anatomical levels of the iliac and femoral artery are
used, as well as different technical approaches. Based on the knowledge that arteriogenesis can only
occur after increasing shear stress in the pre-existing arterioles proximal to the occlusion, the correct
level of ligation of the femoral artery is distal to the origin of the collateral branches. However,
in methods in which the femoral artery is ligated proximal to the origin of the collateral branches,
arteriogenesis is also observed. Kochi et al. demonstrated that the number of collaterals is higher than
previously thought. This may explain the unexpected arteriogenesis after ligation of the femoral artery
at the proximal end. Kochi et al. also demonstrated the presence of collateral arteries in other muscle
groups in the upper thigh besides the adductor muscle group. Furthermore, recent MRI research
demonstrated that the collateral arteries in the quadriceps muscles are better developed than those
in the adductor muscle group. This suggests that the analysis of the other muscle groups may yield
valuable information on arteriogenesis, and should be included in experimental studies.
The hind limb ischemia mouse model has limitations. One of the major limitations is the acute
nature of the ischemia induced in this model, while the PAD in patients is a chronic process, and critical
limb ischemia arises slowly as a result of a gradual build-up of atherosclerosis. Yang et al. [28] and
Padgett et al. [6] used ameroid constrictors to progressively induce hind limb ischemia and mimic the
gradual occlusion that occurs in patients. However, this method is not yet representative of the cellular
response in the thigh after occlusion in PAD patients; therefore, further optimization of the method
is needed.
Another limitation related to the hind limb ischemia model is that the procedure is predominately
performed in young and healthy mice, which do not reflect patients with PAD. PAD patients are old
and have co-morbidities like diabetes mellitus, hypercholesterolaemia, and hypertension. Westvik et al.
showed that old mice show a slower perfusion recovery after inducing hind limb ischemia compared
to young mice [26]. Young wild-type mice do not show the comorbidities of PAD patients. It is well
known that these comorbidities accelerate the development of atherosclerosis and affect vascular
remodeling [12]. The extent to which these comorbidities affect vascular remodeling varies. Van
Weel et al. investigated arteriogenesis using a hind limb ischemia model in different mouse types and
showed that hypercholesterolaemia is more than hyperglycemia or hyperinsulinemia associated with
impaired arteriogenesis [12]. Hypercholesterolaemia leads to impaired arteriogenesis due elevated
blood cholesterol levels which affect monocyte chemotaxis, whereby monocyte influx is reduced [42].
These data suggest that the changed lipid metabolism in diabetes patients may affect the arteriogenesis
more than a disturbed glucose metabolism. Moreover, diabetes mellitus causes endothelial dysfunction
which is multifactorial and results in reduced angiogenesis [43].
Hypertension activates angiotensin, which is associated with endothelial dysfunction due increased
oxidative stress. However, Angiotensin activation can initiate and stimulate arteriogenesis due to
inflammation regulation. Hypertension can also stimulate arteriogenesis through the increase of shear
stress and activation of the renin-angiotensin system [42].
The mouse hind limb ischemia model and PAD patients frequently show similar neovascularization
patterns with arteriogenic responses that are close to the occlusions to form collaterals arteries and
an angiogenic response in the distal ischemic tissue, as was illustrated by comparing the angiogenic
response and VEGF expression in the muscle biopsies of CLI patients and mice after induction of
HLI [31,44,45]. However, there may also be differences in neovascularization patterns observed. In the
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mouse HLI model, neovascularization occurs in a standard, homogenous fashion, due to the fairly
standard way of blocking the blood flow, i.e., by occluding the major arteries in the upper limb in
an acute way. This may be a crucial difference with the situation in PAD patients, where occlusion
usually occurs gradually, but most importantly, it may occur at various locations in the vascular
tree. It is obvious that an occlusion of one of the major arteries above the knee may have different
consequences on endogenous collateral formation and neovascularization than an occlusion below
the knee. Therefore, the neovascularization required to restore the blood flow in PAD patients with
critical limb ischemia will be quite heterogeneous in nature, whereas the mouse models usually focus
on a more standardized neovascularization induction. Unfortunately, mimicking the human situation
is still complex, and really predictive (larger) animal models are not available yet, making the mouse
model the most used model at present.
Furthermore, to choose an appropriate model, it is essential to consider which mouse strain
to use, because the genetic background influences the outcomes. Several studies have shown high
variability between mouse strains in restoring the limb perfusion after the induction of ischemia,
and variability in ability of neovascularization [13,14]. Different strains show different blood recovery
patterns after surgically-induced hind limb ischemia. Many studies have exhibited fast recovery of limb
perfusion in C57BL/6 after inducing hind limb ischemia in comparison to the slow recovery of Balb/C
mice. It has been suggested that the difference in vascular remodeling is due a specific gene locus in
chromosome 7 of the mouse [46,47]. Also, a wide variation in the extent of the native pre-existing
collaterals is observed in different mouse strains, whereby C57BL/6 and BALB/c demonstrate the largest
difference [40]. Due to their slow recovery, Balb/c mice are often used for hind limb ischemia studies,
based on the assumption that this slow response better mimics the situation in patients with PAD.
Recently Nossent et al. showed that especially in Balb/c mice, a stronger upregulation of pro-angiogenic
and pro-arteriogenic genes is observed when compared to C57Bl6 mice, despite the poorer blood
perfusion recovery in Balb/c [7]. This suggests Balb/c mice lack a thus far unknown factor that is
crucial for vascular remodeling, rather than that this model better mimics the situation in patients with
peripheral arterial disease.
Schmidt et al. recently demonstrated more muscle injury within 6 h after inducing ischemia in
Balb/c mice compared to C57BL/6 mice [48]. The muscle injury may contribute to the ability of the
vascular bed to recover after ischemia, and to regenerate. This suggests that understanding of etiology
of the ischemic muscle and its contribution to the restoration of blood flow is needed, and that more
research on this topic is required.
The techniques for the assessment of the results of the hind limb ischemia model are diverse.
However, LDPI remains the essential readout method because of feasibility and reproducibility. The
other techniques can serve as additional techniques since they mostly lack the capability to perform
robust and fast analysis of the blood flow in larger series of mice.
5. Conclusions
The mouse hind limb ischemia model is performed in many variants. No single method for
inducing hind limb ischemia that is appropriate for all research questions. The researchers should
recognize the variants to be able to choose the most suitable model for their experiments, and they
should describe the method and the used anatomical landmarks in order to make comparisons possible
among studies.
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Abstract: Collaterals are unique blood vessels present in the microcirculation of most tissues that,
by cross-connecting a small fraction of the outer branches of adjacent arterial trees, provide alternate
routes of perfusion. However, collaterals are especially susceptible to rarefaction caused by aging,
other vascular risk factors, and mouse models of Alzheimer’s disease—a vulnerability attributed to
the disturbed hemodynamic environment in the watershed regions where they reside. We examined
the hypothesis that endothelial and smooth muscle cells (ECs and SMCs, respectively) of collaterals
have specializations, distinct from those of similarly-sized nearby distal-most arterioles (DMAs)
that maintain collateral integrity despite their continuous exposure to low and oscillatory/disturbed
shear stress, high wall stress, and low blood oxygen. Examination of mouse brain revealed the
following: Unlike the pro-inflammatory cobble-stoned morphology of ECs exposed to low/oscillatory
shear stress elsewhere in the vasculature, collateral ECs are aligned with the vessel axis. Primary
cilia, which sense shear stress, are present, unexpectedly, on ECs of collaterals and DMAs but
are less abundant on collaterals. Unlike DMAs, collaterals are continuously invested with SMCs,
have increased expression of Pycard, Ki67, Pdgfb, Angpt2, Dll4, Ephrinb2, and eNOS, and maintain
expression of Klf2/4. Collaterals lack tortuosity when first formed during development, but tortuosity
becomes evident within days after birth, progresses through middle age, and then declines—results
consistent with the concept that collateral wall cells have a higher turnover rate than DMAs that
favors proliferative senescence and collateral rarefaction. In conclusion, endothelial and SMCs of
collaterals have morphologic and functional differences from those of nearby similarly sized arterioles.
Future studies are required to determine if they represent specializations that counterbalance the
disturbed hemodynamic, pro-inflammatory, and pro-proliferative environment in which collaterals
reside and thus mitigate their risk factor-induced rarefaction.
Keywords: collateral circulation; cerebral collaterals; endothelial cells; ischemic stroke; primary cilia
1. Introduction
Obstructive disease, i.e., stroke and atherosclerosis of the coronary and peripheral arteries, is the
leading cause of morbidity and mortality. Collateral circulation, which is composed of anastomotic
vessels called collaterals, is the most important system capable of mitigating the effects of obstructive
disease [1–5]. However, the number and diameter of collaterals in tissues vary greatly among individuals
for reasons that are only beginning to be understood [1]. Moreover, little is known about the basic
biology of collaterals, in part because of their small diameter and low density in tissues, difficulty in
distinguishing them from other vessels, and lack of methodologies allowing study of their endothelial
cells (ECs) and smooth muscle cells (SMCs) in cell culture. It is known, however, that collaterals are
unique with regard to their: mechanism of formation during development (collaterogenesis) and
its high sensitivity to genetic background-dependent variation, anatomic location in the circulation,
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hemodynamic forces acting on their ECs and SMCs, hallmark tortuosity, high susceptibility to risk
factor-induced rarefaction, robust shear stress-dependent outward remodeling, and protective function
in ischemic disease [1–5].
In mice, collaterals form late during gestation by the sprouting of ephrin-B2+ ECs off of a
small number of distal arterioles that subsequently undergo a tip cell-led proliferation, migration,
and lumenization process to establish anastomoses between adjacent arterial trees [6–8]. This process
varies greatly due to naturally-occurring polymorphisms in certain genes in the collaterogenesis
pathway, resulting in wide differences in collateral extent and thus collateral-dependent blood flow
and tissue injury in experimental models of occlusive arterial disease [9–11]. Collateral blood flow also
varies widely in humans suffering stroke [3,4], coronary, and peripheral artery diseases [12,13], with
recent evidence supporting involvement of the same key variant gene identified in the mouse [14].
Since collaterals interconnect adjacent arterial trees, there is little or no pressure drop across them
in the absence of obstructive disease. Thus, blood flow within collaterals is near zero, oscillating
slowly toward one or the other tree that they anastomose [6,15]. Endothelial cells and SMCs that
compose the collateral wall are therefore continuously exposed to low and disturbed shear stress, high
circumferential wall stress, and low blood oxygen content. Accompanying this adverse hemodynamic
environment, which favors vascular inflammation and endothelial dysfunction elsewhere in the
circulation, collaterals in mice undergo a progressive decline in number and a loss of diameter with
aging, presence of vascular risk factors, and in models of Alzheimer’s disease [16–21]. Supportive
evidence, based on measurement of collateral-dependent flow induced by acute ischemic stroke,
has been reported in humans with aging and presence of vascular risk factors [22–24]. This so
call “collateral rarefaction” has been linked in mice to chronic low-level inflammation, endothelial
dysfunction, and increased proliferation of collateral ECs and SMCs [16–20,25]. Collaterals are also
capable of undergoing robust anatomic outward remodeling in steno-occlusive disease, compared
to similarly sized arterioles [2,5,9,10]. Additionally, different from arterioles in the trees that they
interconnect, collaterals lack myogenic responsiveness and have less SMC tone at baseline [26,27].
Despite these important unique features of collaterals, no studies have examined cellular and
molecular aspects of their endothelial and smooth muscle cells to determine whether they differ from
those of similarly sized arterioles. For example, blood flow in arteries and arterioles of healthy tissues,
and thus fluid shear stress experienced by their ECs, is laminar, orthograde, and high velocity, with
the exception of the inner curvature of the aortic arch and sites immediately downstream of arterial
bifurcations where flow varies from high-velocity and orthograde to low-velocity with transient flow
reversals in a fraction of the fluid laminae during each cardiac cycle (i.e., “disturbed” flow) [28–31].
Endothelial cells at these sites of disturbed shear stress are cobblestone in shape, as opposed to
elsewhere where they are elongated and aligned with the vessel axis. They also evidence higher levels
of proliferation, apoptosis, permeability, lipid uptake, oxidative stress, and markers of inflammation
and aging, i.e., displaying the well-known pro-atherogenic EC phenotype specific to these sites. Flow
and shear stress in collaterals in the absence of obstruction share similarly disturbed conditions [6,15].
Yet this is the normal environment in which collateral ECs and SMCs reside.
The purpose of this study was to examine the hypothesis that collateral ECs and SMCs express
unique morphological and functional phenotypes that serve as adaptations or specializations to
maintain the integrity of the collateral wall and balance against collateral rarefaction favored by the
low and disturbed shear stress, high wall stress, and low blood oxygen levels—the latter caused by
low flow-induced hemoglobin unloading to tissue. Such differences, if present, could offer insights
into how collaterals are able to persist in healthy individuals but also why they are so susceptible
to rarefaction with aging and other vascular risk factors. In addition, knowledge concerning the
molecular features of collateral wall cells is fundamental to better understand how collaterals form
during development, remodel in obstructive disease, and undergo risk factor-induced rarefaction,
and to investigate possible treatments to augment or intervene with these processes.
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2. Results
2.1. Collateral Endothelial Cells Are Aligned with the Vessel Axis Despite their Chronic Exposure to Low and
Oscillatory Shear Stress
As a first-test of the hypothesis that collateral wall cells have unique phenotypes, we assessed the
orientation of collateral ECs using scanning electron microscopy (SEM) and staining of the junctional
protein zona occludens-1 (ZO-1). Despite the unique low and disturbed shear stress present in
collaterals, ECs of collaterals were aligned with the vessel axis to the same extent, i.e., ~4 degrees off the
longitudinal axis, which was present in nearby distal-most arterioles (DMAs) and in the descending
thoracic aorta where blood flow is high-velocity and laminar (Figures 1 and 2). The area, perimeter,
length, and width of collateral ECs were also comparable to ECs lining DMAs (Figure S1).
Figure 1. Pial collateral endothelial cells are aligned with the vessel axis. Scanning electron micrograph
(SEM) of a corrosion cast of Batson’s #17-filled cerebral pial arterial vessels and 2 collaterals, fixed after
maximal dilation, which overlie the watershed zone between the anterior (ACA) and middle (MCA)
cerebral artery trees. Upper inset, Microfil® cast of arterial vessels and collaterals (stars) in optically
cleared brain. SEMs were obtained from six mice (see also Figure S1). Penetrating arterioles are evident
branching from collaterals and pial arterioles.
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Figure 2. Collateral endothelial cells are aligned with the vessel axis despite having low and oscillatory
flow/shear stress in the absence of arterial obstruction. (A) Data were obtained in anesthetized mice
via cranial window and previously published in reference [6]; unlike distal-most arterioles (DMAs)
with diameters comparable to collaterals (COLs) and penetrating arterioles, COLs examined over 30 s
intervals have either no flow or slowly oscillating, low velocity, to-and-fro flow with ~zero net-direction.
After ligation of the MCA trunk (MCAO), flow to its territory reaches that evident in DMAs within
10–30 s. (B–E) Collateral endothelial cells (ECs) have the same “anti-inflammatory” alignment
(~4 degrees from horizontal) as ECs of DMAs and the descending thoracic aorta, despite having
low/disturbed shear stress at baseline. This is in contrast to the “pro-inflammatory” non-alignment
present in the inner curvature of the aortic arch. In this and subsequent figures, data are means ± SE for
“n” number of mice. Data in D determined from SEM images, n = 6 mice. Panel E magnification bar is
25 μm. Panel A 2-sided t-tests for shear stress followed by Bonferroni correction for ** p < 0.01 vs distal
arterioles; Δ p < 0.05 vs penetrating arterioles; 2-sided t-test for ttt p < 0.001 vs before MCAO. ZO-1,
zona occludens-1 immunohistochemistry.
2.2. Endothelial Cells of Collaterals and Distal-Most Arterioles Have Primary Cilia; Collaterals Have Fewer
While examining EC orientation using SEM we noticed the presence of casts of channels penetrating
into a fraction of the ECs lining collaterals (Figure 3). Based on studies in other cell types including
bovine aorta and human umbilical vein ECs [32–34], these are invaginations of the plasmalemma
that abut the ciliary membrane to form the ciliary pocket, which houses the proximal end of luminal
primary cilia (PrC) that were removed by shearing forces (“depilated/de-ciliated”) during infusion of
Batson’s #17. The Batson’s-filled ciliary pockets (i.e., PrC) were commonly located near the nucleus,
in accordance with the base of the cilium being associated with the basal body [34–40]. Distal arterioles
also have cilia (Figure S1). One, two, or rarely three cilia were present in ECs that expressed them
(Figure 3, Figure S2). More than one cilium per EC has not been found in previous studies, to
our knowledge; however, previous reports have only examined large conduit vessels. The above
method, which serendipitously identified PrC, is indirect since ciliary pockets were what were detected.
We therefore confirmed their presence using immunofluorescence (Figure 4). Eighteen percent of
collateral ECs expressed PrC, as compared to 28% of DMAs; thus ECs lining collaterals had 34%
fewer cilia. We have not found other reports that ECs within vessels of the microcirculation express
primary cilia.
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Figure 3. Collateral endothelial cells have primary cilia. (A) SEM of a corrosion cast of pial arterial vessels
and a collateral, fixed at maximal dilation. (B) Stars identify casts of plasmalemmmal invaginations
that contain the proximal end of the primary cilia (PrC) filled with Batson’s #17 after removal of the
PrC by shearing during infusion of the casting agent; each EC has 0–3 PrC. (C) Higher magnification
SEM of a ~2 μm long PrC invagination.
Figure 4. Collateral endothelial cells have fewer primary cilia than distal-most arterioles (DMA).
Immunofluorescent-stained collaterals (COL) with focal plane set within the lumen above the far-wall,
showing primary cilia. Figure S2 shows cilia on DMAs. Inset, higher magnification. Right panel, n = 6
mice, 2-sided t-test.
2.3. Collaterals Are Invested with a Continuous Layer of Smooth Muscle Cells, unlike Distal-Most Arterioles
Whose Smooth Muscle Cells Are Discontinuous
Smooth muscle cells (SMCs) become sparse and discontinuous on distal arterioles in many tissue
types [41–43]. Unlike arterioles that have orthograde flow, collateral blood flow converges from
opposite directions, resulting in an average flow of near or at zero in the center-most segment of the
collateral in the absence of occlusion (Figure 2A). The kinetic energy of flow is therefore converted to
potential energy, which increases the circumferential wall stress of collaterals. Accordingly, we reasoned
that SMC investment of collaterals might be greater than that present on DMAs to balance this increased
wall stress. Figure 5 supports this hypothesis.
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Figure 5. Collaterals are invested with a continuous layer of smooth muscle cells (SMCs), unlike
distal-most arterioles (DMAs) that lack or have discontinuous SMCs. (A), Immuno-fluorescent staining
of SMCs (αSM-actin) and ECs (IB4-lectin). Representative image of pial collaterals, DMAs and
penetrating arterioles (PA). (B), Brightfield image of αSMA-stained collateral and PA filled with yellow
Microfil®, then freed from surrounding pial membrane.
2.4. Gene Expression Differs for Collaterals Versus Distal-Most Arterioles
Given the disturbed hemodynamic, pro-oxidative stress (i.e., low blood oxygen content)
environment in which collateral mural cells reside, plus the high susceptibility of collaterals to
undergo rarefaction with aging, vascular risk factor presence, and eNOS/NO deficiency [16–21,25]
compared to nearby DMAs [17], we postulated that expression of genes involved with inflammation,
cell proliferation, aging, and angiogenesis differ for collaterals and DMAs. To test this hypothesis, we
measured transcript levels of 22 such genes (Figure 6), as well as eNOS immunofluorescence (Figure 7).
Collaterals had increased expression of Pycard, Ki67, Pdgfb, Angpt2, Dll4, Ephrinb2, and eNOS, whereas
16 other genes were not significantly different. Of note, expression of the EC shear stress-sensitive
transcription factors Klf2 and Klf4, which promote anti-proliferative, -inflammatory, and -angiogenic
processes, upregulate eNOS, and are sharply downregulated at vascular sites of low and disturbed
shear stress [35–37,44,45], were, in contrast, not downregulated in collaterals compared to DMAs with
laminar high-velocity flow.
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Figure 6. Gene expression differs for collaterals versus distal-most arterioles. Upper left panel, pial
arterial vasculature perfusion-fixed at maximal dilation then filled with PU4ii polyurethane. Stars
identify penetrating arterioles, including three that bifurcate and descend into the cortex immediately
below the arteriole or collateral (green stars). Ten collaterals and 10 nearby similarly-sized distal-most
arterioles DMAs were dissected from each of 36 mice and pooled into six samples for extraction of
RNA. Transcript abundance was determined by Nanostring n-Counter® for 22 genes, each normalized
to one of six housekeeping genes (Gapdh, βactin, Tubb5, Hprt1, Ppia, Tbp) selected for comparable level
of expression [46]. * p < 0.05, ** p < 0.01 by 2-sided t-test for collaterals versus DMAs.
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Figure 7. Collaterals express increased levels of phospho- and total eNOS compared to arterioles. Top
panels, immunohistochemistry for phospho- (A, red) and total (B, green) eNOS, n = 4 mice, 1-sided
t-tests, 163x magnification. * p < 0.05, ** p < 0.01.
2.5. Changes in Tortuosity over a Collateral’s “Lifetime” Suggests Accelerated Proliferative Senescence of their
Mural Cells
We previously reported that aging, hypertension, and other vascular risk factors cause a loss of
collateral number and a smaller diameter in those that remain [17–19,25]. Aging-induced rarefaction
becomes evident in late middle-age in mice (16 months of age), is not seen in DMAs, is accelerated in
onset by the presence of other vascular risk factors, and is associated with increased cellular markers of
oxidative stress, inflammation, proliferation, and aging, as well as increased vessel tortuosity [17–19,25].
Tortuosity is a hallmark of collaterals. We postulated that it arises from a persistently increased rate of
proliferation of collateral wall cells (confirmed in [18]) that is driven by the disturbed hemodynamic
conditions present in collaterals. The above studies did not examine tortuosity at time points earlier
than 3 months of age. To determine whether collaterals begin to acquire tortuosity from formation
onward, we examined mice on embryonic day E15.5 (collaterals form between E15.5 and E18.5 [6,7])
and on post-natal day-1 and day-21. Tortuosity was absent at E15.5 but became evident by P1 and
was significant by P21 (Figure 8). When viewed in context with our previous data for tortuosity at
later ages (Figure 9; human year-equivalents for the latter five bars are approximately 13, 19, 49, 69,
84 years [47]), these findings support the hypothesis that collateral rarefaction, which becomes evident
in late middle-age in mice [17], is caused by proliferative senescence of collateral ECs and SMCs due to
a lifetime elevation in proliferation in excess of apoptosis that is caused by the disturbed hemodynamic
conditions in which collaterals reside.
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Figure 8. Tortuosity increases progressively with time after formation of collaterals. Images at right,
ephrin-B2LacZ reporter mouse (construction of mutant described in [6]) showing embryonic collaterals.
Bar graph, tortuosity index = l/L (axial length of collateral ÷ scalar length connecting collateral
endpoints). E, embryonic day, P, post-natal day. Data for last four bars from Faber et al. [17] who also
showed that collateral diameter and number begin to decline at or after 16 months of age. Number
of mice (C57BL/6, B6) for bars 1–7: 8,9,8,9,10,7,8. For each mouse tortuosity, was determined for all
MCA–ACA collaterals and averaged. ANOVA followed by 1-sided Bonferroni t-tests, *, **, ***, p < 0.05,
0.01, 0.001, respectively.
 
Figure 9. Persistence/maintenance versus rarefaction/pruning of collaterals “hangs in the balance”.
Proposed model whereby collateral (COL) mural cells reside in an environment of low/disturbed shear
stress, high circumferential wall stress, and low blood oxygen content. This favors a pro-inflammatory,
pro-proliferative, pro-apoptotic, and accelerated aging EC phenotype, leading to loss of collateral
number and diameter (rarefaction). Compared to distal arterioles, collaterals have specializations and
differential gene expression (left box) that provide adaptations that mitigate against factors that promote
collateral rarefaction (right box). Vascular risk factors, e.g., aging, hypertension, EC dysfunction,
and oxidative stress, disturb the balance. Collaterals are more sensitive than other vessels to these
environmental risk factors, like “canaries in a mine-shaft”.
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3. Discussion
The present study identified a number of distinct features of collateral ECs and SMCs that may
underlie or contribute to the unique characteristics of collaterals outlined in the Introduction. We found
that despite the low and oscillatory shear stress present in collaterals at baseline in the absence of
obstruction, their ECs are aligned with the vessel axis to the same degree present in distal-most
arterioles and the descending aorta—vessels with high-velocity orthograde laminar flow. Endothelial
cells of both collaterals and arterioles have primary cilia, and collaterals possess fewer of them. Smooth
muscle cells of collaterals are continuous, unlike those of DMAs. Collaterals have higher levels of
expression of genes associated with both pro- and anti-inflammatory and pro- and anti-proliferation
pathways, compared to DMAs. A bias towards a higher rate of cell proliferation in collateral mural
cells [18] is supported by the observation that collaterals begin to acquire tortuosity shortly after their
formation in the embryo that increases through middle age (16 months, 49 human year-equivalents [47]).
The above findings provide insights into structural and molecular specializations that may underlie
the unique features and functions of collateral vessels.
Convergence of blood flow in collaterals at baseline imposes low and “disturbed” flow/shear
stress forces on their mural cells, i.e., either absence of flow or very low flow that oscillates to-and-fro
(~1–10 times per minute) and averages zero [6,15]. This results in increased wall stress according to the
Bernoulli relationship. When present elsewhere in the arterial circulation, e.g., at bifurcations, the inner
arch of the aorta or downstream of plaques, low and disturbed shear stress favors a non-aligned
cobblestoned EC morphology that is associated with increased oxidative stress, inflammation, markers
of aging, and low eNOS/NO activity (i.e., endothelial dysfunction) [28–31,44,45]. Surprisingly, however,
we found that collateral ECs have the same alignment (and cell dimensions) as ECs in DMAs and the
descending aorta. We did not investigate how this anti-inflammatory structural phenotype is specified.
It is possible that one or more of the other unique features that we identified are involved (see below).
On the other hand, the data in Figure 2 for flow and shear stress were obtained in anesthetized animals.
During awake behaviors, collaterals may have periods of sustained flow in one or the other direction
induced by changes in regional metabolic activity in the territory supplied by the arterial trees that
they cross-connect. It is not known if collaterals contribute in this way to physiological metabolic
regulation of blood flow and oxygen delivery, i.e., neurovascular coupling in brain and functional
hyperemia elsewhere. However, such periods of sustained unidirectional flow could promote the EC
orientation we observed. Irrespective of underlying cause, we speculate that the aligned phenotype of
collateral ECs is part (or a marker) of a group of protective mechanisms that favor maintenance of
collaterals and mitigate their rarefaction (Figure 9).
To our knowledge, this is the first report showing that ECs lining collaterals and arterioles have
primary cilia. They are much more abundant than reported previously for conduit vessels from healthy
individuals (i.e., absent or present on less than 1% of ECs [32,34]): 18% of collateral ECs have PrC
compared to 28% for DMAs. Primary cilia on ECs were described in 1984 by Haust in aorta of rabbits
and humans with atherosclerosis [48]. Subsequent reports described ciliated ECs in capillaries of the
pineal gland of a 20 week-old human fetus [49], developing heart and aortic valve leaflets [33,50,51],
and references therein], surrounding atheromas [52], ectopically in the common carotid artery of
ApoE−/− mice, and in healthy individuals at bifurcations of conduit arteries and the inner curvature
of the aortic arch; by contrast cilia are absent or nearly so in regions of arteries where shear stress is
laminar [33,40,50]. Most other cell types express PrC during development, under certain conditions
of cell culture [53], and in adults [35–37]. Depending on cell type, PrC participate in specification of
embryo asymmetry, centriole disposition, proliferation/cell cycle regulation, autophagy, flow-sensing
mechanotransduction, chemoception, and compartmentalization and trafficking of signaling proteins
among the cilioplasm, cytoplasm, and nucleoplasm (e.g., for Gli and PDGFRα) [35–37]. When present,
cilia are most abundant in non-proliferating cells, with the proximal end anchored in an invagination
of the plasmalemma (ciliary pocket) in ECs and other but not all cell types [33,34,36]. Primary cilia are
complexed with the mother centriole of the basal body that links to the microtubule-organizing center
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(MTOC) [32,35–37,54]. Disassembly/resorption of the cilium during S-phase and centriole liberation
are essential for cell division [36,37,54]. Since PrC are linked to the cytoskeleton via the MTOC,
flow-induced ciliary bending in ECs [55] is capable of being transmitted throughout the cell, including
to cell–cell and cell–matrix junctions [33,37]. Primary cilia transduce fluid shear stress in renal tubular
epithelial cells and ECs through a pathway that that is exceptionally sensitive to shear stress and
involves polycystin-1 and polycystin-2, which are encoded by Pkd1 and Pkd2 [35–37]. Polycystin-1
has mechanosensitive properties while polycystin-2 is a TRP calcium channel. Both proteins are
required to sense shear stress and in turn release nitric oxide [33,37]. Defects in PrC are associated with
many abnormalities. For example, mutations of PKD1 and PKD2 are causal for autosomal dominant
polycystic kidney disease, with kidney ECs and tubular cells of patients evidencing deficient calcium
and NO responses and increased proliferation [33,35–37].
Primary cilia are absent in human umbilical vein ECs maintained under laminar shear stress and
proliferative quiescence in cell culture. In human umbilical veins less than one percent of ECs have
cilia that protrude into the lumen, while in a larger fraction the cilia are located intracellularly [34,55].
Embryonic aorta and ECs cultured from it have a single cilium that projects into the lumen [38–40].
Endothelial cilia are present in regions of high shear stress during embryonic development, along
with expression of the shear stress-sensitive transcription factor, KLF2, which transactivates eNOS
and other anti-inflammatory and anti-proliferative genes [44,45]. In regions with low or disturbed
shear stress PrC are disassembled/absent and expression of Klf2 and eNOS are abolished and reduced,
respectively [33,56]. Expression of Klf2 is also inhibited in non-ciliated ECs isolated from embryonic
arteries, and chemical removal of PrC from ECs in culture has a similar effect, i.e., abolishing Klf2
expression [57]. Interestingly, in ECs of adult ApoE−/− mice, which have endothelial dysfunction but do
not develop plaques, cilia are expressed ectopically in the common carotid artery despite the presence
of laminar flow, compared to wildtype mice that are devoid of cilia [33]. Cilia were lost when high
shear stress was induced via implantation of a flow-restricting cast around the vessel. Casting of
common carotids in wildtype mice induced ciliogenesis only in regions of low and disturbed shear
stress. These findings suggest that expression of PrC on ECs in vivo in adults is limited to regions of
low/disturbed shear stress but can occur ectopically in arteries with laminar flow in the presence of
endothelial dysfunction caused by hyperlipidemia [33] and possibly other vascular risk factors. Of note,
in highly ciliated, disturbed-flow areas such as the inner curvature of the aortic arch or downstream of
plaques, approximately 25% of ECs have a single cilium while the rest are devoid [33], a percentage
similar to what we observed in arterioles and collaterals.
Our findings that PrC are also present on arterioles and collaterals in healthy young adult mice
highlight the need for studies examining cilia function in these vessel types. This includes determining
whether our observation of fewer cilia on collateral ECs than arterioles has functional significance.
Endothelial cells are coupled mechanically, electrically, and diffusionally to adjacent ECs and SMCs [58],
thus only a fraction of ECs may need to express cilia for transduction of mechano-sensitive or other
signals. High shear stress causes disassembly of cilia in cultured ECs, while oscillatory flow reversal
induces their expression [33]. We speculate that cilia on arteriole and collateral ECs may reflect the
lower flow/shear stress in arterioles and very low and disturbed flow in collaterals and that fewer
PrC on collateral ECs may serve to reduce their sensitivity to the prevailing disturbed shear stress
environment. In other words, fewer cilia on collateral ECs may be part of a repertoire of adaptations that
balance against or oppose—through maintained or increased expression of KLF2/4, eNOS, and other
anti-inflammatory/anti-proliferative factors—the low-grade inflammatory, oxidative, proliferative,
and apoptotic signals promoted by the disturbed hemodynamic environment present in collaterals
(Figure 9). Egorova et al. [36] proposed something similar, i.e., that since presence of PrC on ECs is
associated with KLF2 expression, endothelial cilia may signal a brake on EC activation in regions of
low and disturbed flow. A protective role for cilia in these regions [36,37] is supported by the recent
report that removal of endothelial cilia using conditional deletion of Ift88 increased atherosclerosis and
inflammatory gene expression, and decreased eNOS activity in Apoe−/−mice fed a high-fat diet [59], and
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that the endothelium becomes sensitized in athero-prone regions to undergo osteogenic differentiation
in Tg737 (orpk/orpk) cilium-defective mice [60]. It is also possible that if PrC are protective, fewer of
them in collaterals could contribute to the high susceptibility of these vessels to rarefaction from aging
and other vascular risk factors. However, fewer cilia on collaterals might simply reflect a secondary or
bystander effect, being a consequence, for example, of a higher inherent proliferation rate of collateral
ECs as evidenced by the progressive increase in collateral tortuosity (discussed below), since presence
of PrC and their association with the basal body is believed to favor removal of cells from the cell
cycle [35–37]. Future studies will be required to determine if our finding of multiple cilia on ECs
reflects ECs that have undergone proliferative senescence and associated failed cytokinesis and nuclear
polyploidy [39].
It has recently been shown that ECs in the developing mouse retina rely on PrC to stabilize
vessel connections during remodeling of the vascular plexus in regions with low to intermediate shear
stress [61]. Endothelial cilia sense flow in zebrafish embryos, participate in recruitment of mural cells
to arterial fated vessels, and are required for normal vascular morphogenesis [62,63]. The number
and diameter of collaterals declines beginning in middle age [17]. This age-induced rarefaction is
strongly accelerated by genetic or pharmacologically induced eNOS/NO deficiency or the presence of
vascular risk factors [16,19]. Increased shear stress induces collateral outward remodeling following
acute or slowly developing arterial obstruction [1,2,5]. Pkd1+/− mice and patients with autosomal
dominant polycystic kidney disease have endothelial eNOS/NO dysfunction [64]. It will be important
to examine in future studies whether collateral PrC participate in one or more of the above functions
using EC-specific knockdown of polycystin-1, since: 1) deficiency in it leads to altered ciliary function,
2) polycystin-1 together with polycystin-2 participate in flow-sensing by PrC, 3) mutant forms of either
protein cause polycystic kidney disease [35–37], 4) there is evidence that VHL, independent of its
role in the degradation of Hif1α, together with GSK3β are required for structural maintenance of the
cilium [65], and 5) the protein Rabep2, which is required for collaterogenesis [11], is a novel substrate
of GSK3β [66], localizes at the cilium–basal body complex, and knockdown of it leads to defective
ciliogenesis [67]. Other approaches to interfere with cilia presence and function, e.g., with knockdown
of other ciliary proteins such as Pkd2 and Ift88, also will need to be examined.
In contrast to distal arterioles, which have sparse and discontinuous SMCs in various tissues
including retina (we were unable to identify studies in brain) [41–43], SMCs were continuous on
collaterals. We speculate this may be an adaptive increase in wall thickness to balance the increase in
circumferential wall stress caused by the Bernoulli-specified conversion of kinetic energy of flow to
increased potential energy (transmural pressure) as a consequence of flow-convergence in collaterals.
It would be interesting to examine whether the composition and amount of extracellular matrix, which
could assist SMCs in balancing the increased wall stress in collaterals, differs in collaterals versus
arterioles. Of note, despite their increased SMC coverage, collaterals have less rather than more tone
compared to similarly-sized arterioles, and lack myogenic responsiveness—additional unique features
of collateral vessels [26,27].
The disturbed hemodynamic, pro-oxidative environment in which collateral mural cells reside
led us to examine whether expression of genes involved in inflammation, cell proliferation, aging, and
angiogenesis differ for collaterals versus distal arterioles. Collaterals displayed increased mRNA levels
for the pro-inflammatory, pro-apoptosis inflammasome gene, Pycard, the pro-proliferative genes, Ki67,
Pdgfb, and Angpt2, the anti-proliferative gene, Dll4, and the differentiated arterial-type EC marker
gene, Ephrinb2. However, expression of cell cycle inhibitor genes, p21, p27, and p53, were not different,
nor were other genes associated with proliferation, cell cycle arrest, and aging (p16Ink4a, Ampk, Sirt1,
telomerase). Neither were there differences in expression of other genes associated with EC and/or
SMC proliferation (Vegfa, Flk1, Clic4, Pdgfa, Flt1) and that are required (in the case of the first three
genes [7,8]) for formation of collaterals during development or involved with specifying EC and
SMC differentiation and quiescence (Tgfb, Angpt1). Increased expression by collaterals of the above
pro-proliferation genes is consistent with our tortuosity measurements, which suggest that collateral
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mural cells have a higher proliferation rate, compared to other arterial vessels: collateral tortuosity
was evident by the first day after birth, continued to increase through middle age, and then declined.
The latter occurred at the same time that collaterals experience a decline in number and diameter with
advanced aging [17]. These findings support the hypothesis that age-associated collateral rarefaction
is caused by proliferative senescence and subsequent apoptosis of collateral ECs and SMCs due to a
lifetime elevation in proliferation rate caused by the disturbed hemodynamic and low blood oxygen
content environment in which collaterals reside (Figure 9).
Collaterals also displayed increased activity of eNOS, which previous studies have shown opposes
rarefaction of collaterals caused by aging and other vascular risk factors [16,18,19]. eNOS-derived
NO inhibits oxidative stress, inflammation, proliferation, leukocyte adhesion, platelet aggregation,
and cellular aging and promotes SMC relaxation [58,68]. Since shear stress is a proximate stimulus
for eNOS-derived NO, increased eNOS/NO in collaterals with their low and disturbed shear stress
environment may lessen the effect of factors promoting collateral rarefaction (Figure 9). Likewise,
maintained expression of the EC shear stress-sensitive transcription factors, Klf2 and Klf4, in collaterals
despite their low and oscillatory flow, which inhibits expression of these factors elsewhere in the
arterial vasculature with disturbed flow [44], may act as additional “balancing” factors or collateral
specializations, along with increased eNOS, aligned ECs, fewer cilia, robust SMC coverage, and
increased ephrin-B2 and Dll4. Expression of KLF2 and KLF4, which negatively regulate proliferation,
inflammation, and angiogenesis, upregulate eNOS, and are sharply downregulated at sites of low and
disturbed shear stress, were not different in collaterals versus DMAs. Interestingly, PrC promote Klf2,
Klf4, and eNOS expression [35–37,44,69,70].
A limitation of the above studies is that RNA was obtained from dissected vessels, which are
composed of ECs, SMCs, and, although less so, pericytes, fibroblasts, and resident myeloid cells.
Studies are needed that employ separation of cell types and examination of a wider array of genes
and their respective protein levels. However, the difficulty in manually dissecting collaterals and
distal arterioles in the required numbers, the effect of cell dissociation techniques on baseline levels
of RNA and protein, the absence of cell culture models of “collateral” ECs and SMCs, and the as
of yet lack of any collateral-specific marker gene, preclude the use of these approaches. Of note,
however, expression of several of the genes examined are specific or enriched for ECs, e.g., Flk1,
Angpt1, Angpt2, Ephrinb2, DLL4, eNOS, Clic4, Klf2, and Klf4. However, analysis of gene transcription
does not always reflect changes in protein level or function; thus the investigation of oxidative stress,
inflammatory, proliferation, or senescence markers at the protein level may better reflect differences in
cellular characteristics.
4. Materials and Methods
Three to 4 month-old male C57BL/6 (B6) wildtype (lab colony, Jackson Laboratories breeders,
Bar Harbor, ME, USA) or genetically modified mice were studied. Scanning electron microscopy was
performed on the cerebral arterial vasculature that was filled with Batson’s #17. Angiography and
morphometry were performed after filling with yellow Microfil® [18]. Prior to infusion of the casting
agents, and also for immunohistochemistry, the vasculature was cleared of blood and perfusion-fixed
after maximal dilation with 10−4 M nitroprusside. Filling was confined to the pre-capillary vessels
by adjusting the viscosity and input pressure of the casting material. All pial collaterals between
the anterior cerebral artery (ACA) and middle (MCA) trees of both hemispheres were identified;
tortuosity (axial length of the collateral ÷ scalar length connecting the collateral’s endpoints [17])
and lumen diameter, EC orientation, and other morphometrics were obtained at midpoint for each
collateral and an average value obtained for each animal unless indicated otherwise in the figure
legends. Permanent MCA occlusion was by electro-cautery occlusion of the M1-MCA just distal
to the lenticulostriate branches [18]. Right femoral artery (FA) occlusion was achieved by ligating
the superficial FA immediately proximal and distal to the superior epigastric artery, which was also
ligated [18]. Hindlimb perfusion was measured by laser Doppler perfusion imaging of the plantar foot
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and the adductor thigh regions. Values reported are means ± SE, with significance at p < 0.05; n-sizes
(number of animals studied) and statistical tests are given in the figure legends.
All applicable international, national, and/or institutional guidelines for the care and use of
animals were followed, including the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (UNC IACUC #18-123.0-A, 1 April 2019). This article does not contain any studies
with human participants performed by any of the authors.
4.1. Angiography and Morphometry
As previously described in detail [20] animals were anesthetized deeply with ketamine and
xylazine and heparinized. The distal thoracic aorta was cannulated, right atrium perforated, and the
mouse was perfused with PBS containing freshly prepared sodium nitroprusside (10−4 M, for maximal
dilation) and Evans blue dye (for light staining of brain and the endothelial surface) at ~100 mmHg.
One ml of yellow Microfil (Flowtech Inc, Carver, MA, USA) was infused at a viscosity adjusted to fill
the entire pial arterial and collateral circulations with sufficient pressure (~100 mmHg) and duration to
cause limited capillary transit and venous filling to assure complete filling of all precapillary vessels
and collaterals. After the Microfil had set for 20 min, brains were kept in 4% PFA and collaterals were
imaged the next day using a Leica fluorescent stereomicroscope. All collaterals between the anterior
cerebral artery (ACA) and middle cerebral artery (MCA) trees of both hemispheres were counted and
divided by 2 to give the average number per hemisphere. Images were subsequently analyzed (ImageJ,
NIH, Bethesday, MD, USA): Collateral lumen diameter was determined at midpoint at 50X for all
ACA-MCA collaterals and averaged for each mouse.
4.2. Permanent Middle Cerebral Artery Occlusion (pMCAO)
As previously described [20], mice were anesthetized with ketamine and xylazine (100 and
10 mg/kg, ip, respectively) and rectal temperature was maintained at 37 ± 0.5 ◦C. The temporalis muscle
between the eye and ear on one side was retracted after a 4 mm incision. After a 2 mm craniotomy
(18000-17 drill, FST, Foster City, CA, USA), the dura was incised with a 27 gauge needle tip and reflected
to reveal the main trunk of the MCA which was cauterized (18010-00, FST, modified) distal to the
lenticulostriate branches. The incision was closed with suture and Vetbond (3M, Minneapolis, MN,
USA), intramuscular cefazolin 50 mg/kg and buprenorphine were administered, and the animal was
monitored in a warmed cage during recovery from anesthesia to maintain the above rectal temperature.
Mice were euthanized 4 days after pMCAO. Pial collateral morphometry was then performed as
described above.
4.3. Laser Doppler Perfusion Imaging and Hindlimb Ischemia Model
Femoral artery ligation (FAL) was performed and hindlimb perfusion was measured using a
laser Doppler perfusion imager (Model LDI2-IR, Moor Instruments, Wilmington, DE, USA, ~2 mm
penetration and high resolution) as described previously [71]. Briefly, the anterior thigh and adductor
regions were depilated followed by 24 h to recover from any erythema. Mice were then anesthetized
with 1.25% isoflurane/O2, rectal temperature was maintained at 37 ± 0.5 ◦C. A 3 mm incision was
made overlying the femoral vessels 5 mm proximal to the knee. The femoral artery was gently isolated
and ligated twice with 7-0 suture immediately distal to the lateral caudal femoral artery and 1 mm
further distally, followed by transection between the ligatures. The superficial epigastric artery was
also ligated. The skin was closed using 5-0 silk. Mice were placed in a heated chamber to block ambient
light, and rectal temperature was maintained at 37 ± 0.5 ◦C. Less than 5 min after ligation, the plantar
and adductor regions of both legs were laser-scanned. Average perfusion within the region of interest,
drawn to outline the plantar surface of the paws, was calculated using Moor LDI Image Processing
V5.0 software and reported as the ratio of ligated to the non-ligated hindlimb, where the region of
interest was defined according to anatomic landmarks as described previously [71].
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4.4. Quantitative NanoString Expression Analysis
As described previously [46], mice placed under deep anesthesia (ketamine and xylazine, 100
and 10 mg/kg, ip, respectively) were perfused with 1 ml RNAlater®(Sigma-Aldrich Corp, St. Louis,
MO, USA) premixed with 10% Evans blue dye through the thoracic aorta. The brain was then
removed and immersed in RNAlater®. Approximately 10 pial collaterals and 10 nearby similarly sized
distal-most arterioles per mouse (total 36 mice) were micro-dissected and pooled in RNAlater®as 6
samples. Samples were homogenized (TH, Omni International, Marietta, GA, USA) in Trizol Reagent
(Invitrogen, Carlsbad, CA, USA). Total RNA was purified using the RNeasy Micro Kit according to
the manufacturer (Qiagen, Valencia, CA, USA). RNA concentration and quality were determined by
NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA) and Bioanalyzer 2100 (Agilent, Foster City,
CA, USA), respectively. Measurement of transcript number was conducted for 22 selected genes by
the genomics facility at UNC using NanoString custom-synthesized probes (NanoString, Seattle, WA,
USA). Transcript number for each gene was normalized to one of the following 6 housekeeping genes
selected to be in range of the target gene under analysis: Gapdh, βactin, Tubb5, Hprt1, Ppia and Tbp.
4.5. Immunohistochemistry
Mice under deep anesthesia (ketamine and xylazine, 100 and 10 mg/kg, ip, respectively) were
perfused with nitroprusside (10−4 M) in PBS at ~100 mmHg with a reservoir for 3 minutes for maximal
dilation and then with 2% PFA for 15 min for fixation. Brains were blocked with 10% goat serum in
0.3% PBS-triton 1 hr at room temperature. Then the cortex area were incubated with 1:50 anti-eNOS
rabbit IgG (sc-654, Santa Cruz Biotechnology, Santa Cruz, CA, USA); 1:100 anti-phospho eNOS rabbit
IgG (ab75639, Abcam, Cambridge, MA, USA), 1:100 anti-acetylated-tubulin (T7451, Sigma), 1:100
anti-ZO1 (ab96587, Abcam), 1;400 anti-aSMA (Abcam, 32575, clone E184), overnight, 4 ◦C in a shaker,
followed by incubation of 1:200 goat anti rabbit-fluorescent conjugated with Alexa fluor®568 (A10042,
ThermoFisher Scientific, Grand Island, NY, USA) or Alexa fluor®488 (A21208). Images of eNOS and
phorpho-eNOS for pial collaterals and DMAs were taken using a Leica fluorescent stereomicroscope
(Richmond, IL, USA), and the signal strength was measured using ImageJ (Bethesda, MD, USA).
Endothelial cells were probed with Isolectin-GS-IB4-Alexa568 (I121415, ThermoFisher Scientific).
Primary cilia (probed with anti-acetylated-tubulin antibody) in the lumen of pial collaterals were
observed with a Zeiss 710 confocal microscope (Thornwood, NT, USA), with z stack scanning from the
top of cortex down to a depth of ~30 um. Endothelial junctions (probed with ZO-1) were visualized
with a Zeiss 710 confocal microscope.
4.6. Collateral Primary Cilia and Endothelial Orientation Assessed by Scanning Electron Microscopy
Mice were perfused with maximal vessel dilation as described above. Brain arterial vasculature
was then casted using a Batson’s No 17 Plastic Replica and Corrosion Kit (Polysciences, Inc, Warrington,
PA, USA). Briefly, 1 ml of Batson’s 17 was infused through the thoracic aorta. After fully curing, the brain
tissue was removed using maceration solution, and the cerebral vasculature including the pial collateral
regions were carefully persevered for emission scanning electron microscopy. The vasculature was
observed under a Zeiss Supra 25 Field emission scanning electron microscope. Images of pial collateral
and DMAs were saved for analysis of primary cilia and endothelial cell morphology. To measure
the orientation of collateral endothelial cells, we use Photoshop to draw a line coordinate with the
collateral axis and a second line coordinate with the endothelial cell axis (see Figure 2, panel C), and
the angle formed was measured.
4.7. Statistics
Experiments were performed in accordance with the University of North Carolina’s Institutional
Animal Care and Use Committee, the NIH Guide for the Care and Use of Laboratory Animals, the
ARRIVE guidelines, and the following suggested STAIR criteria [72]: investigators were blinded during
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data analysis where possible; no data points were identified as outliers by statistical test and none
were excluded; all results were fully disclosed including negative results; the review, discussion and
citation of the literature was unbiased; pMCAO was used to permanently recruit blood flow across
pial collaterals. Values are mean ± SEM. Statistical analysis (p < 0.05 = significant) is described in the
figure legends.
5. Conclusions
In conclusion, collaterals are unique among blood vessel types with regard to their formation,
structure, function, prevailing shear stress, and susceptibility to variation in their extent caused
primarily by differences in genetic background but also by environmental factors such as aging and
risk factors. The present study provides our first look into how differences in collateral endothelial
and smooth muscle cells may accommodate and contribute to these unique features. Moreover, the
model/hypothesis shown in Figure 9, if correct, may begin to provide answers to two perplexing
questions: Why do collaterals undergo rarefaction with aging and other vascular risk factors? They are
chronically exposed to adverse hemodynamic conditions. How do they resist more extensive pruning
away? Their mural cells have specializations or adaptations in structure and expression of factors that
mitigate the effects of these conditions.
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Abbreviations
ACA anterior cerebral artery




eNOS endothelial nitric oxide synthase
Flt 1 VEGF receptor 1
Flk1 VEGF receptor 2
MCA middle cerebral artery
NO nitric oxide
PA penetrating arteriole
Pkd1 gene that encodes polycystin-1
PrC primary cilia
SMC smooth muscle cell
VECAD
vascular endothelial cell adhesion protein, selectively
expressed by ECs
WT wildtype littermate controls
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Abstract: Arteriogenesis is an intricate process in which increased shear stress in pre-existing
arteriolar collaterals induces blood vessel expansion, mediated via endothelial cell activation,
leukocyte recruitment and subsequent endothelial and smooth muscle cell proliferation. Extracellular
RNA (eRNA), released from stressed cells or damaged tissue under pathological conditions, has
recently been discovered to be liberated from endothelial cells in response to increased shear stress
and to promote collateral growth. Until now, eRNA has been shown to enhance coagulation and
inflammation by inducing cytokine release, leukocyte recruitment, and endothelial permeability,
the latter being mediated by vascular endothelial growth factor (VEGF) signaling. In the context
of arteriogenesis, however, eRNA has emerged as a transmitter of shear stress into endothelial
activation, mediating the sterile inflammatory process essential for collateral remodeling, whereby the
stimulatory effects of eRNA on the VEGF signaling axis seem to be pivotal. In addition, eRNA might
influence subsequent steps of the arteriogenesis cascade as well. This article provides a comprehensive
overview of the beneficial effects of eRNA during arteriogenesis, laying the foundation for further
exploration of the connection between the damaging and non-damaging effects of eRNA in the
context of cardiovascular occlusive diseases and of sterile inflammation.
Keywords: arteriogenesis; VEGF; extracellular RNA; shear stress; endothelial activation; mast cell
degranulation; macrophages; sterile inflammation; collateral artery growth; TACE
1. Introduction
Cardiovascular diseases such as ischemic heart disease, stroke or peripheral arterial occlusive
disease are a major public health burden, accounting for approximately 30% of deaths worldwide in
2017 [1]. These diseases are commonly treated with percutaneous coronary interventions involving
stents or with coronary bypass surgery. Interestingly enough, the body has a natural non-invasive way
of forming a bypass around an occluded vessel called arteriogenesis. During arteriogenesis, blood
flow is redirected through preexisting collateral arterioles upon occlusion of a supplying artery [2].
The main stimulus to initiate arteriogenesis in the pre-existing arteriolar vessels is increased fluid shear
stress, which subsequently leads to endothelial cell activation, leukocyte extravasation and vessel wall
(endothelial and smooth muscle cell) proliferation, substantially increasing the luminal diameter and
restoring perfusion [2]. Whilst many of the steps leading to leukocyte extravasation and vessel growth
have been uncovered, the crucial missing link of how intravascular shear stress is translated into local
endothelial activation and vascular cell growth remained unknown.
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Extracellular RNA (eRNA) released upon increased fluid shear stress during arteriogenesis in vivo
has recently been suggested to be this missing link by initiating the cascade of arteriogenesis through
vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling [3]. eRNA is released
from cells upon cellular stress or damage and is mainly composed of rRNA [3,4]. Other forms of
extracellular RNA such as microRNA have also been suggested to have a regulatory effect on collateral
remodeling during arteriogenesis through modulation of intracellular signaling pathways; however,
whether this effect is positive or negative seems to depend on the specific microRNA [5–8]. In terms
of cardiovascular disease, eRNA released upon cellular damage has proven to have adverse effects
in, e.g., ischemia/reperfusion injury, transplantation or atherosclerosis by mediating vascular edema,
thrombus formation and inflammation [9–14]. This review aims to further elucidate the beneficial role
of eRNA during the various stages of arteriogenesis.
2. The Role of eRNA in Arteriogenesis
2.1. eRNA Acts as a Translator of Shear Stress during Arteriogenesis through an Endothelial
Mechanosensory Complex
The initiating stimulus for collateral remodeling in arteriogenesis is increased arteriolar fluid shear
stress as a result of the occlusion of the main supplying artery [15]. In sharp contrast to other forms of
vessel growth such as vasculogenesis or angiogenesis, vessel remodeling in arteriogenesis is stimulated
by mechanical forces rather than by conditional factors such as hypoxia or ischemia [15,16]. Various
mechanisms for shear stress sensing in endothelial cells have been described such as mechano-sensitive
ion channels or the entire cytoskeleton transmitting changes in membrane tension (tensegrity
architecture) [17]. However, it has recently been suggested that shear stress is in fact translated
into endothelial cell activation through a mechanosensory complex, which was previously found to be
located on endothelial cells in murine aortas predominantly at sites of non-laminar blood flow [18].
This complex comprises platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular endothelial
cell cadherin (VE-cadherin) and VEGFR2, whereby PECAM-1 acts as a mechano-sensor and together
with VE-cadherin mediates VEGFR2 activation and subsequent intracellular signaling (Figure 1) [18].
VE-cadherin is an essential component of the endothelial adherens junction, mediating interactions
with cytoskeletal anchoring molecules, and has been demonstrated to promote endothelial cell survival
by enhancing VEGF-A signaling via VEGFR2 and subsequent phosphatidylinositol-3-OH-kinase
activation as well as by activating protein kinase B (Akt) [19,20]. PECAM-1, also an adhesion molecule,
has been shown to be involved in collateral remodeling in arteriogenesis as deficiency of PECAM-1 led
to an attenuated increase in collateral luminal diameter and leukocyte recruitment to the perivascular
space in a murine model of peripheral arteriogenesis [21]. Interestingly, in mice deficient in PECAM-1,
the diameter of preexisting collaterals was larger than in wildtype mice; however, the number
of preexisting collateral arterioles was comparable in both groups [21]. The signaling pathways
activated by this mechanosensory complex that could also be highly relevant in arteriogenesis include
(1) VEGFR2 activation, crucial for endothelial proliferation and von Willebrand factor (vWF) release,
(2) nuclear factor κB (NFκB) activation, important for enhancing cytokine release and adhesion molecule
expression, and (3) phosphatidylinositol-3-OH-kinase and protein kinase B (Akt) activation, essential
for promoting endothelial cell survival [18].
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Figure 1. Proposed signaling mechanism downstream of the mechano-sensory complex composed of
PECAM-1 (Platelet endothelial cell adhesion molecule (1), VE-cadherin (Vascular endothelial cadherin)
and VEGFR2 (Vascular endothelial growth factor receptor (2) which could be relevant in arteriogenesis.
eRNA released from EC (endothelial cells) upon shear stress enhances binding of VEGF to VEGFR2 and
NRP-1 (Neuropilin-1) thus inducing the signaling mechanisms leading to endothelial cell activation
and proliferation as well as leukocyte recruitment and adhesion. The intracellular compartment (EC)
is depicted in yellow, the extracellular vessel lumen in red. Arrows indicate the various steps of the
signaling pathways. [NF-κB (nuclear factor ’kappa-light-chain-enhancer’ of activated B-cells); PI3K
(Phosphoinositide 3-kinases); PLC (Phospholipase C); PKB/AKT (Protein kinase B)].
2.1.1. eRNA Initiates Arteriogenesis by Locally Enhancing VEGF/VEGFR2 Signaling
VEGF is a glycoprotein produced by a variety of cell types including leukocytes such as neutrophils
or monocytes [22–25] and is critically involved in enhancing endothelial cell proliferation, permeability,
and angiogenesis [26–28]. The role of VEGF in arteriogenesis remained uncertain for a long time;
however, it has now been established that its downstream signaling events are crucial for this
process [3,25]. While it has been demonstrated that the expression of the isoform VEGF-A is
not increased in collateral vessels during the process of arteriogenesis and that administration of
additional VEGF does not significantly improve collateral vessel development [16,29], antibodies
blocking either VEGF or the cognate receptor (VEGFR2) have been shown to interfere greatly with
vessel remodeling [25,30,31]. This indicates that VEGFR2 signaling is relevant in arteriogenesis but
that endogenous VEGF levels are sufficient for this process [25]. Under physiological conditions,
the activation of VEGFR2 induces its dimerization and subsequent tyrosine kinase auto-phosphorylation
and endocytosis, thus activating phospholipase C (PLC) and raising intracellular calcium levels [32].
These intracellular signaling events ultimately lead to endothelial activation including the release
of Weibel–Palade bodies. Hereby, the co-receptor neuropilin-1 (NRP-1) plays an essential role in
linking VEGF and its receptor and in enhancing subsequent intracellular signaling (Figure 2) [32].
In vitro and in vivo studies have demonstrated that NRP-1 is also relevant in arteriogenesis [33,34],
whereby its cytoplasmic domain mediates both the co-endocytosis of NRP-1 and VEGFR2 as well as its
interaction with synectin [32–34]. These results indicate that the VEGF/VEGFR2 system plays a part in
arteriogenesis; nevertheless, they do not explain how VEGFR2 is locally activated in collaterals upon
increased shear stress. This is where eRNA comes into play.
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Figure 2. (a) Shear stress-induced activation of endothelial cells (EC) leads to the release of eRNA
(extracellular RNA) on their abluminal side. (b) eRNA enhances the binding of VEGF (vascular
endothelial growth factor) to NRP-1 (neuropilin (1) thus promoting VEGFR2 (VEGF Receptor (2)
intracellular signaling. (c) VEGFR2 mediated raise of intracellular Ca2+ leads to the exocytosis of
Weibel–Palade bodies and vWF (von Willebrand factor) release, which activates platelets via their GP1bα
(Glycoprotein 1bα) receptor. (d) Upon activation, platelets express P-selectin, which subsequently binds
its ligand PSGL-1 (P-selectin glycoprotein ligand-1) on neutrophils, inducing the formation of PNAs
(platelet-neutrophil aggregates). The bond between P-selectin and PSGL-1 induces a deformational
change, which promotes binding in these molecules (catch bond nature). PNA formation enhances
neutrophil extravasation followed by ROS (reactive oxygen species) release which promotes mast cell
degranulation. The intracellular compartment (EC) is depicted in yellow, the extracellular vessel lumen
in red. Arrows indicate the subsequent steps during arteriogenesis.
VEGFR2 activation and signaling have been demonstrated to be involved in mediating the
pro-inflammatory and permeability-enhancing effects of eRNA on endothelial cells. Binding studies of
eRNA to different VEGF isoforms (VEGF165 and VEGF121) confirmed that eRNA directly interacts with
VEGF, most likely via its heparin binding domain [12]. Whilst eRNA does not alter the expression of
either VEGF [12] or of VEGFR2 in vitro [35], it has been shown to enhance the binding of VEGF to
NRP-1 in vitro [35]. The formation of this complex of eRNA with VEGF, NRP-1 and VEGFR2 thus
promotes PLC-dependent intracellular signaling mechanisms. Since eRNA is released from endothelial
cells upon shear stress in vitro [3], it was proposed that eRNA could also play a role in the early
steps of arteriogenesis by activating the VEGF/VEGFR2 signaling pathway and thereby inducing
endothelial activation. Accordingly, in a murine model of peripheral arteriogenesis, eRNA—mostly
rRNA—was found to be released from endothelial cells of developing collaterals, which were exposed
to increased shear stress, on their abluminal side [3]. The levels of VEGF bound to the glycocalyx of
endothelial cells might be sufficient for initial local signaling induced by eRNA; however, as collateral
remodeling progresses, leukocytes might take over the role of supplying VEGF [24,25]. Crucially,
this shear stress-induced release of eRNA during arteriogenesis is not related to cellular injury, as
no lactate dehydrogenase was released into cell supernatants in vitro [3]. In contrast, eRNA, which
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is involved in other pathological situations such as stroke, was liberated mostly as a result of tissue
damage [9,12]. eRNA seems to play a stimulatory part in arteriogenesis as treatment of mice with
RNA-degrading RNase1 led to a smaller increase in luminal diameter of the growing collateral vessels
compared to saline-treated control mice and also impaired perfusion recovery in vivo [3,36]. In contrast,
administration of DNase or inactive RNase1 did not alter perfusion recovery [3], supporting the notion
that the observed effects of RNase1 resulted from the hydrolysis of eRNA rather than from other
functions of the endonuclease. In accordance with this, the administration of an RNase inhibitor
improved perfusion recovery as well [3], which is highly relevant since eRNA is rapidly degraded
in the circulation by RNases under physiological conditions [37]. Therefore, eRNA released upon
increased fluid shear stress seems to play a pivotal role in the early processes of arteriogenesis by
mediating endothelial cell activation through an enhanced VEGF/NRP-1/VEGFR2 interaction and
subsequent intracellular signaling.
2.1.2. Contribution of eRNA in the Promotion of Collateral Remodeling through Stimulation of
Endothelial NFκB Signaling
The extravasation of leukocytes, particularly of monocytes, is critical in arteriogenesis, since
the cytokines and growth factors released by these cells are essential stimulators of endothelial and
smooth muscle cell proliferation [38,39]. eRNA has previously been established as a strong promoter of
leukocyte adhesion and extravasation, especially of monocytes, as demonstrated in a murine cremaster
model and a murine model of atherosclerosis [11,14]. This pro-inflammatory effect was also confirmed
in the process of arteriogenesis [3], where RNase1 treatment reduced the extravasation of neutrophils
and monocytes in vivo [3]. In this case, no change in blood levels of leukocytes was observed [3],
indicating that eRNA affects local cell interactions but not the systemic cell count. Physiologically
and in arteriogenesis, leukocyte transmigration is facilitated by the interaction between endothelial
adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and leukocyte ligands such
as macrophage-1 antigen (Mac-1) [40,41]. The expression of ICAM-1 has independently been shown
to be upregulated on the one hand by fluid shear stress in vitro and in vivo [42,43] and on the other
hand by eRNA in vitro [14,44]. In an in vivo model of peripheral arteriogenesis, the effects of eRNA
on endothelial cell signaling were also demonstrated to be relevant for subsequent leukocyte adhesion,
as inhibition of eRNA through RNase administration reduced the perivascular macrophage count to a
similar degree as seen in ICAM-1 deficient mice [3].
Two possible ways through which eRNA might affect the expression of ICAM-1 are through
stimulation of the NFκB or of the VEGFR2 signaling pathways. VEGF has been shown to induce
the upregulation of ICAM-1 in a transgenic mouse model of psoriasis [45], whereby its effects on
ICAM-1 expression were demonstrated to be the result of an enhanced VEGF/NRP-1 interaction in a
retinal mouse model [46]. Since eRNA enhances the formation of an activated VEGF/NRP-1/VEGFR2
complex during arteriogenesis, it might promote the expression of adhesion molecules on endothelial
cells through this avenue of signaling. Nevertheless, eRNA has also been shown to promote the
activity of NFκB, which also enhances ICAM-1 expression [47], by inducing the phosphorylation of
the cytoplasmic inhibitor of κB (IκB) in vitro [14]. The role of NFκB signaling in arteriogenesis has
not yet been studied in detail; however, this pathway was found to be continuously activated in
situations of disturbed blood flow such as in atherosclerosis [18]. Furthermore, an increase in the
nuclear translocation of NFκB and hence an increase in the expression of its target genes was observed
in a rat mesenteric model of collateral growth [48]. Moreover, NFκB is also able to induce the expression
of VEGF [49], suggesting that there might be an interplay between these two avenues of signaling in
mediating the effects of eRNA on endothelial activation during arteriogenesis.
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2.2. eRNA Is Relevant for Mast Cell Degranulation during Arteriogenesis by Stimulating vWF Release and
PNA Formation
2.2.1. eRNA Mediates vWF Release from Endothelial Weibel–Palade Bodies by Promoting VEGF/
VEGFR2 Signaling
Through its stimulatory effect on VEGF/VEGFR2 signaling, eRNA mediates endothelial activation
and the release of vWF from Weibel–Palade bodies, which is essential for subsequent platelet activation
and platelet-neutrophil aggregate (PNA) formation in arteriogenesis (Figure 2). Endothelial cell
activation as seen in arteriogenesis is characterized to a large extent by a loss of vascular barrier
function, luminal expression of adhesion molecules for leukocytes and release of cytokines and
pro-coagulatory molecules [50]. eRNA has been associated with all of these events, since it mediates
hyper-permeability and vascular edema formation under conditions of ischemia/reperfusion injury or
transplantation by disrupting endothelial tight junctions and since it promotes thrombus formation by
activating the contact phase system of intrinsic coagulation [4,10,12,13]. In the inflammatory setting of
arteriogenesis where eRNA plays such a prominent role, this raises the question of how thrombus
formation is inhibited, which will be discussed at a later stage of this review. In addition to these
pro-inflammatory and pro-coagulatory effects, eRNA also stimulates the exocytosis of endothelial
cell storage granules, designated as Weibel–Palade bodies, which contain vWF, P-Selectin and other
cytokines [51–53], as indicated by increased vWF release from endothelial cells upon eRNA exposure
in vitro [35]. The exocytosis of Weibel–Palade bodies can also be induced by various other stimuli
including thrombin, VEGF and reactive oxygen species (ROS) [54–56]. Weibel–Palade body exocytosis
by eRNA was inhibited by an antibody against VEGF [35], suggesting that eRNA stimulates vWF
release from endothelial cells via VEGF/VEGFR2 signaling as described above [12]. In the context
of arteriogenesis, the ability of eRNA to induce endothelial activation and vWF release via VEGFR2
activation was confirmed, since RNase1 treatment in a murine model of peripheral arteriogenesis
decreased luminal vWF levels to a similar extent as seen with vWF deficiency or VEGFR2 inhibition [3].
2.2.2. eRNA-Mediated vWF Release Is Pivotal for PNA Formation
vWF is an adhesive and prothrombotic glycoprotein, constitutively produced by endothelial cells
and released from endothelial Weibel–Palade bodies upon cell stimulation. It forms large and ultralarge
multimers and plays a key role in the tethering and adhesion of platelets to the injured vessel wall,
particularly under fluid shear stress conditions [57,58]. In arteriogenesis, the release of vWF and its
interaction with platelets have been demonstrated as pivotal, triggering the activation of platelets and
the formation of PNAs (Figure 2) [59,60]. PNAs in turn have been implicated in the recruitment and
priming of neutrophils during inflammatory processes and were shown to be relevant for the release
of reactive oxygen species (ROS) [61], both of which are relevant in arteriogenesis [60,62]. Following
neutrophil extravasation and ROS release, perivascular mast cells are activated and the subsequent
extravasation of leukocytes and their release of cytokines and growth factors are increased. In this
way, the proliferation of endothelial cells and smooth muscle cells is stimulated, collateral vessels are
able to expand, and perfusion can be sufficiently restored. PNAs are also crucial for the formation of
neutrophil extracellular traps (NETs), comprising the entire decondensated chromatin of neutrophils,
whose formation has also been induced following stimulation of neutrophils with extracellular nucleic
acids [63]. In the context of arteriogenesis, though, the formation of NETs has not yet been described.
However, since the application of DNase had no effect on perfusion recovery in vivo [3], one can
assume that even if NETs are formed during arteriogenesis, they would not have a negative effect on
vessel remodeling.
While free platelets do not usually interact with vWF, they are able to transiently bind to vWF via
their receptor glycoprotein Ibα (GPIbα) under high fluid shear stress, resulting in platelet activation
and adhesion [64]. GPIbα also binds to other pro-coagulatory factors such as thrombin or factors XI and
FXII as well as to adhesion molecules such as P-selectin or Mac-1 on immune cells, thereby facilitating
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cell-cell contacts [65]. Interestingly, the vWF-GPIbα interaction appears to be optimal at high fluid
shear stress, a condition which is predominantly found in arterioles [64–66], which is also where
vessel remodeling takes places during arteriogenesis. This seems to be due to the fact that shear stress
induces conformational changes in the vWF multimers [64], which then facilitate their interactions
with platelets. These interactions are also vital in the high shear stress setting of arteriogenesis, where
both platelet deficiency and GPIbα deficiency resulted in reduced perfusion recovery in vivo [59].
Once platelets are activated through vWF/GPIbα binding, they express P-selectin on their surface,
which is subsequently able to bind to the corresponding P-selectin glycoprotein ligand-1 (PSGL-1)
on neutrophils [67,68], enabling the formation of PNAs [60]. The expression of P-selectin has been
demonstrated to be increased by shear stress as well [67], and additionally, it was suggested that
the resulting adhesive bonds between P-selectin and PSGL-1 are stronger under high fluid shear
stress owing to the catch bond nature of selectins [40]. P-selectin and PSGL-1 seem to mediate the
interactions of platelets with neutrophils at higher rates of shear stress in vitro, while integrin-mediated
interactions seem to be more relevant at lower levels of fluid shear stress [69]. The formation of PNAs
was also observed in vivo in the high fluid shear stress setting of arteriogenesis, whereby this binding
of platelets to neutrophils was abolished in GPIbα knock-out mice [59], underlining the relevance of
vWF release and binding to GPIbα for PNA formation in arteriogenesis.
This important step during collateral remodeling might also be influenced indirectly by eRNA,
marking another point where eRNA could play a role during arteriogenesis. In a murine model
of arteriogenesis, RNase1 treatment decreased the formation of PNAs to a similar extent as was
seen in mice which were either deficient in vWF or treated with a VEGFR2 inhibitor [3], suggesting
that VEGF/VEGFR2-dependent eRNA-mediated effects on vWF release also ultimately affect PNA
formation. Critically, the administration of RNase1 did not change the blood levels of platelets or
neutrophils [3], indicating that eRNA-mediated effects are not systemic but localized to collaterals and
do not involve enhanced release of effector cells from the bone marrow. In addition, activated platelets
are able to trigger the expression of P-selectin on endothelial cells, thus enabling leukocyte rolling
along the activated vessel wall [70]. Such transient interactions of platelets with endothelial cells were
also observed in arteriogenesis [59]. In summary, the release of vWF from endothelial Weibel–Palade
bodies is a critical step in arteriogenesis as vWF subsequently leads to the activation of platelets and the
formation of PNAs, and these processes depend on eRNA, which enhances VEGF/VEGFR2 signaling
and endothelial activation.
2.2.3. The Possible Role of ADAMTS13 in the Suppression of Thrombus Formation in Arteriogenesis
The activation of platelets together with the secretion of highly reactive multimeric vWF from
endothelial cells under inflammatory conditions during the process of arteriogenesis would provide
an ideal setting for thrombus formation. Yet, such an outcome has never been observed, and it
remains to be studied in which way local thrombus formation is inhibited during arteriogenesis.
Following activation of endothelial cells and the initial release of vWF in a multimeric form to promote
platelet adhesion under flow, the readily coagulable nature of these large vWF multimers needs to
be weakened at a later phase to prevent the formation of microthrombi [71]. vWF can be cleaved
via limited proteolysis by the circulating plasma metalloprotease ADAMTS13 (a disintegrin and
metalloprotease with a thrombospondin type 1 motif, member 13) [57]. The deficiency of this protease
has been associated with a thrombotic pathology known as thrombotic thrombocytopenic purpura [72].
The interaction between vWF and ADAMTS13 was revealed to be increased under high shear stress
in vitro and was maintained even after shear stress was eliminated [58,73]. This effect has been
attributed to unfolding of the vWF molecule from a globular to an elongated form upon exposure to
shear stress and subsequent exposition of scissile bonds for cleavage by ADAMTS13 [57]. Cleavage of
vWF by ADAMTS13 could therefore be a potential mechanism through which thrombus formation
could be inhibited in arteriogenesis. In fact, platelet adhesion and aggregation reactions were increased
in the arterioles of ADAMTS13-deficient mice compared to wild-type mice; however, this situation
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could be reversed by the administration of recombinant ADAMTS13 [74]. Furthermore, in a murine
model of stroke, ADAMTS13 deficiency was associated with impaired angiogenesis and brain capillary
perfusion [75]. The pro-angiogenic properties of ADAMTS13 have been proposed to be due to the
phosphorylation of VEGFR2 and upregulation of VEGF, both in vivo and in vitro [75,76], which was
also reflected by the fact that an in vitro siRNA-induced knockdown of ADAMTS13 reduced VEGF
levels in the cell lysate as well as endothelial proliferation [77]. ADAMTS13 therefore seems to influence
VEGF signaling, and since the effect of eRNA on this signaling pathway has proven to be pivotal in
arteriogenesis, there might be a link between eRNA and ADAMTS13 in arteriogenesis as well. Yet, the
exact role of ADAMTS13 during this process still needs to be assessed.
2.2.4. eRNA is Relevant for Mast Cell Degranulation Following PNA Formation
Following PNA formation, the extravasation of neutrophils is mediated through urokinase-type
plasminogen activator (uPA) [60], which, in contrast to tissue plasminogen activator, has been shown
to be vital for the transmigration of leukocytes during arteriogenesis in vivo [62]. The subsequent
release of NADPH oxidase 2 (Nox2)-derived ROS from neutrophils is crucial for inducing mast
cell degranulation [60], whereby neutrophils in PNAs were shown to produce more ROS than
non-complexed neutrophils [61]. Both the surface expression of uPA as well as ROS formation via Nox2
were reduced in P-selectin-deficient and PSGL-1-deficient cells in vitro [60], underlining the importance
of PNAs in triggering the steps leading to mast cell degranulation in arteriogenesis. Perivascular
mast cells in turn have been established as key players during collateral remodeling and have been
suggested to act in three ways: (1) by releasing cytokines, which promote the recruitment of growth
factor producing leukocytes, (2) by themselves supplying growth factors for the growing collateral,
and (3) by activating matrix metalloproteases (MMPs), responsible for extracellular matrix remodeling
(Figure 3) [60]. Mast cell degranulation in arteriogenesis has also been shown to be promoted following
eRNA stimulation of endothelial VEGF/VEGFR2 signaling, as RNase1 administration impaired mast
cell degranulation in an in vivo model of arteriogenesis to a comparable degree as VEGFR2 inhibition
and vWF deficiency did without affecting the perivascular mast cell count [3].
ROS ROS
 
Figure 3. (a) PNA (platelet neutrophil aggregate) formation leads to uPA (Urokinase-type plasminogen
activator) mediated neutrophil extravasation and subsequent ROS (reactive oxygen species) release. (b) ROS,
released from neutrophils, initiates mast cell degranulation and consecutive release of cytokines, growth
factors and eRNA in microvesicles. (c) eRNA and cytokine (especially MCP-1) mediated recruitment and
extravasation of monocytes enhances local inflammatory processes leading to (d) collateral artery growth
(arteriogenesis) and extracellular matrix remodeling. The extracellular vessel lumen is depicted in red, EC
in yellow, SMC in orange, and the perivascular space in gray. Arrows indicate the subsequent steps during
arteriogenesis. [EC: endothelial cells; SMC: smooth muscle cells].
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2.3. eRNA Released from Mast Cells Provides a Second Stimulatory Boost for Collateral Remodeling
As previously described, eRNA released by endothelial cells upon cellular stress such as fluid shear
stress has been attributed an essential role as the translator of shear stress into endothelial activation
during the initial stages of collateral remodeling. However, eRNA is rapidly degraded by circulating
RNases and could thus only unfold its actions over a short period of time [37]. Arteriogenesis, on the
contrary, is a chronic process. Mast cells, whose degranulation is stimulated by the downstream effects
of endothelial cell-derived eRNA, also release eRNA in the form of microvesicles concomitantly with
degranulation [44]. This release of eRNA has been shown to promote local inflammatory processes
and leukocyte extravasation [44]. Microvesicles (MV) are a type of extracellular vesicles that have
been described to be released from a variety of cell types including endothelial cells, leukocytes,
platelets and mast cells [78–81], often upon cell stress [82], to be involved in cell communication and
inflammation including during angiogenesis [82,83], and to be selectively enriched with different types
of RNA [84]. Microvesicles/microparticles are generated via budding from the cell membrane and
can reach a diameter of up to 1000 nm, whereas exosomes, another type of extracellular vesicle, are
released via exocytosis and are generally smaller than 100 nm [82]. In the context of arteriogenesis,
this additional release of eRNA in microvesicles might act as a booster of the initial effects mediated
by endothelial cell-derived eRNA. What remains to be determined is the exact mechanism through
which mast cell-derived eRNA unfolds its effects. However, it is plausible that it also stimulates
VEGF/VEGFR2 signaling in endothelial cells. This is supported by the fact that various leukocytes
including neutrophils and monocytes, whose extravasation is critical in arteriogenesis, secrete VEGF
and have been demonstrated to do so in arteriogenesis [22–25]. In addition, treatment of endothelial
cells with MVs derived from mast cells potentiated the release of vWF from endothelial cells just as
endothelial cell-derived eRNA did [44]. Besides acting as a positive feedback mechanism for endothelial
activation, an important effect of mast cell-derived eRNA might also be the stimulation of the expression
of adhesion molecules on endothelial cells as was shown for ICAM-1 in vitro [44]—potentially through
VEGFR2 or NFκB signaling.
Furthermore, eRNA released by mast cells might also directly influence leukocyte adhesion,
transmigration and cytokine/chemokine release such as of TNFα or MCP-1 during arteriogenesis
and might thus amplify the budding local inflammatory response. TNFα is a key pro-inflammatory
cytokine released by a variety of cell types including granulocytes, macrophages and smooth muscle
cells and is able to enhance leukocyte adhesion, coagulation, and endothelial permeability [85–87].
Its ability to promote MCP-1 expression and monocyte extravasation are extremely relevant in
arteriogenesis [88], as is its stimulation of neutrophil and T-cell extravasation [60,89–91]. In a murine
model of peripheral arteriogenesis, the inhibition of TNFα lead to reduced perfusion recovery and, in a
rabbit model, to a decrease in luminal vessel diameter, smooth muscle cell proliferation and leukocyte
extravasation [92,93]. MCP-1 has been established as a major trigger of monocyte recruitment and
accelerator of collateral growth during arteriogenesis [94–97], and key sources of this chemokine
include macrophages, endothelial cells and smooth muscle cells [98–100]. eRNA was found to promote
the release of TNFα from monocytes by activating the TNFα converting enzyme (TACE/ADAM17),
which releases soluble TNFα from its membrane-bound form [101]. The inhibition of TACE reduced
both the eRNA-mediated release of TNFα in vitro and the adhesion of leukocytes following eRNA
administration in vivo [14]. This effect of eRNA on TACE activation in macrophages in vitro was found
to involve NFκB signaling [102]. The effects of eRNA on TACE activity in arteriogenesis have not yet
been explored; however, it would be interesting to see if eRNA released by mast cells could stimulate
the release of TNFα via TACE and thus boost the local inflammatory response. Nevertheless, both
TNFα and eRNA were demonstrated to have similar effects on cell adhesion to the endothelium in
murine cremaster venules in the context of arteriogenesis [3,14]. The stimulatory effect of eRNA on cell
adhesion was abolished by pre-treatment with a VEGFR2 inhibitor (Semaxanib), again highlighting
that eRNA enhances VEGFR2 activation, whereas the TNFα-mediated effect was not diminished by
pre-treatment with Semaxanib [3], since the release of TNFα occurs at a later stage of arteriogenesis
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following VEGFR2 activation and signaling. The expression of MCP-1, on the other hand, was increased
by MV-derived eRNA from mast cells in vitro [44]. eRNA released by mast cells might therefore
activate TACE and thus stimulate TNFα and subsequent MCP-1 release in arteriogenesis, thereby
enhancing the local inflammatory response and leukocyte transmigration. In addition, NFκB, whose
activation can be stimulated by eRNA as previously touched upon, can also induce the expression
of pro-inflammatory cytokines such as TNFα [103], suggesting that mast cell-derived eRNA might
also promote local inflammation through this avenue of signaling. However, the exact ways through
which this second release of eRNA enhances leukocyte extravasation and collateral remodeling during
arteriogenesis still have to be confirmed.
At this point, it is interesting to note that eRNA administration in vitro was shown to prompt a
shift in macrophage polarization towards the pro-inflammatory M1 phenotype with an upregulation
of pro-inflammatory cytokines such as TNFα and a concurrent downregulation of anti-inflammatory
cytokines [104]. In the context of arteriogenesis, the pro-inflammatory M1 macrophage phenotype is
important during the initial stages of vessel remodeling, which would correlate with the release of
eRNA during arteriogenesis and would suggest that the previously described eRNA-induced shift
in macrophage polarization could also occur during arteriogenesis, whilst the anti-inflammatory M2
phenotype is more relevant during later stages of vessel remodeling [105].
3. eRNA in Other Forms of Vessel Growth
The role of eRNA in other forms of vessel growth, namely vasculogenesis and angiogenesis, has
not been studied in great detail so far. In vasculogenesis, tRNA and rRNA were found to stimulate
the formation of new vessels and the leukocyte differentiation of embryonic bodies via increased
VEGF signaling and ROS generation [106]. VEGF signaling is crucial in vasculogenesis [107], and
upon eRNA exposure, the expression of VEGF165, NRP-1 and other hypoxia related factors such as
HIF-1α was increased [106]. ROS formation was also enhanced after eRNA administration [106],
which is significant, since the interplay between intracellular VEGF signaling and ROS generation is a
central issue of embryoid body differentiation [108]. In angiogenesis, the focus has been more on the
stimulatory role of endogenous RNases namely of angiogenin, also known as hRNase5, as a strong
promoter of endothelial cell proliferation through its effects on rRNA and ribosome synthesis and its
regulatory role in translation during cellular stress [109,110].
4. Conclusions
The remodeling of pre-existing arteriolar collaterals during arteriogenesis is a complex process
requiring the highly-coordinated interplay of different leukocytes to promote endothelial and smooth
muscle cell proliferation and to ultimately establish perfusion. eRNA has been demonstrated to
translate fluid shear stress into endothelial activation during arteriogenesis, further stimulating vWF
release, PNA formation, mast cell degranulation and leukocyte recruitment, culminating in the
beneficial process of arteriogenesis to promote perfusion recovery. In contrast to the beneficial role of
eRNA in arteriogenesis, eRNA has been formerly established as a damaging or pathological factor in a
variety of cardiovascular diseases based upon its modulation of endothelial cell and leukocyte function,
whereby administration of RNase1 was demonstrated to serve as a tissue- and vessel-protective
regimen. It remains to be established which particular molecular interactions and binding partners as
well as which putative cellular receptors for eRNA appear to be responsible for its either adverse or
beneficial functions in the cardiovascular system.
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Abbreviations
ADAMTS13 A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13
eRNA Extracellular RNA
ICAM-1 Intercellular adhesion molecule 1
Mac-1 Macrophage-1 antigen
MCP-1 Monocyte chemoattractant protein 1
MMP Matrix metalloprotease
MV Microvesicle
NFkB Nuclear factor kB
Nox2 NADPH oxidase 2
NRP-1 Neuropilin-1
PECAM-1 Platelet endothelial cell adhesion molecule 1
PLC Phospholipase C
PNA Platelet-neutrophil aggregate
ROS Reactive oxygen species
TACE TNFa converting enzyme
TNFa Tumor necrosis factor a
uPA Urokinase-type plasminogen activator
VE-cadherin Vascular endothelial cell cadherin
VEGF Vascular endothelial growth factor
VEGFR2 Vascular endothelial growth factor receptor 2
vWF Von Willebrand factor
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Abstract: Arteriogenesis, the growth of a natural bypass from pre-existing arteriolar collaterals, is an
endogenous mechanism to compensate for the loss of an artery. Mechanistically, this process relies
on a locally and temporally restricted perivascular infiltration of leukocyte subpopulations, which
mediate arteriogenesis by supplying growth factors and cytokines. Currently, the state-of-the-art
method to identify and quantify these leukocyte subpopulations in mouse models is immunohistology.
However, this is a time consuming procedure. Here, we aimed to develop an optimized protocol to
identify and quantify leukocyte subpopulations by means of flow cytometry in adductor muscles
containing growing collateral arteries. For that purpose, adductor muscles of murine hindlimbs were
isolated at day one and three after induction of arteriogenesis, enzymatically digested, and infiltrated
leukocyte subpopulations were identified and quantified by flow cytometry, as exemplary shown
for neutrophils and macrophages (defined as CD45+/CD11b+/Ly6G+ and CD45+/CD11b+/F4/80+
cells, respectively). In summary, we show that flow cytometry is a suitable method to identify and
quantify leukocyte subpopulations in muscle tissue, and provide a detailed protocol. Flow cytometry
constitutes a timesaving tool compared to histology, which might be used in addition for precise
localization of leukocytes in tissue samples.
Keywords: peripheral arterial disease; arteriogenesis; shear stress; flow cytometry; leukocytes;
immunohistology; inflammation; collateral artery growth
1. Introduction
Peripheral occlusive diseases, including atherosclerosis, myocardial infarction and stroke,
are a wide spectrum of arterial-based pathologies, reported as one of the leading causes of death
worldwide [1]. Currently, the therapeutic options mainly consist of surgical interventions such as
Int. J. Mol. Sci. 2020, 21, 3593; doi:10.3390/ijms21103593 www.mdpi.com/journal/ijms55
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balloon dilatation and stent implantation, as well as bypass surgery [2]. However, the body possesses
an endogenous mechanism to compensate for stenosis and obstructions by forming natural bypasses.
This process is called arteriogenesis [3]. Understanding the mechanisms of arteriogenesis can help to
design new therapeutic options to accelerate the process of arteriogenesis in patients with the final aim
of minimizing invasive interventions and avoiding amputation.
Previous studies, predominantly performed on murine hindlimb models [4], showed that
arteriogenesis essentially depends on the recruitment of leukocytes to the perivascular space,
where these cells subsequently supply growth factors for collateral remodeling [5,6]. At present,
immunohistochemical (IHC) staining is the technique of choice for analyzing and quantifying the
leukocyte subpopulations involved in this process. However, this method is very time-consuming.
Analysis by flow cytometry offers an elegant and time-saving alternative to IHC especially in regard to
the quantification of leukocytes.
2. Materials
2.1. Mice
C57BL/6J, 8–12 weeks old male mice from Charles River were used. Animal studies were conducted
in compliance with ethical standards and with the approval of the Government of Upper Bavaria,
Germany. Mice were anesthetized with the standard solution of fentanyl (0.05 mg/kg), midazolam
(5 mg/kg) and medetomidine (0.5 mg/kg) applied subcutaneously (s.c.). To antagonize the narcosis,
a combination of naloxone (1.2 mg/kg), flumazenile (0.5 mg/kg) and atipamezole (2.5 mg/kg) was
applied s.c. To prevent postsurgical pain, mice were treated with buprenorphine (0.05 mg/kg) every
12 h until day 3.
2.2. Reagents
• Fentanyl (CuraMED Pharma, Karlsruhe, Germany)
• Midazolam (Ratiopharm GmbH, Ulm, Germany)
• Medetomidine (Pfizer Pharma, Berlin, Germany)
• Buprenorphine (Reckitt Benckiser Healthcare, London, UK)
• Naloxone (Inresa Arzneimittel GmbH, Freiburg, Germany)
• Flumazenile (Inresa Arzneimittel GmbH, Freiburg, Germany)
• Atipamezole (Zoetis, Berlin, Germany)
• Phosphate buffered saline (PBS, Sigma-Aldrich, Taufkirchen, Germany, cat. D8537)
• 1% fetal bovine serum (FBS, Sigma-Aldrich, Taufkirchen, Germany, cat. F7524)
• Ethylenediaminetetraaceticacid (EDTA, Invitrogen, Waltham, MA, USA, cat. 15575020)
• 0.02% sodium azide (Sigma-Aldrich, Taufkirchen, Germany, cat. 71289)
• Collagenase IV (10,000 U/ml, Worthington, Freehold, NJ, USA, cat. CLS4)
• DNase I (20 mg/ml, Roche, Penzberg, Germany, cat. 11284932001)
• RPMI 1640 medium (Gibco, Dubline, Ireland, cat. 31870-074)
• Percoll (GE Healthcare, Chicago, IL, USA, cat. 17-0891-01)
• Hank’s Balanced Salt solution (HBSS, Sigma-Aldrich, Taufkirchen, Germany, cat. H9394-500ML)
• Mounting medium (Thermo Fisher Scientific, Schwerte, Germany, cat. TA-030-FM)
• 4% paraformaldehyde (PFA, Morphisto, Frankfurt am Main, Germany, cat. 1176.00500)
The following antibodies were used for flow cytometry:
• PE/Cy7 anti-mouse CD45.2 (Biolegend, Eching, Germany, cat. 109829, clone: 104, 1/300 dilution)
• BUV737 anti-CD11b (BD Biosciences, Heidelberg, Germany, cat. 564443, clone: M1/70,
1/800 dilution)
56
Int. J. Mol. Sci. 2020, 21, 3593
• Brilliant Violet 785 anti-mouse F4/80 (Biolegend, Eching, Germany, cat. 123141, clone: BM8,
1/100 dilution)
• PerCP/Cy5.5 anti-mouse Ly6G (Biolegend, Eching, Germany, cat. 127615, clone: 1A8,
1/300 dilution)
• Anti-CD16/32 (BD Biosciences, Heidelberg, Germany, cat. 553142, clone: 2.4G2, 1/300 dilution)
• DAPI (4’, 6-diamidin-2-phenylindole, Sigma-Aldrich, Taufkirchen, Germany, Cat. D9542-5MG,
1/1000 dilution)
The following antibodies were used for immunohistological staining:
• Neutrophils (Ly6G, eBiosciences, San Diego, CA, USA, cat. 16-9668-82, 1/50 dilution)
• Macrophages (CD68-AF488, Abcam, Cambridge, UK, cat. ab201844, 1/100 dilution)
• Endothelial cells (CD31-AF647, BioLegend, cat. 102516, 1/50 dilution)
• Anti-mouse AF546 secondary antibody (Invitrogen, Waltham, MA, USA, cat. A11081,
1/200 dilution)
The following equipment were employed for measurements:
• Bijou sample container (Sigma-Aldrich, Taufkirchen, Germany, cat. Z645338-700EA)
• Scissors (Fine Science Tools, Heidelberg, Germany, cat. 812005-10)
• Falcon tubes 15mL and 50mL (Thermo Fisher Scientific, cat. 10468502/10788561)
• Falcon cell strainer (Thermo Fisher Scientific, cat. 352350)
• 96 well plate (V-bottom, Costar, Schwerte, Germany, cat. 3897)
2.3. Flow Cytometry
Flow cytometry measurements were performed using BD LSRFortessa (BD Biosciences) and
analyzed on BD FACSDiva v8.0 and FlowJo-v10 software (BD Biosciences).
2.4. Immunohistochemical Analysis
Images were acquired using a Zeiss epifluorescent microscope (Carl Zeiss Microscopy GmbH,
Munic, Germany) and analyzed using AxioVisionRel 4.8 software (Carl Zeiss Microscopy GmbH).
3. Methods
3.1. Reagent Preparation
For flow cytometric cell analysis, the following reagents were prepared: FACS buffer, enzyme
solution, and three gradient Percoll solutions.
The FACS buffer was prepared as a solution of PBS, 1% fetal bovine serum, 2.5 mM EDTA and
0.02% sodium azide.
Two-fold concentrated enzyme solution was prepared using a solution of collagenase IV and DNase
I at a concentration of 400 U/ml (collagenase IV) and 0.4 mg/mL (DNase I) in RPMI-1640, respectively.
For isotonic Percoll stock solution, 45 mL Percoll and 5 mL 10× PBS were mixed. The solution
was then prepared in three concentrations (70%, 37% and 30%). For 70% and 30% Percoll, the prepared
Percoll stock solution was diluted with Hank’s Balanced Salt solution with phenol red. For 37%
Percoll, the prepared Percoll stock solution was diluted with PBS. Different diluents were used for easy
recognition of phases.
3.2. Surgical Procedure for Artery Ligation and Tissue Collection
The murine hindlimb ischemia model is a widely used mouse model to study arteriogenesis
in detail [7]. The femoral artery of the right leg is ligated, while the left leg is sham operated and
serves as an internal control [8]. After femoral artery ligation (FAL), the blood flow is redirected into
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preexisting arteriolar connections, which thereupon experience increased shear stress [9,10], and results
in perivascular recruitment of leukocytes supplying growth factors and cytokines to the growing
vessels [5,6].
Depending on the experimental setup, the muscle tissue, in which collaterals are located, can be
removed at various time points after arterial occlusion. To analyze the numbers and subpopulations of
recruited leukocytes, we have chosen two time points: day 1 and day 3 after femoral artery ligation.
For this purpose, the hindlimbs of the mice were perfused with FACS buffer via an aortic catheter
(inserted distal to the outlet of the renal arteries). Thereafter, the adductor muscle of the mouse was
removed along the dashed line as shown in Figure 1, whereby the femoral artery (FA) and profunda
femoris artery (PA) were omitted from isolation. The muscle section was immediately rinsed with
FACS buffer and further processed on ice.
Figure 1. Tissue sampling on the right hindlimb of a C57BL/6J mouse. The part of the M. adductor
containing the collaterals (arrows) was extracted along the dashed line. The collaterals connect the
profunda femoris artery (PA) to the femoral artery (FA). The epigastric artery (EA) serves as orientation
for the ligation. Scale bar 1 mm.
3.3. Stepwise Preparation of a Single Cell Suspension from Collected Tissues
To prepare a single cell suspension for flow cytometric analysis, collected tissue samples were
processed using the following protocol:
1. Place the muscle tissue (isolated from one hindlimb) in a bijou vial containing 1 mL of RPMI
medium and finely cut the muscle with microsurgical scissors.
2. Add 1 mL of enzyme solution to digest the tissue (final concentration of collagenase IV and
DNase I are 200 U/mL and 0.2 mg/mL, respectively).
3. Incubate the tube in a laboratory shaker for 1 h at 37 ◦C with 120 rpm.
4. Filter the digested tissue through a 70 μm cell strainer and fill up to 50 mL with FACS buffer.
5. Centrifuge the cells for 5 min at 4 ◦C with 420 g, then carefully discard the supernatant.
6. Resuspend the cell pellet in 4 mL of 70% Percoll.
7. Gently cover the solution with 4 mL of 37% Percoll followed by 1 mL of 30% Percoll.
8. Centrifuge for 30 min at room temperature with 940 g. Centrifuge acceleration and braking
should be set to minimum to avoid disintegration of the Percoll gradient.
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9. Remove the interphase cells located between the 70% and 37% phases, transfer them to a 15 mL
Falcon tube and fill up to 15 mL with the FACS buffer.
10. Centrifuge the cells for 5 min at 4 ◦C with 420 g, then discard the supernatant.
11. Resuspend the cells in 100 μl FACS buffer for further processing (if the leukocyte subpopulation
of interest is not frequent, cells from mice of the same group can be pooled).
3.4. Cell Staining for Flow Cytometry
For cell staining, the single cell suspension that was prepared from collected tissues was processed
using the following protocol:
1. Transfer the cell suspension to a 96-well V-bottom plate.
2. Centrifuge the cells for 5 min at 4 ◦C with 420 g, then discard supernatant by decantation.
3. Resuspend the cells in 50 μL Fc-Block (FACS buffer containing 1.6 μg/mL anti-CD16/32).
4. Incubate for 10 min at 4 ◦C.
5. Add 50 μL of a two-fold concentrated staining solution (50μL FACS buffer with anti-CD45.2,
anti-CD11b, anti-Ly6G and anti-F4/80).
6. Incubate the solution for 20 min at 4 ◦C in the dark.
7. Centrifuge for 5 min at 4 ◦C with 420 g, then discard the supernatant.
8. Resuspend the cells twice in 200 μL FACS buffer.
9. Centrifuge for 5 min at 4 ◦C with 420 g, then discard the supernatant.
10. Resuspend the stained cells in 100 μL FACS buffer.
11. Add 1 μL of 20 μg/mL DAPI in PBS to the cell suspension just before the measurement.
12. Analyze the cell suspension using a flow cytometer.
3.5. Immunohistochemical Staining
Adductor muscle tissue samples were collected after perfusion as previously described [8].
For staining, 10 μm thick frozen sections were used. The following protocol for staining was used:
1. Fix the sections in 4% PFA for 5 min.
2. Wash the sections in PBS for 5 min, repeat twice.
3. Add blocking buffer (1% BSA in PBST) to sections to prevent nonspecific binding.
4. Incubate for 30 min at room temperature.
5. Dilute the primary antibodies against all leukocytes, macrophages, neutrophils and endothelial
cells in blocking buffer.
6. Incubate the sections in a humidified dark chamber at 4 ◦C overnight.
7. Wash the sections in PBS for 5 min, repeat twice.
8. Incubate the sections with anti-mouse AF546 secondary antibody (only for CD45 and Ly6G) for
1 h at room temperature.
9. Wash the sections in PBS for 5 min, repeat twice.
10. Follow the overnight incubation with antibody against endothelial cells.
11. Wash the sections in PBS for 5 min, repeat twice.
12. Incubate the sections with DAPI for 10 min at room temperature.
13. Wash the sections in PBS for 5 min, repeat twice.
14. Fix the sections with mounting medium, then store at 4 ◦C.
3.6. Statistical Analyses
Statistical analysis was performed using GraphPad Prism v. 8 software. Data are mean ± standard
error of the mean (S.E.M.). Significances between two time points were calculated by unpaired student’s
t-test. p < 0.05 was considered statistically significant.
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4. Results
Figure 2a shows the gating strategy used for the identification of leukocyte subpopulations,
i.e., neutrophils and macrophages. First, we gated on leukocytes based on forward scatter (FSC) and
side scatter (SSC) properties and excluded small cell debris. Next, we gated on single cells by plotting
the height against the area for forward scatter (FSC-H vs FSC-A), and the width for side scatter against
the area for forward scatter (SSC-W vs FSC-A). After doublets exclusion, we distinguished live cells
(identified as DAPI negative) CD45.2+ leukocytes. Within live leukocytes we identified CD11b+ and
Ly6G+ neutrophils, CD11b+ and F4/80+ macrophages. The proportion of neutrophils and macrophages
were quantified on day 1 and 3 after ligation (Figure 2b). IHC staining demonstrated a localization of
neutrophils and macrophages in the perivascular space of growing collateral arteries in the adductor
muscle of mice as exemplary shown for day 3 after induction of arteriogenesis by FAL (Figure 2c).
a
b c
Figure 2. Gating strategy of flow cytometry and immunohistological analyses. (a) Sequential
gating strategy for the identification of neutrophils (CD45.2+CD11b+Ly6G+) and macrophages
(CD45.2+CD11b+F4/80+) in the murine adductor muscle containing growing collateral arteries at
day 1 after FAL. (b) Bar graphs showing the frequencies of neutrophils and macrophages at day
1 and day 3 after FAL. n = 3 mice/group, data are represented as mean ± S.E.M., * p < 0.05 from
unpaired student’s t-test. (c) Representative immunohistochemical stains demonstrate the presence
of neutrophils (Ly6G+) and macrophages (CD68+) (indicated by arrows) in the perivascular space of
growing collaterals in the adductor muscle of a mouse 3 days after FAL. Collaterals were stained with
an endothelial marker (CD31) and nuclei with DAPI. Scale bar 20 μm.
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5. Conclusions
Flow cytometry is an effective and high-throughput method to analyze and quantify infiltrated
leukocyte subpopulations in muscle tissue. If necessary, it can be supplemented by IHC studies on the
localization of those leukocytes.
The protocol includes some limitations. Inadequate perfusion of the animals may be associated
with residuals of leukocyte in vessels, resulting in inconsistent data. Poor enzymatic muscle digestion
may lower the cell yield. In addition, cell preparation that involves washing and centrifugation might
lead to cell loss of an unknown extent.
However, when accurately performed, flow cytometry is an elegant method that can be used to
complement results obtained from histological analysis, especially those pertaining to cell differentiation
and cell counting. Further, flow cytometric analysis gives the possibility to calculate the absolute
number of leukocytes per mg muscle tissue by the addition of counting beads to the cell suspension.
With the increasing functions of flow cytometers, the further development of tissue extraction methods
as well as the capacity to stain various markers on cell surfaces and in the cell interior, the application
spectrum of flow cytometry is extremely broad.
Author Contributions: Conceptualization, K.K., N.S., S.B., S.R. and E.D.; methodology, K.K., N.S., S.R. and
L.R.; validation, K.K., N.S., S.R., L.R. and B.U.S.; investigation, K.K., N.S., S.R. and L.R.; data curation, K.K.;
writing—original draft preparation, K.K., N.S., S.R., and S.B.; writing—review and editing, N.S., S.R., A.-K.K.,
M.L., L.R., B.U.S. and E.D.; supervision, B.U.S., E.D.; project administration, B.U.S. and E.D.; funding acquisition,
B.U.S. and E.D. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by the Lehre@LMU program (A.-K.K., E.D.) and the Förderprogramm für
Forschung und Lehre (FöFoLe) (S.B., E.D.) from the LMU Munich. The work in the Schraml lab was supported
by the German Research Foundation (Emmy Noether grant: Schr 1444/1-1; and project number 360372040—SFB
1335—project 8, to Schraml) and the European Research Council (ERC-2016-STG-715182).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
IHC immunohistochemical
FACS Fluorescence Activated Cell Sorting
FA femoral artery
FAL femoral artery ligation





1. WHO. Global Health Estimates 2016: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000–2016;
World Health Organiozation: Geneva, Switzerland, 2018.
2. Shishehbor, M.H.; Jaff, M.R. Percutaneous Therapies for Peripheral Artery Disease. Circulation 2016, 134,
2008–2027. [CrossRef] [PubMed]
3. Schaper, W.; Scholz, D. Factors regulating arteriogenesis. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1143–1151.
[CrossRef] [PubMed]
4. Troidl, C.; Jung, G.; Troidl, K.; Hoffmann, J.; Mollmann, H.; Nef, H.; Schaper, W.; Hamm, C.W.;
Schmitz-Rixen, T. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis.
Curr. Vasc. Pharmacol. 2013, 11, 5–12. [CrossRef] [PubMed]
5. Arras, M.; Ito, W.D.; Scholz, D.; Winkler, B.; Schaper, J.; Schaper, W. Monocyte activation in angiogenesis and
collateral growth in the rabbit hindlimb. J. Clin. Investig. 1998, 101, 41–50. [CrossRef] [PubMed]
6. Chillo, O.; Kleinert, E.C.; Lautz, T.; Lasch, M.; Pagel, J.I.; Heun, Y.; Troidl, K.; Fischer, S.; Caballero-Martinez, A.;
Mauer, A.; et al. Perivascular Mast Cells Govern Shear Stress-Induced Arteriogenesis by Orchestrating
Leukocyte Function. Cell Rep. 2016, 16, 2197–2207. [CrossRef]
61
Int. J. Mol. Sci. 2020, 21, 3593
7. Aref, Z.; de Vries, M.R.; Quax, P.H.A. Variations in Surgical Procedures for Inducing Hind Limb Ischemia in
Mice and the Impact of These Variations on Neovascularization Assessment. Int. J. Mol. Sci. 2019, 20, 3704.
[CrossRef] [PubMed]
8. Limbourg, A.; Korff, T.; Napp, L.C.; Schaper, W.; Drexler, H.; Limbourg, F.P. Evaluation of postnatal
arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat. Protoc. 2009, 4, 1737–1746.
[CrossRef] [PubMed]
9. Lasch, M.; Nekolla, K.; Klemm, A.H.; Buchheim, J.I.; Pohl, U.; Dietzel, S.; Deindl, E. Estimating hemodynamic
shear stress in murine peripheral collateral arteries by two-photon line scanning. Mol. Cell. Biochem. 2019,
453, 41–51. [CrossRef] [PubMed]
10. Pipp, F.; Boehm, S.; Cai, W.J.; Adili, F.; Ziegler, B.; Karanovic, G.; Ritter, R.; Balzer, J.; Scheler, C.;
Schaper, W.; et al. Elevated fluid shear stress enhances postocclusive collateral artery growth and gene
expression in the pig hind limb. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1664–1668. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
62
 International Journal of 
Molecular Sciences
Article
IL10 Alters Peri-Collateral Macrophage Polarization
and Hind-Limb Reperfusion in Mice after Femoral
Artery Ligation
Alexander M. Götze 1,*, Christian Schubert 2, Georg Jung 3, Oliver Dörr 4, Christoph Liebetrau 5,
Christian W. Hamm 5, Thomas Schmitz-Rixen 3, Christian Troidl 4,† and Kerstin Troidl 2,3,†
1 Department of Trauma-, Hand- and Reconstructive Surgery, Johann-Wolfgang-Goethe-University,
60590 Frankfurt am Main, Germany
2 Max-Planck Institute for Heart- and Lung-Research, 61231 Bad Nauheim, Germany;
christian.schubert@mpi-bn.mpg.de (C.S.); kerstin.troidl@mpi-bn.mpg.de (K.T.)
3 Department of Vascular and Endovascular Surgery, Johann-Wolfgang-Goethe-University,
60590 Frankfurt am Main, Germany; Georg.Jung@kgu.de (G.J.); schmitz-rixen@em.uni-frankfurt.de (T.S.-R.)
4 Department of Cardiology, Justus-Liebig-University, 35392 Gießen, Germany;
oliver.doerr@innere.med.uni-giessen.de (O.D.); c.troidl@kerckhoff-fgi.de (C.T.)
5 Department of Cardiology, Kerckhoff Heart and Thorax Center, 61231 Bad Nauheim, Germany;
c.liebetrau@kerckhoff-klinik.de (C.L.); c.hamm@kerckhoff-klinik.de (C.W.H.)
* Correspondence: a.goetze@icloud.com; Tel.: +49-172-2363336
† These authors contributed equally to this work.
Received: 31 March 2020; Accepted: 15 April 2020; Published: 17 April 2020
Abstract: Arteriogenesis is a process by which a pre-existing arterioarterial anastomosis develops into
a functional collateral network following an arterial occlusion. Alternatively activated macrophages
polarized by IL10 have been described to promote collateral growth. This study investigates the effect
of different levels of IL10 on hind-limb reperfusion and the distribution of perivascular macrophage
activation types in mice after femoral artery ligation (FAL). IL10 and anti-IL10 were administered
before FAL and the arteriogenic response was measured by Laser-Doppler-Imaging perioperatively,
after 3, 7, and 14 d. Reperfusion recovery was accelerated when treated with IL10 and impaired
with anti-IL10. Furthermore, symptoms of ischemia on ligated hind-limbs had the highest incidence
after application of anti-IL10. Perivascular macrophages were immunohistologically phenotyped
using CD163 and CD68 in adductor muscle segments. The proportion of alternatively activated
macrophages (CD163+/CD68+) in relation to classically activated macrophages (CD163−/CD68+)
observed was the highest when treated with IL10 and suppressed with anti-IL10. This study
underlines the proarteriogenic response with increased levels of IL10 and demonstrates an in-vivo
alteration of macrophage activation types in the perivascular bed of growing collaterals.
Keywords: arteriogenesis; collateral artery; macrophages; macrophage polarization; M2 macrophages; IL10
1. Introduction
Arteriogenesis is the process by which a pre-existing arterioarterial anastomosis develops into a
functional collateral network following an arterial occlusion. The remodeling processes involved in
collateral vessel growth are complex and are dependent on mechanical, cellular and molecular factors [1].
Several authors have demonstrated the pertinence of monocytes and macrophages in enhancing
collateral vessel growth [1–3]. While there is still debate over whether perivascular macrophages are
recruited from circulating monocytes or tissue resident precursors, their proarteriogenic effects, however,
are still evident [4–6]. Macrophage activation types have become a growing focus in arteriogenesis
research, in particular alternatively activated macrophages [7]. Macrophage heterogeneity and
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plasticity are reflected by their ability to respond to environmental cues giving rise to a spectrum
of distinct functional phenotypes or activation states, fulfilling a variety of functions. The extremes
of these functional states are commonly defined as M1, M2, or M2-like polarized macrophages [8].
M1 or classically activated macrophages induced by LPS, IFN-γ, and TNF are associated with
inflammation and tumor resistance. They differ from M2 macrophages with regard to their arginine
metabolism by exhibiting high levels of iNOS and subsequent NO-synthesis, as well as the production
of proinflammatory cytokines and chemoattractant proteins. M2/M2-like or alternatively activated
macrophages induced by IL4/IL13, immune complexes, agonists of TLR or IL1R, glucocorticoids and
IL10, on the other hand, regulate inflammatory responses and promote tissue remodeling, angiogenesis
and tumor progression [9]. They are characterized by their arginase/ornithine production, a precursor of
cell proliferation, collagen production and ECM remodeling, and the production of anti-inflammatory
cytokines [9,10]. While both M1 and M2 macrophages have been shown to contribute to collateral
vessel growth, a systemic modulation of known activators of macrophage differentiation demonstrated
a determinate proarteriogenic role of M2 macrophages induced by IL10 [11]. This M2 activation
phenotype, also referred to as M2c, not only acts as a regulator of immune responses but also as an
effector cell of tissue remodeling and repair [9]. It is important to note that the M1/M2 taxonomy
of macrophages only represents a limited attempt to categorize the vast variety of functional states
observed in vitro. In vivo, this M1/M2 paradigm undermines the complexity of macrophage plasticity
and diversity. Functional and phenotypical characteristics of M1 and M2 activation states are not
limited to but may instead be shared by more than one macrophage population, allowing them to
cater to situational and tissue specific needs. This dogma change has created the need to explore other
classifications that more appropriately reflect macrophage behavior in vivo and are subject of current
research [12]. Jetten et al. [6] showed that collateral growth was unaffected in mice with a deletion of
the IL10 receptor on myeloid cells (IL10Rfl/fl/LysMCre+), arguing that the M2c activation phenotype is
not required in arteriogenesis. When treated with exogenously polarized M2c macrophages, however,
an improved reperfusion of collateral vessels compared to untreated IL10Rfl/fl/LysMCre+ mice was still
observed. As such, this study investigates the in vivo effect of varying levels of IL10 on arteriogenesis
as well as the distribution of macrophage activation types around growing collateral vessels.
2. Results
2.1. Modulation of Blood Concentration Levels of IL10 after Pharmacological Stimulation with IL10 and Anti-IL10
To investigate whether blood concentration levels of endogenous IL10 were affected by an
intravenous administration of IL10 or anti-IL10 via tail vein injection, a Mouse Magnetic Luminex
Assay was used to determine the blood concentration levels of IL10 prior to (baseline, BL) and 24 h (24 h)
after the respective treatments. A control group received NaCl 0.9%. At BL, blood concentration levels
of IL10 were below the detection limit of 1.59 pg/mL in all groups. At 24 h, elevated blood concentration
levels of IL10 were found only in the IL10 treatment group with 6.35 ± 2.20 pg/mL (p < 0.05), indicating
that an external administration of IL10 leads to a sustainable change in endogenous blood concentration
levels of IL10 for at least 24 h when applied via tail vein injection. Blood concentration levels of IL10 in
mice treated with anti-IL10 or NaCl 0.9% remained below the detection limit (Figure 1).
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Figure 1. Modulation of blood concentration levels of IL10 after pharmacological stimulation with IL10
and anti-IL10. IL10, anti-IL10, and NaCl were administered via tail vein injection. Blood concentration
levels of IL10 were measured before (baseline, BL) and 24 h after pharmacological stimulation. At BL
endogenous IL10 levels were below the detection limit of 1.59 pg/mL in all subjects. After an external
administration of IL10, blood concentration levels remained significantly increased after 24 h. An effect
of anti-IL10 could not be detected, as baseline levels of IL10 remained below the detection limit.
* indicates p < 0.05; n = 3 in each group.
2.2. Alteration of Macrophage Polarization in the Perivascular Bed of Growing Collateral Vessels after
Pharmacological Stimulation with IL10 and Anti-IL10
Adductor muscle samples were harvested 3 days (3 d) and 7 d after FAL to analyze the effect
of a treatment with IL10 and anti-IL10 on the polarization of macrophages in the perivascular bed
of growing collateral vessels. The samples were sectioned and stained using antibodies targeting
known macrophage markers CD68 and CD163 [11,13] (Figure 2a). The two largest collateral vessels
of each section were selected and the ratio of macrophages of the alternatively activated phenotype
CD163+/CD68+ to the classically activated phenotype CD163−/CD68+ per visual field was calculated.
Mice treated with NaCl had a median ratio of CD163+/CD68+ to CD163−/CD68+ macrophages of 0.46
(IQR: 0.37–1.20) on day 3 (3 d) and 0.40 (IQR: 0.37–0.55) 7 d after FAL. When treated with IL10 the ratio
is skewed towards the alternatively activated phenotype on both 3 d and 7 d after FAL with a ratio of
1.00 (IQR: 0.45–1.44) and 1.19 (IQR: 0.52–1.69). Contrariwise, the ratio is skewed towards the classically
activated phenotype after application of anti-IL10 on both 3 d and 7 d after FAL with a ratio of 0.25
(IQR: 0.18–0.35) and 0.27 (IQR: 0.00–0.53), differing significantly from that of the IL10 treatment group
(p < 0.05) (Figure 2b).
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Figure 2. Alteration of macrophage polarization in the perivascular bed of growing collateral vessels
after pharmacological stimulation with IL10 and anti-IL10. (a) Confocal micrographs of macrophage
differentiation subtypes 3 d and 7 d after FAL. Sections of adductor muscles segments containing
growing collateral vessels (V) were stained using DAPI and macrophage differentiation markers
CD68 and CD163. The ratio of the alternatively (CD163+/CD68+) activated phenotype, indicated by
white arrows, and classically (CD163−/CD68+) activated phenotype varies with indicated application.
Scale bar: 25μm. (b) Quantification of macrophage polarization in the perivascular bed of growing
collateral vessels after pharmacological stimulation with IL10 and anti-IL10 3 d and 7 d after FAL.
The distribution of macrophage subtypes was skewed towards the alternatively activated phenotype
after IL10 application. When anti-IL10 was injected, the opposite effect was observed, and the
distribution was skewed towards the classically activated phenotype. * indicates p < 0.05; 3 d: n = 6 in
each group; d7: NaCl and IL10 n = 4, anti-IL10: n = 6.
2.3. Evaluation of Hind-Limb Perfusion Recovery after FAL and Pharmacological Stimulation with IL10 and
Anti-IL10
To assess the effect of varying blood concentration levels of IL10 on growing collateral vessels
IL10 and anti-IL10 were externally applied in mice after FAL. Hind-limb perfusion was assessed using
Laser-Doppler-Imaging before and shortly after FAL, on 3 d, 7 d, and 14 d and compared to a control
group receiving NaCl. Immediately after FAL an acute reduction of hind-limb perfusion was observed
in all groups (NaCl: 0.13 ± 0.01, IL10: 0.16 ± 0.03, anti-IL10: 0.13 ± 0.01). Hind-limb reperfusion
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in the NaCl (n = 6) group showed an adequate increase to 0.34 ± 0.04, 0.62 ± 0.07, and 0.62 ± 0.07
on 3 d, 7 d, and 14 d respectively. Elevated blood concentration levels of IL10 led to a significantly
higher hind-limb perfusion on 3 d and 14 d (n = 5, 3 d: 0.54 ± 0.09, p < 0.05, 14 d: 0.83 ± 0.7, p < 0.05).
Although hind-limb perfusion on 7 d was elevated compared to the control group, the difference was
not significant (0.77 ± 0.09, p = 0.07) (Figure 3a). Contrariwise, application of anti-IL10 showed a
significant impairment of hind-limb perfusion on 7 d (n = 5, 0.42 ± 0.4, p < 0.05). On 3 d and 14 d,
however, no significant difference was observed (3 d: 0.35 ± 0.05, p = 0.86, 14d: 0.61 ± 0.07, p = 0.89)
(Figure 3b).
Figure 3. Evaluation of hind-limb perfusion recovery after femoral artery ligation (FAL) and application
of IL10 and anti-IL10 (L/R ratio). Hind-limb perfusion was measured prior to and immediately after FAL,
on 3 d, 7 d and 14 d. (a) IL10 led to a significant acceleration of hind-limb perfusion recovery on 3 d
(IL10: 0.54 ± 0.09 vs. NaCl: 0.34 ± 0.04, p < 0.05) and 14 d (IL10: 0.83 ± 0.07 vs. NaCl: 0.62 ± 0.07,
p < 0.05) while (b) anti-IL10 led to a brief but significant impairment of hind-limb perfusion recovery
on 7 d (anti-IL10: 0.42 ± 0.04 vs. NaCl: 0.62 ± 0.07, p < 0.05). (c) Representative Laser-Doppler-Images
of ligated and non-ligated hind-limbs. *indicates p < 0.05; NaCl: n = 6, IL10 and anti-IL10: n = 5.
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2.4. Macroscopic Observations on Ligated Hind-Limbs after FAL and Application of IL10 and Anti-IL10
Ligated hind-limbs were inspected prior to FAL, 3 d and 7 d after FAL. Macroscopic observations
associated with an acute ischemia of the affected hind-limb, termed critical ischemic events (CIE),
were recorded after FAL and treatment with IL10 and anti-IL10. CIE were categorized as follows:
inflamed hind-limb, necrotic digits, necrotic hind-limb and amputation. In total (n = 115) CIE occurred
in 20%. Necrotic digits were observed most frequently in 65%, followed by a necrotic hind-limb in 17%,
an amputation in 13% and an inflamed hind-limb in 4% of CIE. The highest incidence of CIE was
observed after application of anti-IL10 (anti-IL10: 37.1% vs. NaCl: 11.1% p < 0.01). The incidence of
CIE when treated with IL10 was similar to the control group (IL10: 13.6% vs. NaCl: 11.1% p = 0.73)
(Figure 4).
 
Figure 4. After FAL and pharmacological stimulation with IL10 or anti-IL10 the onset of critical
ischemic events (CIE) were recorded. The highest incidence of CIE was observed after application of
anti-IL10 (anti-IL10: 37.1% vs. NaCl: 11.1% p < 0.01, IL10: 13.6%). **indicates p < 0.01; NaCl: n = 36,
IL10: n = 44, anti-IL10: n = 35
3. Discussion
In this study we have shown that modulation of IL10, in particular elevated levels of circulating IL10,
alters collateral reperfusion after femoral artery ligation (FAL) as well as the distribution of macrophage
activation types in the perivascular bed of growing collaterals. Although, the inhibitory effect of an IL10
antibody on circulating IL10 blood levels could not be directly detected due to technical limitations,
contrary to elevated levels of circulating IL10, the opposite pertaining to both collateral reperfusion
and the distribution of macrophage activation types was observed. The remodeling processes in
arteriogenesis involve a controlled destruction of vessel components, activation of endothelial and
smooth muscle cell de-differentiation, proliferation and migration, and adventitial restructuring in
which monocytes/macrophages were shown to be key orchestrators [1,14]. These seemingly disparate
tasks mediated largely by a singular cell type are explained by their heterogeneity and plasticity in
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response to environmental and situational needs. Previous findings have demonstrated that M1 and
M2 macrophages form around growing collateral vessels in a distinct temporal and spatial pattern
suggesting a collaborative mechanism of action in collateral artery growth [11]. The M1 phenotype,
found proximate to the vessel lumen, is associated with the production of the pro-inflammatory
cytokines IL1 and IL6, both described to have autocrine growth effects on vascular smooth muscle cells
(VSMC) [15]. Other arteriogenic stimulants expressed by the M1 phenotype include NOS, TNF and
MCP-1 [1,2,15,16]. M2 macrophages, on the other hand, are found distal to the vessel lumen [11] and
have been ascribed a more prominent role in mediating the growth processes. Takeda et al. [7] showed
that improved collateral perfusion after FAL was due to an expansion of the M2 phenotype among
tissue-resident macrophages in Phd2 haplodeficient (Phd2+/-) mice and that soluble factors secreted by
Phd2+/- macrophages in vitro led to increased smooth muscle cell (SMC) proliferation and migration.
IL10 is a known activator of the M2c phenotype and we have shown that increased levels of IL10 also led
to an improved collateral reperfusion after FAL. Furthermore, an immunohistochemical analysis using
the established macrophage polarization marker CD163 [17,18], revealed that perivascular macrophages
were proportionally skewed towards the M2 phenotype. The supposed proarteriogenic effects of M2
macrophages induced by IL10 are further supported by the observation that the application of an IL10
antibody led to a transient impairment of collateral reperfusion and was accompanied by an increased
onset of ischemic symptoms on ligated hind limbs. Also, the distribution of perivascular macrophages
was conversely skewed towards the M1 phenotype. These findings do not undermine the role of M1
macrophages in arteriogenesis. The delayed and transient dip in reperfusion recovery we observed
after the application of an IL10 antibody may support the hypothesis, that adluminally located M1
macrophages contribute to collateral vessel growth particularly in early phases through the recruitment
of circulating monocytes and expression of arteriogenic relevant cytokines and proteins (IL1, IL6, TNF,
NOS, MCP-1). They do, however, highlight the potential role played by M2 macrophages with regard to
VSMC differentiation and adventitial restructuring to accommodate the growing collateral vessel. M2
macrophages induced by IL10 secrete high levels of TGFb1, known to stimulate VSMC differentiation
and extracellular matrix (ECM) deposition [15,19,20]. They also produce high levels of MMP9 [21],
which along with MMP2 was significantly increased in the adventitia of growing coronary collateral
vessels [22]. This supports the hypothesis that IL10 induced M2 macrophages may play an active role
in the augmentation of adventitial ECM proteolysis and remodeling, thus, facilitating arteriogenic
growth. Our findings suggest that varying levels of IL10 in vivo influence collateral reperfusion,
which may be explained by a shift in the distribution of macrophages towards the M2 phenotype
at the site of collateral growth. From a clinical standpoint, this presents itself as a new therapeutic
approach to promote collateral vessel growth in patients suffering from peripheral artery disease.
The expression of CD163 on M2 macrophages, however, also poses concerns regarding their use in
revascularization therapy. CD163+ macrophages in human atherosclerotic lesions were found to
increase plaque instability by promoting angiogenesis within areas of intraplaque hemorrhage, in itself
thought to be a result of plaque neovascularization and increased microvessel permeability, resulting
in a vicious cycle [23]. Seen as a whole, these observations underline the diversity of macrophage
functions and activation states with regard to tissue specific cues and needs. A mere distinction
between classically activated M1 and alternatively activated M2 macrophages limited by CD163 as an
M2 marker alone will not suffice to fully describe the roles played by the macrophage activation states
we observed around growing collateral vessels. Further studies utilizing other macrophage markers
will be required to elucidate the underlying mechanism involved in our findings. While these remain
hypothetical, the results presented in our study shed light on new therapeutic strategies in promoting
collateral vessels growth.
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4. Materials and Methods
4.1. Animal Models
Animal handling and all experimental procedures carried out were in full compliance with the
Directive 2010/63/EU of the European Parliament on protection of animals used for scientific purposes.
Approval was given by the responsible local authority, the hessian governmental council for animal
protection and handling (permit reference numbers V54-19c20/15-B2/1152, permit date: 23.05.2017).
Throughout this study all mice had access to water and food ad libitum.
4.2. Mouse Model of Hind-Limb Ischemia
To evaluate collateral vessel growth perfusion recovery was measured after femoral artery
ligation (FAL) using the model described in [24]. For all experiments 10-14 weeks old male
C57BL/6 mice from our own breeding program were used with an approximate bodyweight
of 30 g. Prior to each experiment all mice were inspected to ensure a healthy state. Anesthesia
was performed by intraperitoneal injection using ketamin hydrochloride (120mg/kg bodyweight) and
xylazine hydrochloride (16 mg/kg bodyweight). Pre- and post-operative analgesia was performed
by subcutaneous injection with buprenorphine (0.1 mg/kg bodyweight). FAL was carried out on the
left hind-limb by ligating the femoral artery immediately distal to the origin of the deep femoral
branch to redirect blood flow to the collateral arteries. After termination of experiments the mice
were euthanized by an anesthetic overdose using ketamin hydrochloride (180mg/kg bodyweight) and
xylazine hydrochloride (16 mg/kg bodyweight) followed by exsanguination.
4.3. Pharmacological Stimulation
FAL was performed on C57BL/6 mice. Mice were randomly allocated to each group receiving either
recombinant murine interleukin 10 (IL10) (20 μg/kg bodyweight) or purified anti-mouse IL10 antibody
(anti-IL10) (0.5 μg/kg bodyweight) diluted in sodium chloride solution (NaCl 0.9%) immediately
after FAL, on day 3 and 7 after FAL. The control group received NaCl 0.9%. The application was
carried out via intravenous injection into the tail vein. IL10 was purchased from PeproTech (Hamburg,
Germany). Anti-IL10 was purchased from BioLegend (Koblenz, Germany).
4.4. Measurement of Blood Concentration Levels of IL10
Retro orbital blood samples were obtained from mice before and 24 h after pharmacological
stimulation with IL10 and anti-IL10 as described above. The control group received NaCl 0.9%.
Anesthesia war provided as described above. A Mouse Magnetic Luminex Assay (Thermo Fisher
Scientific, Waltham, MA, USA) was used to measure the concentration of endogenous IL10 in the blood
samples at baseline and 24 h after pharmacological stimulation.
4.5. Hind-limb Perfusion Measurement after Pharmacological Stimulation and FAL
Hind-limb perfusion was assessed and quantified via erythrocyte motion detection through
Laser-Doppler-Imaging using a PeriScan PIM3 System (Perimed Instruments, Järfällä, Sweden,
Software: LDPIwin for PIM3 3.1.3) before and immediately after FAL, on day 3, 7 and 14 after FAL.
For each measurement mice were positioned on a heating plate at 37 ◦C for 3min prior to and during
each measurement to ensure standardized conditions at a distance of 10 cm and a pixel resolution
of 256 × 256. A 2 cm × 3 cm area including both feet was scanned and a region of interest (ROI) of
approximately 80 mm2 containing each foot was defined. Mean perfusion (arbitrary units) was used to
calculate hind-limb perfusion and expressed as the ligated limb to non-ligated limb ratio as described
in [25]. Follow-up measurements were performed under anesthesia as described above.
70
Int. J. Mol. Sci. 2020, 21, 2821
4.6. Immunohistochemistry
Mice were perfused with 10 mL vasodilation buffer (100 μg adenosine, 1 μg sodium nitroprusside,
0.05% BSA in PBS, pH 7.4) followed by 10 mL 4% PFA post mortem. Mm. adductores of ligated
hind-limbs were harvested on day 3 after FAL and cryosectioned with a thickness of 10 μm.
Immunostaining was performed using the following antibodies: RAT ANTI MOUSE CD68: Alexa Fluor
488 Antibody (AbD Serotec, Düsseldorf, Germany), CD163 (M-96) Antibody (Santa Cruz Biotechnology
Inc., Dallas, TX, USA), Donkey anti-Rabbit IgG: Alexa Fluor 546 (Thermo Fisher Scientific, Waltham,
MA, USA), DAPI. The two largest collateral vessels were selected. Immunopositive cells were
classified as classically activated macrophages (CD68+/CD163−) or alternatively activated macrophages
(CD68+/CD163+). Confocal imaging was carried out using a Leica SP5 (Wetzlar, Germany). Acquired
images were processed with ImageJ Software (National Institutes of Health, Maryland, MD, USA) for
further analysis.
4.7. Data Analysis
Statistical analysis was performed using Prism (GraphPad Software, San Diego, USA). Data was
tested for normality using a D’Agostino-Pearson omnibus normality test. Parametric data is reported
as mean ± standard error of mean. Non-parametric data is reported as median (IQR). Unpaired and
parametric samples were analyzed using a Student’s t-test. Unpaired and non-parametric samples
were analyzed using a Mann–Whitney-U test. When more than two groups were compared at different
time points, a two-way ANOVA was used for parametric samples followed by a Holm–Sidak’s multiple
comparison test. For comparison of more than 2 groups with non-parametric samples a Kruskal–Wallis
test was used followed by a Dunn’s multiple comparison test. Proportions were compared using a
Chi-square test. Values of p < 0.05 were considered statistically significant.
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Abstract: Vascular remodeling and angiogenesis are required to improve the perfusion of ischemic
tissues. The hypoxic environment, induced by ischemia, is a potent stimulus for hypoxia inducible
factor 1α (HIF-1α) upregulation and activation, which induce pro-angiogenic gene expression.
We previously showed that the tyrosine phosphatase SHP-2 drives hypoxia mediated HIF-1α
upregulation via inhibition of the proteasomal pathway, resulting in revascularization of wounds
in vivo. However, it is still unknown if SHP-2 mediates HIF-1α upregulation by affecting 26S
proteasome activity and how the proteasome is regulated upon hypoxia. Using a reporter construct
containing the oxygen-dependent degradation (ODD) domain of HIF-1α and a fluorogenic proteasome
substrate in combination with SHP-2 mutant constructs, we show that SHP-2 inhibits the 26S
proteasome activity in endothelial cells under hypoxic conditions in vitro via Src kinase/p38
mitogen-activated protein kinase (MAPK) signalling. Moreover, the simultaneous expression of
constitutively active SHP-2 (E76A) and inactive SHP-2 (CS) in separate hypoxic wounds in the mice
dorsal skin fold chamber by localized magnetic nanoparticle-assisted lentiviral transduction showed
specific regulation of proteasome activity in vivo. Thus, we identified a new additional mechanism
of SHP-2 mediated HIF-1α upregulation and proteasome activity, being functionally important for
revascularization of wounds in vivo. SHP-2 may therefore constitute a potential novel therapeutic
target for the induction of angiogenesis in ischemic vascular disease.
Keywords: SHP-2; tyrosine phosphatase; HIF-1; 26S proteasome; hypoxia; vascular remodeling;
angiogenesis
1. Introduction
The transcription factor hypoxia inducible factor 1α (HIF-1α) is involved in vascular remodeling
and angiogenesis [1]. Ischemic cardiovascular disease is characterized by reduced tissue perfusion
and reduced tissue oxygen partial pressure (hypoxia), which represent a strong stimulus for HIF-1α
activation [2]. HIF-1α induces the expression of several angiogenic genes, such as vascular endothelial
growth factor (VEGF), platelet derived growth factor (PDGF) or matrix metalloprotease 2 (MMP-2),
which are potent inducers of angiogenesis and arteriogenesis [1,3]. It has therefore been the target
of therapeutic strategies to increase tissue perfusion in ischemic limbs [4,5] and to improve wound
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healing [6,7]. During normoxic conditions, HIF-1α is hydroxylated on prolyl residues within its
oxygen-dependent degradation (ODD) domain, leading to von-Hippel-Lindau protein (pVHL)
dependent ubiquitinylation and subsequent degradation by the proteasome [8,9]. Hypoxia inhibits
the proteasomal degradation of HIF-1α by inhibition of the prolyl hydroxylation domain containing
enzymes (PHD), resulting in stabilization of HIF-1α and subsequent accumulation within the cell [8,9].
Additionally, it has been shown that HIF-1α may be degraded by the protease calpain [10].
The tyrosine phosphatase SHP-2 has been demonstrated by us to positively influence angiogenesis
in vitro and in vivo [11–13] and may constitute an interesting future therapeutic target within this
context. In an earlier study we demonstrated that SHP-2 is important for HIF-1α stabilisation and
activity during hypoxia, resulting in enhanced hypoxia induced HIF-1α dependent revascularisation of
wounds in vivo [12]. Further, we showed that SHP-2 activates the Src kinase upon hypoxia, which in turn
influenced HIF-1α prolyl hydroxylation [12]. Finally, we found that the impaired HIF-1α accumulation
observed upon SHP-2 inactivation could be rescued by treatment with a PHD inhibitor as well as the
proteasome inhibitors MG132 and Epoxomicin [12]. However, while our data indicated that SHP-2
influences HIF-1α accumulation during hypoxia by affecting the activity of the PHD, thus determining
the proteasomal degradation of HIF-1α, we did not investigate whether the effect may additionally be
caused by regulation of proteasome activity.
The 26S proteasome is responsible for the degradation of ubiquitinylated proteins and consists of
a 20S core particle and two 19S regulatory particles [14]. The 20S core particle exhibits three peptidase
activities (caspase-like; C-L, trypsin-like; T-L and chymotrypsin-like; CT-L), which are responsible
for the cleavage of protein substrates. Ubiquitinylated proteins are recognized and bind to the 19S
regulatory particle, which is in addition responsible for the ATP-dependent unfolding of the substrate
protein and the opening of the 20S core particle, where degradation occurs [14]. The activity of the
26S proteasome has been shown to be regulated by phosphorylations via threonine/serine kinases
as well as tyrosine kinases on several subunits of the 19S and 20S particles [15]. However, not very
much is known regarding the role of phosphatases in regulating 26S proteasome activity. Moreover,
its regulation during hypoxia still needs to be investigated.
In this study, we investigated the activity of the 26S proteasome during hypoxia and the connection
to SHP-2 in endothelial cells in vitro and in hypoxic wounds in vivo. We found SHP-2 to inhibit the
26S proteasome activity in hypoxic cells, as assessed by measuring 26S peptidase activity as well as
the accumulation of a HIF-1-ODD-Luc reporter construct. Importantly, we demonstrated that SHP-2
regulates 26S proteasome activity in hypoxic wounds in vivo.
2. Results
2.1. SHP-2 Inactivation Leads to Increased Proteasome Dependent HIF-1α Degradation during Hypoxia
As HIF-1α has been shown to be degraded by the proteasome as well as calpain [10], we first
investigated whether this is also true in endothelial cells upon hypoxia. Treatment with the specific
proteasome inhibitor epoxomicin or the calpain inhibitor MG101, respectively, resulted in an increase
in HIF-1α protein accumulation (Figure 1A). We previously observed that SHP-2 inactivation impaired
HIF-1α accumulation [12], which was rescued by treatment with proteasome inhibitors. We now
additionally investigated the involvement of calpain. As seen in Figure 1B, overexpression of a dominant
negative SHP-2 (SHP-2 CS) impaired HIF-1α accumulation under hypoxic conditions compared
to cells overexpressing SHP-2 wildtype (WT). Treatment with the calpain inhibitor MG101 could
not rescue this effect. Having observed a proteasome dependent [12] but calpain independent
degradation of HIF-1α upon SHP-2 inactivation, we next investigated 26S proteasome activity
in endothelial cells under hypoxia. For this, we induced the lentiviral expression of a construct
containing the oxygen-dependent degradation (ODD) domain of HIF-1α [16], which guides its
proteasomal degradation upon ubiquitinylation [3], fused to a luciferase gene (HIF1-ODD-Luc) with
simultaneous expression of mCherry, in endothelial cells. The expression of HIF1-ODD-Luc thus
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inversely correlates with 26S proteasome activity and has been used as a measure of proteasome
activity before [16]. First, to test its function in endothelial cells, luciferase activity upon treatment with
proteasome inhibitors or hypoxia was measured 72 h after transduction with HIF1-ODD-Luc. As seen
in Figure 1C, treatment with the proteasome inhibitors Bortezomib and MG132 as well as hypoxic
exposure (4 h) significantly increased the accumulation of HIF1-ODD-Luc, reflecting the inhibition of
the 26S proteasome. The transduction of endothelial cells with a control reporter construct lacking the
HIF-1α ODD (Ctrl-Luc) showed a strong constitutive expression of luciferase, as expected, which did
not differ between normoxic and hypoxic conditions (Figure S1). Expression of dominant negative
SHP-2 (CS) impaired HIF1-ODD-Luc accumulation compared to SHP-2 WT expressing cells upon
hypoxia, thus demonstrating an increase in 26S proteasome activity (Figure 1D).
Figure 1. SHP-2 inactivation enhances proteasome dependent hypoxia inducible factor 1α (HIF-1α)
degradation in endothelial cells during hypoxia. (A) HIF-1α protein levels were increased during
hypoxia upon inhibition of the 26S proteasome (Epoxomicin, 10 μM) as well as calpain (MG101, 5 μM)
(n = 3). Graph underneath blot shows the protein band densities normalized to β-actin. (B) Expression
of dominant negative SHP-2 (CS) prevents hypoxic HIF-1α protein upregulation, which could not be
rescued by calpain inhibition (MG101, 5 μM; * p < 0.05; n = 3). Graph underneath blot shows the protein
band densities normalized to β-actin. (C) The reporter construct HIF1-ODD-Luc accumulated upon
inhibition of the proteasome (Bortezomib 64 nM; MG132 10 μM) during normoxia as well as under only
hypoxia (* p < 0.05; n = 16–25), confirming the specificity of the reporter constructs. (D) Expression of
dominant negative SHP-2 (CS) increased HIF-1α degradation by the proteasomal pathway, as detected
by lower expression of HIF1-ODD-Luc (* p < 0.05, n = 17).
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2.2. SHP-2 Regulates Proteasomal Degradation of HIF-1α in Hypoxic Wounds In Vivo
As we previously found SHP-2 inactivation to prevent HIF-1α accumulation and activity in
endothelial cells upon hypoxia, resulting in impaired wound healing angiogenesis in vivo [12] and, as we
now observed that SHP-2 inactivation increases 26S proteasomal activity under hypoxia in endothelial
cells in vitro, we investigated the proteasomal activity in vivo. For this, HIF1-ODD-Luc or Ctrl-Luc
were expressed in wounds of the dorsal skin of mice by localized magnetic nanoparticles-assisted
lentiviral transduction (Figure S3). By using lentiviruses (LV) coupled to magnetic nanoparticles
(MNP) and the application of an external magnetic field, the simultaneous transduction of three
individual wounds in the same animal can be achieved [12]. As seen in Figure 2A and Figure S2B,
HIF1-ODD-Luc only accumulated in the malperfused wound and not after transduction of healthy
tissue, confirming that the wound is hypoxic and that proteasome activity is higher in normoxic
tissues. As a positive control, wounds were transduced with Ctrl-Luc, which causes a continuous
strong expression of luciferase, as this construct does not contain the HIF-1α ODD domain. Next,
we performed co-transductions of individual wounds in the same animal with HIF1-ODD-Luc and
the different SHP-2 constructs, to investigate the influence of SHP-2 on proteasome activity in vivo.
Whereas the expression of inactive SHP-2 CS in hypoxic wounds significantly inhibited HIF1-ODD-Luc
accumulation via increased proteasome activity, introduction of the constitutively active SHP-2 E76A
(Glu76 to Ala76) enhanced the HIF1-ODD-Luc protein accumulation compared to SHP-2 WT expressing
wounds (Figure 2B and Figure S2C). This indicates that SHP-2 regulates HIF-1α stabilization and
accumulation in hypoxic wounds by decreasing 26S proteasome activity.
Figure 2. SHP-2 inactivation induces HIF-1α degradation via the proteasome pathway in hypoxic
wounds in vivo. (A) Wounds in the same dorsal skin fold chamber in mice were simultaneously
transduced with HIF1-ODD-Luc or Ctrl-Luc lacking HIF1-ODD using site directed lentiviral magnetic
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targeting [12]. HIF1-ODD-Luc was expressed in wounds (1) but was degraded by the proteasome
in healthy tissue (2), demonstrating the specificity of the lentiviral constructs and that the wounds
are hypoxic (* p < 0.05; n = three animals). (3) Ctrl-Luc lacking the HIF-ODD domain was therefore
constitutively expressed in the wound (* p < 0.05; n = three animals). (B) Wounds in the same dorsal
skin fold chamber in mice were simultaneously co-transduced with HIF1-ODD-Luc and different
SHP-2 constructs. While HIF1-ODD-Luc accumulated in hypoxic wounds upon transduction with
SHP-2 WT, expression of dominant negative SHP-2 (CS) impaired this, demonstrating an increased 26S
proteasomal activity (* p < 0.05; n = 3–4 animals). Expression of constitutively active SHP-2 (E76A)
further enhanced HIF1-ODD-Luc accumulation, demonstrating enhanced inhibition of 26S proteasome
activity (* p < 0.05; n = 3–4 animals). Wounding was performed the day after implantation of the dorsal
skin fold chamber. Transduction of wounds was performed 24h after wounding and measurements of
luciferase activity were performed eight days after transduction (see also Figure S2A).
2.3. The Proteasomal Degradation of HIF-1α is Dependent on Src Kinase and p38 MAPK Activation
In a former study, we could show that SHP-2 induces HIF-1α expression via a Src kinase dependent
mechanism in endothelial cells upon hypoxia [12]. We thus hypothesized that the observed effect
of SHP-2 on 26S proteasome activity and HIF-1α stabilization in this study may be mediated by Src
as well. To test this, endothelial cells were transduced with the HIF1-ODD-Luc reporter construct
and treated with the pharmacological Src inhibitor PP2 upon hypoxia. Whereas hypoxia induced the
stabilization, and thus accumulation, of HIF1-ODD-Luc, representing a decrease in proteasome activity,
Src inhibition significantly impaired this response (Figure 3A). Src kinases have been demonstrated to
induce the activation of p38 MAPK during hypoxia [17]. Thus, we next explored whether this was the
case in endothelial cells. The hypoxia induced HIF-1α accumulation was prevented upon inhibition
of p38 MAPK (Figure 3B). Moreover, hypoxia induced the phosphorylation and thus activation of
p38 MAPK and this was abrogated when treating cells with the Src kinase inhibitor PP2 (Figure 3C).
Moreover, treatment with the p38 MAPK inhibitor SB203580 increased proteasome activity, reflected
by reduced HIF1-ODD-Luc accumulation (Figure 3D). Finally, the phosphorylation of p38 MAPK was
impaired in endothelial cells expressing SHP-2 CS and enhanced in cells expressing the constitutively
active SHP-2 E76A compared to the expression of SHP-2 WT upon hypoxia (Figure 3E).
2.4. SHP-2 Activity Inhibits the Chymotrypsin-Like Activity of the 26S Proteasome upon Hypoxia
As previously published data from our group showed that treatment with epoxomicin and MG132,
which are both inhibitors of the CT-L activity of the 26S proteasome [18], rescued the low HIF-1α
protein level caused by SHP-2 inactivation [12], we next detected the 26S CT-L proteolytic activity in
endothelial cells under hypoxia. We used experimental conditions optimized to investigate proteolytic
protease activity of the 26S proteasome as previously described [19]. For this, cells expressing SHP-2 WT
were exposed to hypoxia and the chymotrypsin-like (CT-L) activity of the 26S proteasome was assessed
by a specific fluorogenic proteasome substrate (Suc-LLVY-AMC). Hypoxia significantly reduced CT-L
activity (Figure 4A and Figure S4), and endothelial cells expressing constitutively active SHP-2 E76A
exhibited an even lower 26S CT-L activity upon hypoxia compared to SHP-2 WT expressing cells
(Figure 4B), indicating a downregulation of the CT-L proteolytic activity of the 26S proteasome.
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Figure 3. The proteasomal HIF-1α degradation is dependent on Src kinase and p38 mitogen-activated
protein kinase (MAPK) signaling. (A) Whereas hypoxia inhibited 26S proteasome activity in endothelial
cells, as seen by increased expression of HIF1-ODD-Luc, inhibition of Src kinase (PP2, 100 nM) reversed
this (* p< 0.05; n= 9). (B) Inhibition of p38 MAPK (SB203580, 10μM) in endothelial cells impaired hypoxia
induced HIF-1α expression (n= 6). (C) Src kinase inhibition (PP2, 100 nM) reduced hypoxia induced p38
MAPK activation (n= 2). (D) p38 MAPK inhibition (SB203580, 10 μM) increased 26S proteasome activity,
as measured by a lower level of HIF1-ODD-Luc reporter expression (* p < 0.05; n = 4). (E) Expression
of dominant negative SHP-2 (CS) impaired hypoxia induced p38 MAPK phosphorylation, whereas
expression of constitutively active SHP-2 (E76A) enhanced this compared to SHP-2 WT (* p < 0.05;
n = 4). Graphs underneath blots show the protein band densities normalized to β-actin.
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Figure 4. SHP-2 inhibits 26S chymotrypsin-like (CT-L) proteasomal activity during hypoxia.
(A) The CT-L activity of the 26S proteasome was decreased upon hypoxia (* p < 0.05, n = 11),
as measured by the fluorogenic substrate Suc-LLVY-AMC. Treatment with epoxomicin (10 μM) was
used as a positive control and effectively inhibited the CT-L proteolytic activity of the 26S proteasome
(* p < 0.05; n = 3). (B) Expression of constitutively active SHP-2 (E76A) also significantly impaired
the CT-L activity of the 26S proteasome compared to SHP-2 WT during hypoxia (* p < 0.05, n = 9),
whereas the expression of dominant negative SHP-2 (CS) showed a tendency towards increased CT-L
activity (n = 9).
3. Discussion
Vascular remodeling and angiogenesis are important for maintaining tissue perfusion upon
ischemia [2]. We previously demonstrated that the tyrosine phosphatase SHP-2 drives hypoxia
mediated HIF-1α upregulation, resulting in revascularization of wounds in vivo [12]. Here, we show
that this is achieved by SHP-2 dependent inhibition of 26S proteolytic activity via Src kinase/p38
MAPK signalling.
In a former study, we demonstrated that SHP-2 promotes HIF-1α stabilization and activity in
endothelial cells during hypoxia as well as revascularization of hypoxic wounds in vivo by increasing
HIF-1α activity, resulting in higher expression of VEGF, MMP-2 and PDGF [12]. Moreover, we showed
SHP-2 to negatively influence the proteasomal degradational pathway, as the impaired HIF-1α
expression seen upon SHP-2 inactivation was rescued by inactivation of the proteasome as well as the
PHD [12]. While these results indicate that SHP-2 influences the prolylhydroxylation of HIF-1α and in
this way its proteasomal degradation, we further investigated here the mechanisms of SHP-2 and its
regulation of proteasomal activity. The data obtained in this study confirm our previous findings and
additionally reveal a second mechanism of promoting HIF-1α upregulation by directly affecting 26S
proteasomal activity. Inactivation of SHP-2 prevented the cellular accumulation of HIF1-ODD-Luc,
which inversely correlated with 26S proteasomal activity, in endothelial cells in vitro. The in vivo
relevance of SHP-2 mediated proteasome regulation was confirmed in hypoxic wounds of intact animals
using co-transduction of HIF1-ODD-Luc and SHP-2 constructs. Of note, expression of constitutively
active SHP-2 further enhanced HIF1-ODD-Luc levels, demonstrating an increased inhibition of the 26S
proteasome. This correlates well with the impaired 26S CT-L proteolytic activity measured in cells with
constitutive SHP-2 activation. Thus, we conclude that SHP-2 activity negatively affects proteasomal
activity during wound healing under hypoxic conditions in vivo.
As we previously found SHP-2 dependent Src kinase activation to be involved in HIF-1α
upregulation during hypoxia [12], we now investigated if it is also important for proteasomal activity.
Indeed, Src integrity was crucial for 26S proteasomal activity and in addition, was important for
activation of the p38 MAPK upon hypoxia. p38 MAPK, in turn, positively affected HIF-1α upregulation
while negatively influencing 26S proteasomal activity, a mechanism which was promoted by SHP-2.
These results are not only in accordance with but additionally extend the study from Lee et al.
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performed in HeLa cells, demonstrating that p38 MAPK negatively affects 26S proteolytic activity also
in endothelial cells [20]. This inhibition was further shown to be due to the phosphorylation of Thr-273
on the subunit Rpn2 in the 19S regulatory particle [20]. Whether this is the case during hypoxia, remains
to be investigated. Posttranslational phosphorylation of the 26S proteasome has repeatedly been shown
to regulate its enzymatic activities [15]. Several stimuli, such as stress, metabolic changes, and growth
factor signalling have been demonstrated to induce its phosphorylation [15]. Here, we identified
hypoxia as a novel stimulus of 26S proteasomal inactivation, particularly the CT-L activity. In addition,
we found the caspase-like (C-L) activity to be deprived upon hypoxia (Figure S4). Intriguingly,
we measured an increased trypsin-like (T-L) activity during hypoxia, suggesting that the different
proteolytic activities of the 26S proteasome may be differentially regulated. One may hypothesize that
the differential regulation of activities is involved in substrate specificity of proteasomal degradation.
However, more investigations are needed to elucidate the mechanisms behind this. The observed
reduction in CT-L and C-L activity, however, is supported by the fact that the 26S proteasome relies
on the activity of ATPases in the 19S regulatory particle for substrate de-ubiquitinylation, unfolding
and 20S gate opening and activation [15], which do not function upon ATP deprivation, as is the
case during hypoxia. Moreover, we observed that inhibition of Src kinase/p38 MAPK signalling
rescued proteasomal activation. Additionally, an inhibition of 26S proteasomal activity via direct
dephosphorylation of subunits by SHP-2 was not investigated here and has to be the focus of further
studies. However, this is per se possible, as Zong et al. demonstrated the phosphatase PP2A to
negatively affect 20S proteolytic activity via dephosphorylation [21]. Nevertheless, this is to our
knowledge the first study to report a regulation of 26S proteolytic activity by SHP-2.
In summary, we were able to further characterize the mechanism behind the regulation of hypoxia
mediated HIF-1α upregulation by SHP-2, which is essential for revascularisation of malperfused
wounds. Moreover, we demonstrate for the first time that the 26S proteasomal activity is regulated
by SHP-2 during hypoxia in vitro and is functionally relevant in vivo. We show that SHP-2 not only
inhibits the proteasomal degradation pathway by influencing HIF-1α prolylhydroxylation [12] but in
addition by directly inhibiting 26S proteolytic activity via p38 MAPK (for a summary of our findings,
see Figure 5). We thus believe that SHP-2 is important for HIF-1α upregulation in vitro and in wounds
in vivo by inhibition of the proteasomal pathway via activation of Src kinase/p38 MAPK signalling.
Together with our previous results, this regulation may be achieved by redundant and or additive
pathways, involving external regulators of the proteasome (PHD and pVHL activation), and directly
via the CT-L activity of the 26S proteasome. Finally, our findings confirm SHP-2 to be essential for
hypoxic HIF-1α upregulation in vivo. SHP-2 may therefore constitute a novel therapeutic target in
ischemic vascular disease, aiming for the revascularization of ischemic tissues.
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Figure 5. Illustration of 26S proteasome regulation and HIF-1α accumulation by SHP-2 in hypoxia.
HIF-1α is constitutively expressed but degraded by the proteasomal pathway during hypoxia (left).
Upon hypoxia (right), the degradation of HIF-1α is inhibited. In our previous study, we found SHP-2
to influence the prolyl hydroxylation of HIF-1α, which targets it for degradation [12]. In this study,
we found a second mechanism of SHP-2 mediated HIF-1α upregulation: SHP-2 positively affects Src
kinase and p38 MAPK activity during hypoxia, which in turn negatively influences the activity of the
26S proteasome. As a consequence, HIF-1α is stabilized and accumulates in the cell, promoting hypoxic
angiogenesis and vascular remodeling.
4. Materials and Methods
4.1. Antibodies and Chemicals
Rabbit phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP™ (#4511) and β-Actin (13E5) antibodies
were from Cell Signaling Technology, Frankfurt am Main, Germany. HIF-1α clone H1α67, HIF-1α
clone EP1215Y, anti-mouse and -rabbit horseradish peroxidase-conjugated secondary antibodies were
from Merck Millipore, Darmstadt, Germany. Src-Inhibitor PP2 was purchased from Sigma-Aldrich
(#P0042), Darmstadt, Germany. p38 MAPK inhibitor (SB203580), MG132 and MG101 were from Tocris,
Wiesbaden-Nordenstadt, Germany. Bortezomib and Epoxomicin were from Calbiochem. All other
chemicals were from Sigma-Aldrich, Darmstadt, Germany.
4.2. Human Microvascular Endothelial Cell (HMEC) Culture
Human dermal microvascular endothelial cells (HMEC) [22] were cultivated as described
earlier [23]. In detail, HMEC were cultivated in DMEM (Sigma-Aldrich, Darmstadt, Germany)
containing 10% fetal calf serum (Biochrom, Berlin, Germany) and 1% Penicillin-Streptomycin
(Sigma-Aldrich, Darmstadt, Germany) and kept in an incubator with 5% CO2 at 37 ◦C.
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4.3. Lentiviral Constructs and Transductions
Wild type (WT) SHP-2 and catalytically inactive mutant SHP-2 CS (Cys459 to Ser459) plasmid
vectors were kind gifts from the Bennett laboratory [24]. The constitutively active SHP-2 E76A
(Glu76 to Ala) was generated as previously described [12]. The lentiviral constructs containing the
above mentioned cDNAs were generated as described earlier [12] and lentiviral particles were produced
as described elsewhere [25]. Flow cytometry of transduced HEK293T cells was used to determine the
biological titer as previously described [25]. The FUW-ODD-Luc-mCherry lentiviral plasmid (referred
to as HIF1-ODD-Luc in this manuscript) and the control vector FUW-Luc-mCherry (referred to as
Ctrl-Luc in this manuscript) were kindly provided by Kimbrel et al. [16] and packaged into lentiviral
particles as previously described [25]. The ODD-Luc insert encodes a reporter fusion protein consisting
of the oxygen-dependent domain (ODD) from hypoxia-inducible factor 1a (HIF-1a) and firefly luciferase,
inversely reflecting proteasomal activity, with simultaneous expression of mCherry after a self-cleavage
2A site. Lentiviral transduction of HMECs was carried out using a multiplicity of infection (MOI)
of five. Lentiviral particles were diluted in Hank’s solution and applied onto subconfluent HMEC.
After incubation for 4–6 h at 37 ◦C, culture medium was added. The next day the medium was changed,
and cells were left 72 h before assaying.
4.4. Hypoxia Treatment
For hypoxia treatment, HMECs were incubated in cultivation media in a hypoxia chamber
(Cell Systems, Troisdorf, Germany) at pO2 8 ± 2 mmHg equivalent to a O2 concentration of 1 ± 0.2%
for 4 h as previously described [26]. To reach these experimental hypoxic conditions, the chamber was
flooded for four minutes with 15–20 L/min with an anoxic gas mixture (5% CO2, 95% N2). After hypoxia,
the media was discarded, and cells quickly washed once with phosphate buffered saline and lysed for
further processing.
4.5. In Vitro 26S Proteasome Activity
The 26S CT-L proteasome activity was measured as previously described [19]. In detail, HMEC
were subjected to hypoxia (4 h), rinsed with cold phosphate buffered saline supplemented with calcium
(PBS+) and lysed at 4 ◦C with lysis buffer (1mM DTT, 1× Roche PhosphoStop Tablet in homogenizing
buffer containing 20 mM HEPES, 1 mM MgCl2, 150 mM NaCl, and 0.5 mM EDTA). 10 μg protein in
assay buffer containing 1mM DTT, 50 μM ATP and 100 μM Suc-LLVY-AMC (R&D systems, Wiesbaden,
Germany) in homogenizing buffer was measured at 37 ◦C with excitation wavelength 339 nm and
emission wavelength 439 nm for 2 h.
4.6. In Vitro Luciferase Assay
HMEC were seeded in 24-well plates and transduced the following day. Indicated inhibitor
treatments and hypoxia was performed 72 h post transduction and cells were lysed on ice for 30 min
(250 mM Tris base pH7.8, 0.1% Triton-X). Then, 10 μL of cell lysate were transferred to a black 96-well
plate in triplicates and 100 μL luciferin assay buffer (60 mM DTT, 10 mM MgSO4, 1 mM ATP, 25 mM
Glycil-Glycin, 0.3 mM D-Luciferin) were added to each well. Bioluminescence was detected using the
Spectrafluor (Tecan, Männedorf, Switzerland) with a one-second integration time and normalized to
protein concentrations.
4.7. In Vivo Transduction and Luciferase Imaging
Animal studies were conducted in accordance with the German animal protection law and
approved by the district government of upper Bavaria (Regierung von Oberbayern, approval reference
number AZ55.2-1-54-2532-172-13). The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). 16–20-week old male and female C57 BL6/J mice (Charles River) were anesthetized
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(5 mg/kg midazolam, 0.5 mg/kg medetomidin, and 0.05 mg/kg fentanyl) and the dorsal skinfold
chamber was implanted as described before [27]. Wounds were introduced using a hot probe as
previously described 24 h after dorsal skinfold chamber implantation [12]. Proteasomal activity in
avascular wounds in the dorsal skin of mice was detected by localized magnetic nanoparticles-assisted
transduction of individual wounds in the same animal with HIF1-ODD-Luc (FUW-ODD-Luc-mCherry)
and Ctrl-Luc (FUW-Luc-mCherry) lentiviral vectors as well as co-transductions of with the ODD-Luc
vector and SHP-2 WT, CS and E76A lentiviral vectors, respectively, as previously described [12].
Luciferase activity was detected eight days after transduction by application of 3 mg/mL D-Luciferin
directly to the imaging window of the dorsal skinfold chamber. Bioluminescence was imaged using
the IVIS® spectrum in vivo imaging system from PerkinElmer at medium binning and exposure times
between five and 10 minutes. Signal intensities were quantified using the Fiji software.
4.8. Immunoblotting
Cell lysates were prepared and subjected to SDS-PAGE followed by western blotting as previously
described [28]. Protein band intensities were measured using the Hokawo software (Hamamatsu,
Herrsching, Germany) and normalized to the respective β-Actin protein bands, which was used as
equal loading control.
4.9. Statistical Analysis
Data are presented as means ± SEM. Statistical analyses were performed with Sigma Plot 10.0.
The Student’s t-test was used for comparisons between two groups of normal distributed data, rank-sum
test was performed for comparisons of two groups of not normally distributed data. The one-way
analysis of variance (one-way ANOVA) was performed for multiple comparisons. Differences were
considered significant at an error probability level of p < 0.05.
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Abbreviations
Ctrl-Luc Lentiviral control luciferase reporter construct lacking the HIF-1α ODD
HIF1-ODD-Luc
Lentiviral construct containing the oxygen-dependent degradation (ODD) domain of
HIF-1α fused to luciferase
HMEC Human microvascular endothelial cells
SHP-2 Src homology domain containing tyrosine phosphatase 2
SHP-2 WT SHP-2 wildtype construct
SHP-2 CS Dominant negative SHP-2 construct where Cys459 was exchanged to Ser459
SHP-2 E76A Constitutively active SHP-2 construct where Glu76 was exchanged to Ala76
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Abstract: The process of arteriogenesis is severely compromised in patients with diabetes mellitus
(DM). Earlier studies have reported the importance of Egr-1 in promoting collateral outward
remodeling. However, the role of Egr-1 in the presence of DM in outward vessel remodeling was
not studied. We hypothesized that Egr-1 expression may be compromised in DM which may lead to
impaired collateral vessel growth. Here, we investigated the relevance of the transcription factor Egr-1
for the process of collateral artery growth in diabetic mice. Induction of arteriogenesis by femoral
artery ligation resulted in an increased expression of Egr-1 on mRNA and protein level but was severely
compromised in streptozotocin-induced diabetic mice. Diabetes mellitus mice showed a significantly
reduced expression of Egr-1 endothelial downstream genes Intercellular Adhesion Molecule-1
(ICAM-1) and urokinase Plasminogen Activator (uPA), relevant for extravasation of leukocytes which
promote arteriogenesis. Fluorescent-activated cell sorting analyses confirmed reduced leukocyte
recruitment. Diabetes mellitus mice showed a reduced expression of the proliferation marker Ki-67
in growing collaterals whose luminal diameters were also reduced. The Splicing Factor-1 (SF-1),
which is critical for smooth muscle cell proliferation and phenotype switch, was found to be elevated
in collaterals of DM mice. Treatment of DM mice with insulin normalized the expression of Egr-1
and its downstream targets and restored leukocyte recruitment. SF-1 expression and the diameter of
growing collaterals were normalized by insulin treatment as well. In summary, our results showed
that Egr-1 signaling was impaired in DM mice; however, it can be rescued by insulin treatment.
Keywords: arteriogenesis; endothelial cells; smooth muscle cells; diabetes mellitus; Egr-1; streptozotocin;
collateral arteries; insulin
1. Introduction
Peripheral artery disease (PAD) is one of the common vascular complications in diabetes mellitus [1].
Patients with PAD exhibit poor lower extremity function and develop critical limb ischemia and
ulceration, ultimately leading to limb amputation [2–4]. Moreover, compared to healthy individuals,
diabetic patients with PAD exhibit cardiovascular co-morbidities, neuropathy, and higher mortality [5–8].
Patients with PAD show poorer outcomes after leg bypass surgery with higher incidence of restenosis,
longer hospitalization, and reduced amputation-free survival [8–11].
Arteriogenesis, which is an endothelial dependent process [12], is characterized by outward
remodeling of pre-existing anastomoses in conducting arteries, and through this process, the blood
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flow to peripheral tissues can largely be restored. The process of collateral artery growth is strongly
dependent on perivascular recruitment and accumulation of leukocytes, particularly macrophages,
which supply growth factors and cytokines to the growing vessel [13]. In addition, lymphocytes
accumulate in the perivascular space [14]; however, little is known about their function. It is well
established that the presence of DM limits the process of arteriogenesis [15]. Indeed, it has been
previously shown by van Weel et al. [16] that reperfusion recovery after femoral artery ligation (FAL)
was significantly reduced in streptozotocin (STZ)-induced diabetic mice, as shown by laser Doppler
perfusion measurements. The exact mechanisms through which impairment of arteriogenesis in DM
occurs are not clear. Elevated vasomotor function attenuating the sensing of shear stress and defects
in downstream monocyte signaling are reported as major contributors to the vascular impairments
seen in arteriogenesis [17].
Early growth response-1 (Egr-1) is a zinc finger transcription factor, which is expressed after
exposure of cells to mediators associated with growth and differentiation [18]. Several studies have
shown a link between the activation of Egr-1 through hypoxia, ischemia/reperfusion, mechanical stress,
shear stress, emphysema, atherosclerosis, and acute vascular injury [19]. Early growth response-1
has been reported to play a critical role in a hind limb ischemia model [20], and in a separate study,
it was shown that adenoviral-mediated Egr-1 delivery improved perfusion recovery [21]. Early growth
response-1 is important for leukocyte recruitment and vascular cell proliferation during arteriogenesis
in vivo in mice subjected to FAL [22]. Thus, with increased Egr-1 expression playing a critical
role in both arteriogenesis and regulation under hyperglycemic conditions, the present study was
performed to understand the influence of DM on Egr-1 expression and its consequent biological
events. We hypothesized that Egr-1 expression may be compromised in DM which may lead to
impaired collateral vessel growth. In the present study, we investigated the role of Egr-1 in collateral
artery growth in vivo in streptozotocin-induced diabetic mice employing a hind limb model in which
arteriogenesis was induced by FAL.
2. Results
C57Bl6J mice were made diabetic using streptozotocin. The diabetic mice showed a significant
rise in blood glucose levels (328 ± 38 mg/dL) compared to non-diabetic mice (144 ± 10 mg/dl) 24 h
post-ligation. In accordance with this, diabetic mice treated with insulin showed a significant decrease
in glucose levels (216 ± 35 mg/dL) compared to the diabetic group (Table 1) at the same timepoint.
Table 1. Plasma glucose levels measured 24 h post-Femoral Artery Ligation prior to sacrifice (n = 7
in each group).
Group Random Plasma Glucose (mg/dL)
Control 144 ± 10
Streptozotocin 328 ± 38 *
Streptozotocin + Insulin 216 ± 35 **
* p < 0.05 compared to Control group, ** p < 0.05 compared to Streptozotocin group.
2.1. Reduced Upregulation of Egr-1 in Growing Collaterals of Diabetic Mice
The Egr-1 mRNA expression levels were significantly increased in growing collaterals of control
mice, diabetic mice, and diabetic mice treated with insulin compared to resting collaterals isolated
from the sham-operated side (Figure 1a). However, the increase in the expression levels of Egr-1 was
significantly less pronounced in diabetic mice compared to non-diabetic mice and control mice 24 h
post-FAL (2ˆ−ddCT, 3.19 ± 0.172 versus 22 ± 0.25, p < 0.05) (Figure 1a). Treatment of diabetic mice with
insulin significantly increased Egr-1 expression compared to the diabetic mice (3.45 ± 0.25) (Figure 1a),
resulting in similar levels as in the control group. Western blot analyses revealed a significantly lower
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expression of Egr-1 protein in the diabetic group compared to both the non-diabetic control group and
the insulin treated group (Figure 1b) 24 h after the surgical procedure.
Figure 1. Gene expression studies of (a) mRNA levels and (b) protein levels of collateral arteries
obtained from occluded and sham-operated mice 24 h after the surgical procedure. (a) Dot plots
representing the results of qRT-PCR analyses (n = 5 per group, * p < 0.05 (each group compared to
each other group), # p < 0.05 compared to corresponding occ group from one-way ANOVA with
Bonferroni’s multiple comparison test). Results were normalized to the expression level of the 18S
rRNA. (b) Quantitative analyses (upper panel) and corresponding representative pictures of a Western
blot (lower panel) showing the protein expression of Egr-1 as well as of α-tubulin, which was used for
normalization, 24 h post-FAL (n = 4 per group, * p < 0.05 (each group compared to each other group)
from one-way ANOVA with Bonferroni’s multiple comparison test).
2.2. Expression of Egr-1 Downstream Genes in Collaterals of Diabetic Mice Was Restored by Insulin Treatment
The mRNA expression levels of Egr-1 downstream target genes, namely, Intercellular Adhesion
Molecule-1 (ICAM-1), urokinase Plasminogen Activator (uPA), and Monocyte Chemoattractant
Protein-1 (MCP-1) [18,23,24], were measured via qRT-PCR. Our results revealed decreased expression
of ICAM-1 (Figure 2a) and uPA (Figure 2b) in the diabetic group compared to the non-diabetic control
group (1.49 ± 0.49 versus 2.84 ± 0.49 and 1.53 ± 0.64 versus 3.2 ± 0.60, respectively). Mice treated
with insulin showed a significant rise in ICAM-1 (2.35 ± 0.34) and uPA (3.56 ± 0.10) expression
compared to the diabetic group. The expression of MCP-1 decreased in diabetic mice (2.34 ± 0.15);
however, its expression levels did not significantly rise upon treatment with insulin (2.65 ± 0.29)
(Figure 2c). As previous results have shown that the transcriptional repressor Splicing Factor-1 (SF-1),
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which controls smooth muscle cell proliferation, is upregulated in growing collaterals during the
process of arteriogenesis [22], we also investigated the expression level of the corresponding transcript.
Our data showed a significant upregulation of SF-1 in the diabetic group (2.25 ± 0.36) compared to the
non-diabetic group (1.15 ± 0.26), but its expression level was normalized again by insulin treatment
(0.72 ± 0.04) (Figure 2d).
Figure 2. Gene expression of downstream targets of Egr-1 in collateral tissues obtained from mice
after induction of arteriogenesis was performed by qRT-PCR (n = 5 in each group, * p < 0.05 (each
group compared to each other group) using a one-way ANOVA with Bonferroni’s multiple comparison
test). The relative expression is represented as 2ˆ−ddCT. The relative expressions of (a) ICAM-1, (b) uPA,
(c) MCP-1, and (d) SF-1 were normalized to the expression level of the 18S rRNA.
2.3. Insulin Treatment Restored Vessel Growth in Diabetic Mice
The luminal collateral vessel diameter, which was measured 7 days post-FAL, was found to
be significantly decreased in the diabetic group (23.61 ± 2.1 μm) compared to the control group
(30.76 ± 2.5 μm); however, it was restored to control levels by insulin treatment (29.58 ± 1.8 μm)
(Figure 3a). Moreover, qRT-PCR results on the cell proliferation marker Ki-67 revealed significantly
reduced Ki-67 mRNA expression in the diabetic group (1.36 ± 0.37) compared to the non-diabetic
control group (2.35 ± 0.50); however, Ki-67 expression levels increased when STZ mice were treated
with insulin (3.02 ± 0.15) (Figure 3b).
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Figure 3. Upper panel: pictures of superficial collateral arteries of STZ-treated mice 7 days after femoral
artery ligation (FAL, occ, left picture) or sham operation (right picture). Arrows indicate pre-existing
(resting) collaterals of the sham-operated site or growth-induced collaterals of the experimental site.
The ligation (*) of the femoral artery was executed downstream of the profound artery. Scale bars:
5 mm. Lower panel: (a) dot plots represent the inner luminal vessel diameter measured 7 days post-FAL
(n = 4 per group, at least two collateral arteries per mouse and two sections were evaluated, * p < 0.05
(each group compared to each other group), # p < 0.05 compared to the corresponding occ group using
a one-way ANOVA with Bonferroni’s multiple comparison test). (b) Dot plots show the expression
level of the proliferation marker Ki-67 in collaterals of control, STZ, and STZ + insulin-treated mice
24 h after FAL. Results were normalized to the expression level of the 18S rRNA (n = 5 per group,
* p < 0.05 (each group compared to each other group) using a one-way ANOVA with Bonferroni’s
multiple comparison test).
2.4. Diminished Leukocyte Infiltration Was Improved in Diabetic Mice by Insulin Treatment
Fluorescent-activated cell sorting (FACS) studies from blood collected from non-ligated mice
showed significantly increased levels of CD11b+ cells in diabetic (55%) and insulin-treated groups (77%)
compared to the non-diabetic control group (33%) with respect to CD45+ cells, whereas the levels of
CD19+ or CD3+ cells decreased in both the diabetic (10% and 14%, respectively) and the insulin-treated
group (7% and 30%, respectively) (Figure 4a). There were no significant changes in leukocyte count
in the adductor muscle of sham-operated mice in STZ-treated and STZ and insulin-treated mice
compared to control mice (data not shown). However, in diabetic mice, there was a significant decrease
in CD11b+ (27% versus 13%), CD19+ (45% versus 18%), and CD3+ (55% versus 33%) cells three days
post-ligation compared to control mice. Interestingly, insulin treatment increased the number of
leukocytes in STZ-induced DM mice (Figure 4b).
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Figure 4. Dot plots represent the results of FACS analyses on CD11b+, CD19+, and CD3+ cells performed
on (a) whole blood of control, STZ, and STZ + insulin-treated mice without any surgical treatment
and on (b) adductor muscles isolated from mice 3 days post-FAL (a,b: n = 3 per group, each group
compared to each other group using a two-way ANOVA with Bonferroni’s multiple comparison test).
3. Discussion
PAD is one of the common complications of DM that inflicts substantial damage to the lower limbs
and has a very poor outcome. In mice, it was shown that impaired arteriogenesis is a major problem
in hypercholesterolemia and DM [16]. While in the study by van Weel et al. [16], the influence of DM
on perfusion recovery was less compared to that of hypercholesterolemia, our study showed a more
pronounced impact of ligation on collateral vessel growth in DM. This may be due to the different
experimental setup, age groups of animals under study, timepoints measured, and animal strains
used. The mechanism by which impaired arteriogenesis occurs in DM is not fully understood. Earlier,
Pagel et al. [22] reported the importance of Egr-1 in promoting collateral outward remodeling through
augmenting leukocyte infiltration and endothelial cell proliferation. In the present study, we report
that there was a decreased expression of Egr-1 at the transcript and protein levels in collaterals of mice
rendered diabetic by administration of streptozotocin. The decreased expression of Egr-1 correlated
with decreased collateral artery diameter in the diabetic mice. Important downstream targets of Egr-1,
namely, ICAM-1 and uPA, were found to be decreased, too. ICAM-1 plays a critical role in endothelial
monocyte adhesion, which is essential for arteriogenesis. An earlier study identified an upregulation
of ICAM-1 mRNA in growing collateral arteries after induction of arteriogenesis by femoral artery
ligation [25]. Moreover, it was shown that the process of arteriogenesis is reduced in ICAM-1 deficient
mice [26]. Treatment of the diabetic mice with insulin improved the expression of Egr-1, increased the
collateral artery diameter, and normalized the expression of downstream targets of Egr-1. A proposed
model is shown in Figure 5.
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Figure 5. Graphical representation showing the mechanisms by which Egr-1 controls leukocyte
recruitment, and hence, the process of collateral artery growth. While this process is impaired in DM
due to the reduced Egr-1 expression, it can be rescued by insulin treatment.
Earlier studies have clearly shown that induction of arteriogenesis in C57Bl6 mice by FAL resulted
in an increased expression of Egr-1 at the transcript and the protein levels in growing collaterals [22].
Interestingly, Egr-1 deficient mice have been shown to have increased basal levels of CD11b+monocytes
in the peripheral blood; however, levels of collateral perivascular macrophages as well as CD3+ T
cells and CD19+ B cells in adductor muscles harvesting growing collaterals were reduced. Moreover,
FAL in Egr-1−/−mice was associated with poor leukocyte recruitment and reduced collateral artery
growth [22]. Our results showed that induction of DM, which was associated with reduced expression
levels of Egr-1, also resulted in increased systemic levels of CD11b+ cells, and after induction of
arteriogenesis, in reduced levels of CD11b+, CD3+, and CD19+ cells. Interestingly enough, treatment
with insulin rescued perivascular leukocyte counts.
Decreased expression of Egr-1 in DM mice in our study may support earlier findings showing
that Egr-1 is critical for collateral vessel development and that functional regulation of Egr-1 may be
compromised in DM. Evidence of induction and expression of Egr-1 by elevated levels of glucose
in murine glomerular endothelial cells and aortic smooth muscle cells have been reported. Exposure to
insulin or high concentrations of D-glucose increased the expression of Egr-1 on the mRNA and
protein level in glomerular endothelial cells and increased its promoter activity irrespectively of
the concentration of insulin [27,28]. TNF-α is downstream of Egr-1 and induces the expression
of MCP-1. However, in arteriogenesis, increased levels of TNF-α, relevant for MCP-1 expression,
are dependent on mast cell activation [14]. Vedantham et. al. demonstrated a novel mechanism linking
glucose metabolism to increased inflammatory and prothrombotic signaling in diabetic atherosclerosis
via activation and post-translational modification of Egr-1. Hyperglycemia-induced hyper-acetylation
of Egr-1 in endothelial cells was reported to be an important event linking diabetes to accelerated
atherosclerosis [29]. Though acetylation of Egr-1 was not studied, it will be interesting to pursue future
studies to understand the role of Egr-1 in the pathophysiology of arteriogenesis. Our observations in this
study are contrary to those observed in diabetic atherosclerosis. There may be a possibility of additional
regulation of Egr-1, as indicated by the shift in bands of Egr-1. Post-translational modifications of
Egr-1 such as acetylation and phosphorylation have been reported to play an important role in the
transcriptional activity and stability of Egr-1 [17,30]. Phosphorylation/dephosphorylation events may
act as regulators for restricting the function of Egr-1. Furthermore, SP-1 has been reported to compete
for DNA binding sites of Egr-1 [17]. Recently, a splice form of Egr-1 was reported which lacks the
N-terminal activation domain between amino acids 141 and 278 [31]. It will be interesting to further
understand the mechanism through which hyperglycemia interferes with Egr-1 upregulation during
the process of arteriogenesis.
Leukocyte infiltration mediated through downstream target genes of Egr-1, namely, ICAM-1, uPA
and MCP-1, was found to be decreased during collateral artery growth in diabetic mice. Endothelial
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uPA is vital for neutrophil adherence to the endothelial cells [32]. Neutrophils accumulate around
day 1 after FAL in the perivascular space of growing collaterals and have a relevant function in the
recruitment of macrophages and lymphocytes, which appear at day 3 [14]. Indeed, it has been
shown that uPA deficiency is associated with reduced perivascular leukocyte accumulation and
results in reduced collateral artery growth after induction of arteriogenesis via FAL [33]. These data
comply with reported findings that Egr-1 mediates leukocyte infiltration through activation of the
abovementioned genes in arteriogenesis [21]. Furthermore, the expression of the cell proliferation
marker Ki-67 was found to be decreased in the growing collaterals of diabetic mice, highlighting
the fact that, indeed, there was a decrease in the proliferation of vascular cells. SF-1, an important
transcriptional repressor critical for smooth muscle proliferation and phenotype switch [33], was found
to be elevated in our study in support of an earlier report demonstrating that Egr-1−/−mice exhibited
increased expression of SF-1 in growing collateral arteries [21]. One of the interesting findings of our
study as the beneficial effect of insulin on collateral artery growth in DM mice. SF-1 regulates gene
expression of pro-inflammatory cytokines in smooth muscle cells [33] and antagonizes platelet-derived
growth factor BB (PDGF-BB)-induced growth and differentiation of vascular cells [34]. Several earlier
reports have shown a regulation of Egr-1 by insulin. Furthermore, Gousseva et al. [28] have reported
an insulin-mediated increase in Egr-1 promoter activity and cell proliferation in bovine aortic smooth
muscle cells. Egr-1 has a role in adipocyte insulin resistance through activation of the MAPK-ERK
pathway [35]. Our studies clearly show that diabetic mice treated with insulin show an increased
expression of Egr-1, accompanied by an augmented expression of Egr-1 downstream target genes
relevant for leukocyte recruitment. Indeed, our results show that insulin treatment, moreover, goes
along with increased numbers of leukocytes—relevant for the process of arteriogenesis—in collateral
harboring muscles.
In summary, Egr-1 expression decreased after induction of arteriogenesis in growing collaterals of
streptozotocin-induced diabetic mice compared to control mice. Decreased Egr-1 expression led to poor
collateral growth. Insulin treatment, however, normalized the Egr-1 expression, thereby promoting
arteriogenesis. Though this was an observational study, this study assumes significance as it is the first
time associating Egr-1 with impaired arteriogenesis in DM. It will be interesting to see whether the
same processes occur in patients with DM. Further investigations exploring the mechanism by which
hyperglycemia suppresses Egr-1 expression during the process of arteriogenesis will lead to better
understanding of impaired arteriogenesis in DM.
4. Materials and Methods
4.1. Animal Studies
All studies with mice were performed after approval by the Institutional and Local Animal
Ethics Committee (CPCSEA Approval number: H01/SASTRA/IAEC/RPP-23/12/15). Male C57B6NTac
(Taconic Biosciences, USA) mice were procured through Vivo Biotech Ltd., Telangana, India and were
maintained in an air-conditioned room (25 ◦C) with a 12 h light/12 h dark cycle. Feed and water
were provided ad libitum to all the animals. Mice were rendered diabetic by treating them with
STZ according to published protocols [36]. Briefly, eight-week-old male mice were made diabetic by
administration of 50 mg/kg STZ dissolved in fresh citrate buffer (0.05 mol/L, pH 4.5) i.p. per day for five
consecutive days. Those mice displaying blood glucose levels ≥ 250 mg/dL were considered diabetic
(DM mice). The non-diabetic (NDM mice) control mice received citrate buffer alone. One group of
mice received insulin after confirmation of hyperglycemia. Insulin was administered subcutaneously
at a daily dose of 0.20 mL/100 g (4–5 U) until the end of the experiment.
4.2. Femoral Artery Ligation and Collection of Collaterals
Femoral artery ligation was performed as published earlier [37]. In brief, using a silk braided
suture (0/7) the right femoral artery was ligated distally from the origin of the profunda femoris
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branching, while the left leg was sham operated. Adductor muscles and collateral arteries were
collected as previously described [20]. To carry out fluorescent-activated cell sorting (FACS) analyses,
adductor muscles were collected 3 days after the surgical procedure and for histological analysis,
the adductor muscles were harvested 7 days after FAL. Gene expression studies on RNA and protein
levels were performed with collateral arteries isolated 24 h after induction of arteriogenesis.
4.3. RNA Isolation and Quantitative Real-Time PCR Studies
Gene expression studies were performed using quantitative real time PCR (qRT-PCR). Total RNA
was isolated using the RNeasy kit (TaKaRA). After DNase I (Qiagen, Hilden, Germany) digestion,
one microgram of total RNA was reverse transcribed by random hexamers and Superscript RT-PCR
System (Invitrogen, Carlsbad, CA, USA). After purification, the cDNA was used for qRT-PCR using
specific primers for Egr-1, MCP-1, ICAM-1, SF-1, and Ki-67 [21]. Results were normalized to the
expression level of the 18S rRNA.
4.4. FACS Analyses of Blood and Muscle Tissue
Whole blood withdrawn from the left ventricle 3 days post-ligation was analyzed by flow
cytometry analyses (BD FACS Aria III, CA, USA) according to standard protocols. Furthermore,
the adductor muscles from C57B6NTac mice were perfused with PBS (phosphate buffered saline) to
eliminate the blood, harvested, and placed in small cell culture dishes. The tissue was cut into small
pieces and digested 45 min at 37 ◦C using PBS buffer (50 mL) containing collagenase II (1 mg/mL),
hyaluronidase (0.5 mg/mL) (both Sigma, St. Louis, MO, USA), dispase (1 mg/mL) (Gibco, Invitrogen,
Carlsbad, CA, USA), and BSA (bovine serum albumin) (0.6 mg/mL) (Sigma). The suspension was then
filtered with PBS/2%BSA through a 70 μm cell strainer (BD Falcon™), spun 10 min at 95 g, and the
pellet finally resuspended in 100 μL PBS/2%BSA. The resulting cell suspension was analyzed by
FACS using a panel of monoclonal antibodies against CD3 (T cells); (BioLegend Cat. No. 100201),
CD11b (neutrophils, monocytes) (BioLegend Cat. No. 305902), CD19 (B cells) (BioLegend Cat. No.
115501), and CD45 (pan-leukocytes marker) (BioLegend Cat. No. 103101). Leukocyte populations
were identified by fluorescence and scatter light characteristics. Cells from both peripheral blood and
tissue were gated based on forward scatter (FSC-A)/side scatter (SSC-A). Leukocytes were identified
by their positive staining with CD45. The final gating was based on CD45+/CD11b+, CD45+/CD19+,
and CD45+/CD3+ cells (14).
4.5. Histological Analyses
Histological analyses were performed on adductor muscles (harboring collateral arteries) isolated
from C57B6NTac mice as described earlier [20]. Briefly, 7 days after the surgical procedure both hind
limbs were perfused with PBS containing 0.1% adenosine and 0.05% BSA (Sigma), then 4 min with
fixing solution (4% buffered paraformaldehyde) via cannulation of the aorta. Thereafter, tissue samples
were paraffin-embedded, cut in cross-sections, and H&E staining was performed to measure luminal
collateral artery diameters.
4.6. Western Blot
Western blot analysis was performed on protein extracts, which were isolated from collaterals
24 h after femoral artery ligation or sham operation of DM and NDM mice according to standard
procedures. Briefly, 30 μg of protein from all the tissue lysates was loaded onto a 10% sodium dodecyl
sulfate (SDS) gel and ran at a power of 110 V. The protein in the gel was shifted to an immune-blot
polyvinylidene difluoride (PVDF) membrane (1620112, Bio-Rad, USA) at 100 V for 1 h using Trans-Blot
Turbo Transfer System (Bio-Rad). The blots were probed for Egr-1 protein (Egr-1 antibody (588)-Santa
Cruz BioTechnology Cat.no #sc110). α-Tubulin served as a housekeeping protein (alpha tubulin
antibody (B-7): Santa Cruz Biotechnology Cat.no. #sc-5286). The density of Egr-1 to α-tubulin was
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measured through the Quant-One software (Bio-Rad). The immunoblots are a representation of at
least three independent experiments.
4.7. Statistical Analysis
All values are expressed as means ± SD unless mentioned. Statistical analyses were conducted as
indicated in the figure legends using GraphPad software PRISM6 (GraphPad Software, USA). The limit
of statistical significance was set at p < 0.05.
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Abbreviations
SF-1 Splicing Factor 1
DM Diabetes Mellitus
NDM Non-Diabetes Mellitus
Egr-1 Early growth response-1
uPA urokinase Plasminogen Activator
MCP-1 Monocyte Chemoattractant Protein-1
ICAM-1 Intercellular Adhesion Molecule-1
FAL Femoral Artery Ligation
STZ Streptozotocin
PAD Peripheral Artery Disease
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Abstract: Many pathological conditions are characterized or caused by the presence of an insufficient
or aberrant local vasculature. Thus, therapeutic approaches aimed at modulating the caliber
and/or density of the vasculature by controlling angiogenesis and arteriogenesis have been under
development for many years. As our understanding of the underlying cellular and molecular
mechanisms of these vascular growth processes continues to grow, so too do the available targets
for therapeutic intervention. Nonetheless, the tools needed to implement such therapies have often
had inherent weaknesses (i.e., invasiveness, expense, poor targeting, and control) that preclude
successful outcomes. Approximately 20 years ago, the potential for using ultrasound as a new tool for
therapeutically manipulating angiogenesis and arteriogenesis began to emerge. Indeed, the ability of
ultrasound, especially when used in combination with contrast agent microbubbles, to mechanically
manipulate the microvasculature has opened several doors for exploration. In turn, multiple studies
on the influence of ultrasound-mediated bioeffects on vascular growth and the use of ultrasound for
the targeted stimulation of blood vessel growth via drug and gene delivery have been performed and
published over the years. In this review article, we first discuss the basic principles of therapeutic
ultrasound for stimulating angiogenesis and arteriogenesis. We then follow this with a comprehensive
cataloging of studies that have used ultrasound for stimulating revascularization to date. Finally,
we offer a brief perspective on the future of such approaches, in the context of both further research
development and possible clinical translation.
Keywords: arteriogenesis; therapeutic revascularization; ultrasound; microbubbles; biomaterials;
drug and gene delivery
1. Therapeutic Vascular Remodeling
The vascular system facilitates the transport of oxygen and essential nutrients to all tissues, aids
in maintaining body temperature and tissue fluid levels, and removes metabolic waste byproducts,
regulating each process through specific mechanisms for different physiological states. In the case of
disease pathology, the vasculature can be driven from quiescence and can actively alter its structure,
engaging in processes such as vasculogenesis (de novo vessel formation), angiogenesis (new vessels
sprouting from existing vessels), arteriogenesis (collateral artery growth), and vessel regression
(disassembly of vascular structures). Alzheimer’s disease, atherosclerosis (leading to peripheral arterial
disease and myocardial ischemia), and osteoporosis are prominent examples of conditions characterized
or influenced by insufficient vascularization or vessel regression [1]. Insight into the complex and
highly integrated cellular, molecular, and genetic mechanisms underlying the aforementioned vascular
growth and remodeling processes is steadily increasing through worldwide research efforts. In turn,
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there has been an expansion in the potential of clinically relevant therapies that seek to augment
angiogenesis or arteriogenesis in states of vascular deficiency or regression.
Many current treatments for vascular disorders involve invasive surgical procedures that risk
severe complications and are not available to all patients [2–6]. Therefore, with the goal of minimizing
invasiveness and undesired side effects, novel cell-, molecule-, and gene-based interventions for
therapeutic revascularization are being explored in a wide range of studies, all seeking the potential
development of clinically relevant therapies. For instance, adult stem cells, i.e., adipose-derived
cells, bone marrow-derived cells (BMDCs), and circulating endothelial progenitor cells (EPCs),
have been investigated for their ability to promote enhanced vascular growth and remodeling in
tissues afflicted by an ischemic injury [7–10]. Vascular growth factors and cytokines like vascular
endothelial growth factor-A (VEGF-A) [11–13], platelet-derived growth factor-BB (PDGF-BB) [14,15],
and granulocyte-macrophage colony-stimulating factor (GM-CSF) [16–18], and genes encoding various
pro-angiogenic and pro-arteriogenic molecules [19–21], have also been explored in the context of tissue
ischemia. Furthermore, our emerging understanding of the roles of various epigenetic factors (e.g., DNA
methylation [22] and non-coding RNAs [23,24]) in regulating vascular growth and remodeling now
offers opportunities for new therapeutic targets [25].
However, considerable limitations exist not only in designing revascularization therapies that
influence only the intended molecular targets, but also in physically delivering the therapeutic agents
only to the disease site in a way where unrelated tissues are not affected. For instance, adsorption from
the gut to the bloodstream (i.e., oral administration) may pose risks to systemic tissues and organs, and
intravenous injection and catheter-based administration methods face similar difficulties. Implanting
controlled release devices can involve an invasive procedure and also present the risk of infection or
an adverse biomaterial response. Direct injection of a therapeutic agent into and/or near ischemic
tissue is perhaps the most commonly used mode of delivery for revascularization, but this invasive
approach often lacks a sustained vascular remodeling response and can yield the poor dispersion of
therapeutic agents away from injection site(s). Thus, in the context of therapeutic revascularization,
substantial opportunities remain for developing more efficient delivery approaches that offer high
spatial accuracy and minimal invasiveness.
2. Ultrasound Technology: Basic Principles and Contrast Agents
One minimally-invasive technology that has the potential to both achieve high spatial accuracy and
yield wide therapeutic dispersion through tissue for revascularization is therapeutic ultrasound (US).
Before discussing how ultrasound may be applied therapeutically for revascularization, we provide here
a brief background on the basic principles that govern US and its potentially beneficial effects on tissue.
An US waveform is transmitted into a region of interest when specific piezoelectric elements positioned
on the face of a transducer are activated by an appropriate electrical signal. The generated acoustic
energy propagates through the tissue, encountering regions of varying acoustic (i.e., mechanical)
impedance. These mechanical heterogeneities modify the ultrasound beam through attenuation and
diffraction as well as reflection and scattering. In diagnostic ultrasound imaging, reflected and scattered
energy returns to the transducer, which now behaves as a receiver, converting the mechanical acoustic
energy into electrical energy. A meaningful image can then be displayed when these electrical signals
are processed appropriately.
After many years of use as a minimally invasive imaging modality, it was discovered that US
in conjunction with gas-filled contrast agent microbubbles (which enhance blood echogenicity and,
consequently, the contrast between tissues during an US exam) could also be used for other applications.
These microbubbles (MBs) circulating within the bloodstream can be destroyed by US, facilitating the
assessment of tissue perfusion by its correlation to MB replenishment in a given region [26,27]. Concerns
about the possible deleterious bioeffects from ultrasonic MB destruction have fueled investigations
into the impact of this phenomenon on surrounding tissues. Observations from these studies have
shown that localized regions of microvessels experienced increases in permeabilization as indicated by
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red blood cell (RBC) extravasation from sites of intravascular US +MB interactions [28–31]. Based
on these findings, significant interest was generated in possibly exploiting these US +MB-induced
bioeffects for beneficial purposes including the direct stimulation of vascular remodeling through the
bioeffects of ultrasonic MB activation as well as the targeted delivery of therapeutic agents.
Figure 1. Activation of microbubbles with ultrasound can elicit arteriogenesis. Confocal micrographs
illustrating the expression of SM α-actin (green fluorescence) in relation to microvessels, as labeled
with BS-I lectin (red fluorescence). Images were taken 14 days after muscles were exposed to US-MB
treatment (A) or sham treatment (B). Panel (C) represents the untreated muscle. Note the increased
number and caliber of SM α-actin+ vessels with US +MB treatment (A). Bar = 30 μm. Adapted from
Song et al. [32].
3. Ultrasound Activation of Microbubbles to Facilitate Angiogenesis and Arteriogenesis
Interactions between relatively low-power US and circulating MBs elicit a range of bioeffects
through mechanisms that remain only partially understood [33,34]. In addition to the increase
in microvascular permeability discussed in the previous sections [29,30], hemolysis (i.e., RBC
destruction) [35–38] and arterial vasospasms [39] have been shown to occur near sites of US +MB
interactions. Additionally, cavitation of MBs by US may cause free radical production [40–42],
heating [43–45], shockwave emanation resulting in microstreaming [46–48], and bubble fragmentation
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producing microjets [34,49]. These effects may individually or collaboratively impact the surrounding
microenvironment to elicit the tissue level consequences (e.g., capillary disruptions, wound healing
pathways, hemostasis, inflammation signaling pathways). Components of these pathways are known
to be involved in modulating vascular remodeling; thus, it was postulated that selectively instigating
these pathways, among others, through the targeted destruction of MBs with US might result in a
localized neovascularization response in treated tissues.
Indeed, this hypothesis was verified by an exploration of the vascular remodeling response in
the gracilis muscle of a rat hindlimb exposed to low-power US and intravascular MBs [32]. Here,
the application of 1-MHz pulsed US following intravenous injection of MBs induced capillary disruption
sites as visualized by RBC extravasation. This elicited an arteriogenic response (Figure 1), which, in turn,
enhanced blood flow in the hindlimb skeletal muscle. Furthermore, a follow-up study demonstrated
the ability of this US +MB treatment scheme to significantly augment the vascular remodeling response
of, and subsequently restore the perfusion to, a rat hindlimb affected by an arterial occlusion [50].
The experimental procedures from the rat studies were recapitulated in normal mice [51], in part to lay
the foundation for studies addressing possible mechanisms behind the US +MB-induced neovascular
adaptations. This transition to a mouse model provided a platform that was also advantageous for
both mechanistic experiments involving genetic and/or cellular alterations and for experiments in
a model of hindlimb ischemia. Although transient and failing to match the duration and extent of
the response observed in the rat study, mouse hindlimb skeletal muscle exposed to a comparable US
+ MB treatment indeed exhibited a significant increase in neovascularization in comparison to the
sham-treated muscles.
An investigation into the method by which these therapeutic vascular remodeling responses occur
in the ischemic mouse and rat hindlimb revealed that the recruitment of CD18+ (integrin beta chain-2+)
BMDCs is necessary for angiogenesis, arteriogenesis, and CD11b+monocyte recruitment, as animals
with CD18-/- BMDCs did not exhibit vascular remodeling [52]. A separate study demonstrated that
treatment with US +MBs induced the recruitment of CD45+ leukocytes including macrophages and
T-lymphocytes to the treated tissue. Both of these cell types produce VEGF-A, and VEGF-A levels
were elevated in the treated muscle, corresponding to increased capillary density, surface vascularity,
blood flow, and functional improvement in the previously-ischemic skeletal muscle [53].
The selected parameters of the US +MB application have been shown to play a role in the ensuing
vascular responses. For example, the influence of raising peak US rarefactional pressure to 3.8 MPa
(in contrast to the previously described studies, which used pressures as high as 1.4 MPa), which
ensures collapse of 100% of all MBs within the US focal region, has been tested. Animals treated
at this high US pressure exhibited a marked decrease in capillary density immediately following
treatment as well as clear evidence of hemorrhage. While capillary density increased somewhat in the
weeks following treatment, it only reached 70% of baseline by 27 days post-treatment, suggesting that
100% MB collapse by high pressure US causes capillary destruction from which normal rats cannot
recover [54]. Further study by this group explored the effects of different concentrations of MBs at a
lower US pressure (0.7 MPa), and found that increased concentrations of MBs were associated with a
greater degree of vascular permeability and VEGF expression [55].
While the majority of studies investigating the role of US activation of MBs to promote vascular
remodeling have been in the context of skeletal muscle, several other tissues have also been investigated.
US +MBs have been used to stimulate revascularization in the myocardium following acute myocardial
infarction. In a mouse model, US activation of MBs resulted in increased microvascular density and
reduced scar size, along with a transient up-regulation of VEGF-A and IGF-1 in the myocardium
and improved left ventricular function [56]. Recently, there has been increased interest in the
potential application of US and MBs to induce remodeling of brain vasculature. Focused US (FUS) in
combination with MBs can be used to temporarily open the blood–brain barrier (BBB) at specific sites in
the brain [57–60], consistent with the increased vascular permeability observed in other tissues. It has
been observed that following disruption of the BBB by FUS and MBs, there is an acute upregulation of
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proinflammatory cytokine genes as well as angiogenesis-related genes in microvessels [61]. Further
investigation of this phenomenon revealed that the transcriptional changes did in fact correspond with
functional responses—following FUS activation of MBs in the hippocampus, there was a transient
increase in blood vessel density as well as increased newborn endothelial cell density and frequency of
small blood vessel segments [62].
4. Ultrasound and Microbubbles to Deliver Genes, Molecules, or Cells to Facilitate Angiogenesis
and Arteriogenesis
As described previously, observations that US-mediated destruction of MBs could enhance blood
vessel permeability have spurred interest in using these phenomena to facilitate the targeted delivery of
therapeutic agents. The general premise is to co-administer a therapeutic agent, either freely circulating
in the bloodstream alongside MBs, or physically associated with the MBs (i.e., bound/tethered to their
surface or contained within the MB (Figure 2)) into the bloodstream while the MBs are circulating.
Following US-induced cavitation of the MBs, there is increased permeability of the vessels at the site of
US exposure, allowing for increased extravasation or uptake of the therapeutic agent in the circulation
(Figure 2). Demonstrating this targeted delivery concept, Price et al. delivered polymer microspheres
into the interstitium of rat spinotrapezius muscle via microvessel disruptions caused by ultrasonic
MB destruction [31]. One of the first studies to show successful US + MB-targeted gene delivery
involved the transfer of the P-galactosidase gene into rat myocardium through echocardiographic
MB destruction [63]. While gene delivery to the myocardium with this US +MB technique has been
investigated in several other studies [36,53,64–68], the potential treatment of various pathologies using
US +MB-mediated gene transfer has also been explored in numerous other tissues including skeletal
muscle [69–74], liver [75–83], and brain [84–97].
Figure 2. Overview of approaches to US +MB-mediated drug and/or gene delivery. (A) The therapeutic
agent (nanoparticles in this example) may be co-administered with contrast agent microbubbles, attached
to microbubble shells, incorporated into the microbubble shell, and/or contained within the microbubble.
(B) The application of US activates the oscillation of microbubbles. At high enough peak-negative
acoustic pressures, microbubbles can be fragmented. In some approaches, microbubble activation
may lead to dissociation of a bound therapeutic from the microbubble. (C) Ultrasound–microbubble
interactions simultaneously act to permeabilize the surrounding microvasculature, facilitating delivery
of the therapeutic via diffusion and/or convection from the bloodstream to the ultrasound-targeted
tissue. Adapted from Chappell and Price. [98].
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Using US +MBs to facilitate nucleic acid delivery to specifically modulate vascular remodeling
remains a relatively underexplored technology. The delivery of a VEGF-A gene to the rat myocardium
has been demonstrated using US-targeted MB destruction. After treatment, increased levels of VEGF-A
mRNA and protein were evident as well as increased capillary and arteriolar density within the
myocardium [65]. The VEGF-A gene is also delivered to skeletal muscle in rats following a hindlimb
ischemia surgery. In this study, the authors noted increased levels of the VEGF-A mRNA shortly after
US +MB treatment as well as enhanced tissue perfusion, which was attributed to an observed increase
in arteriolar density [73]. Moreover, it has been shown that genes may be delivered in a highly-targeted
manner to hindlimb skeletal muscle using ultrasound in combination with non-viral gene nanocarriers
(Figure 3) [70]. Although not yet utilized in a therapeutic revascularization capacity, this nanocarrier
approach offers enticing options for technology development in this space going forward.
 
Figure 3. Overview of the strategy for eliciting ultrasound-targeted transfection of hindlimb adductor
muscles via the delivery of non-viral gene nanocarriers. (Left) Contrast agent microbubbles are
intravenously co-injected with gene-bearing nanocarriers. (Middle) Pulsed ultrasound is then applied
to the adductor muscle group, which activates microbubble oscillation and facilitates nanocarrier
delivery to the muscle tissue. (Right) Reporter gene expression is evident only where ultrasound has
been applied. Adapted from Burke et al. [70].
US and MB interactions have also been used to stimulate vascular remodeling in tissues other than
skeletal muscle. One particularly interesting example entails the use of ultrasound to deliver a VEGF-A
gene to the placental basal plate in a pregnant baboon to stimulate uterine artery remodeling [99].
Meanwhile, myocardium obviously also represents an important target for therapeutic revascularization.
Delivery of a hepatocyte growth factor (HGF) plasmid to the myocardium in a canine model of
myocardial infarction resulted in increased capillary density as well as reduced infarct size and scar
tissue formation [100]. An HGF plasmid has also been delivered with US + MBs in a rat model
of myocardial infarction. This treatment resulted in reduced left ventricular hypertrophy and scar
formation as well as increased capillary and arterial density in the US-treated region [68]. Additionally,
recent studies have explored the potential of the US +MB approach to deliver therapeutic genes to the
brain. Following evidence that VEGF-A delivery to the brain promotes angiogenesis and functional
recovery after ischemic stroke [101–103], US +MBs were employed to deliver a VEGF-A plasmid to
the peri-ischemic region of the brain after infarction. The VEGF-A treatment reduced infarct size and
apoptosis, and increased vessel density through stimulation of angiogenesis [92].
While not within the strict definition of “vascular remodeling” as applied in this review article
(i.e., vasculogenesis, angiogenesis, and arteriogenesis), a few groups have investigated the use of US
for targeted delivery in the context of neointimal hyperplasia, and such studies may offer insight into
therapeutic revascularization strategies. In a handful of studies, US +MB-mediated approaches have
been utilized to deliver an NFκB cis-element ‘decoy’ to inhibit neointimal hyperplasia development
104
Int. J. Mol. Sci. 2019, 20, 3081
in arterial injury models. Delivery of this decoy in a rat carotid artery injury model was found to
prevent the upregulation of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1) in the neointimal area otherwise activated by arterial injury as well as the influx
of macrophages and T-lymphocytes into the intima and media [104]. Similar observations were made
following delivery of the ‘decoy’ in murine [105] or porcine [106] arterial injury models, suggesting
the potential of this approach for minimizing neointimal hyperplasia following angioplasty or other
coronary interventions. In addition, US +MB delivery of an siRNA against ICAM-1 has also been
shown to suppress the development of neointimal formation following a murine arterial injury, and
inhibit the accumulation of T cells within the injured artery [107].
The US +MB-targeted delivery method can be used to deliver more than just nucleic acids to
stimulate therapeutic revascularization. Intramuscular injections of bone marrow mononuclear cells
(BM-MNCs) have been demonstrated to promote angiogenesis and functional recovery of ischemic
muscle in both animals [108] and humans [109], motivating the development of a noninvasive delivery
system for these cells. In a rat model of hindlimb ischemia, intravenous injection of BM-MNCs
immediately after US activation of MBs resulted in a significant enhancement in blood flow recovery,
increased capillary and arteriolar density, and augmented collateral vessel formation [110]. US +MBs
have also been used to deliver BM-MNCs to the myocardium in a hamster model of cardiomyopathy.
US-mediated delivery of the BM-MNCs resulted in increased capillary density as well as expression of
VEGF-A and FGF-2 by the myocardial tissue. The BM-MNCs were found to adhere to the US-targeted
vascular endothelium within the myocardium, and endothelial progenitors within the BM-MNC
population were shown to trans-differentiate into endothelial-like cells to repair US-stimulated
endothelium and supply angiogenic factors (VEGF-A and FGF-2) to promote neovessel formation.
The authors also observed reduced fibrosis and improved cardiac function and blood flow in the US +
MB + BM-MNC treated group relative to the controls [111].
US can also be used to deliver proteins. VEGF-A was delivered to the heart with US +MBs as early
as 2000, although functional impacts on angiogenesis and arteriogenesis were not investigated [112].
In 2007, US +MBs were used in conjunction with granulocyte colony-stimulating factor (G-CSF) in
the ischemic hindlimb muscles of mice. Here, instead of utilizing an intravenous injection strategy,
G-CSF was injected subcutaneously. Specifically, mice were pre-treated with either a single or repeated
subcutaneous injection of G-CSF after hindlimb ischemia surgery. One day following the final injection,
the hindlimb muscle was targeted with US +MBs. Animals that received the G-CSF and US +MBs
exhibited increased capillary density and collateral growth relative to animals that received only the
G-CSF (no US) or just the US + MBs (no G-CSF) [113]. In 2008, we made use of an intravascular
co-injection strategy, rather than pre-treatment. We first demonstrated the ability of US + MB
interactions to facilitate the delivery of intra-arterially injected nanoparticles to the hindlimb skeletal
muscle (Figure 4). Next, we injected nanoparticles containing FGF-2 intraarterially along with the
MBs, and then used US to activate the MBs in the ischemic gracilis muscle of mice following hindlimb
ischemia surgery. The therapy increased both the number and maximum intraluminal diameter of
collateral arterioles (stimulating arteriogenesis, but not apparent angiogenesis) (Figure 5) [114].
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Figure 4. Muscle cross-sections illustrating nanoparticle (NP) delivery. (A–I) Representative images of
sections taken from gracilis muscles treated with ultrasound (US) +microbubbles (MB) + nanoparticles
(NP) (A–C), ultrasound+ nanoparticles (D–F), and microbubbles+ nanoparticles (G–I) are shown. Note
the deposition of nanoparticles (red) in muscle treated with ultrasound +microbubble + nanoparticles.
J: Bar graph representing the fraction of interstitial area (regions outside of muscle fibers and vascular
structures) or endothelial cell area (cells comprising the walls of blood vessels) occupied by fluorescent
polystyrene nanoparticles. Values are means with standard deviations. * Indicates significantly different
(p < 0.05) to the interstitial area of all other groups. + indicates significantly different (p < 0.05) to the
endothelial cell area of all other groups. Adapted from Chappell et al. [114].
 
Figure 5. The delivery of FGF-2 bearing nanoparticles by ultrasonic microbubble destruction elicits
arteriogenic remodeling in gracilis adductor muscle. (A–D) Representative whole-mount images of
fluorescently-labeled SM α-actin+ vessels in gracilis adductor muscles seven and 14 days after FGF-2
(A,B) and bovine serum albumin (BSA) (C,D) treatment. Note the significant increase in arteriolar
caliber and density in FGF-2-treated muscles. (E) Bar graph of arteriole-line intersections at both time
points for FGF-2, BSA, and sham surgery treatment. Values are means with standard errors. * Indicates
significantly different (p < 0.05) to BSA and sham surgery at day 14. Adapted from Chappell et al. [114].
While US provides a high degree of spatial targeting for treatment, modifications to the MB
contrast agents themselves can provide an additional level of specificity. A number of studies have
been conducted to modify the shell of the MBs to include targeting ligands, so that the MBs will
selectively bind to particular regions of interest. For example, MBs coated with ligands that bind to
P-selectin have been developed to target MBs (and thus, their imaging and therapeutic delivery effects)
to the endothelium of inflamed blood vessels [115–121]. Other inflammation-related markers that
have been used for targeting include E-selectin [122–124], ICAM-1 [125,126], and VCAM-1 [127–130].
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A number of ligands against endothelial markers of angiogenesis including αvβ3-integrins [131–133],
VEGF receptor-2 (VEGFR2) [134–137], and endoglin [138,139] have also been used to target MBs to
specific tissues or areas of the vasculature. While the majority of these studies have used the targeted
MBs for diagnostic imaging purposes or the delivery of reporter genes or molecules, the method holds
great potential for therapeutic applications related to vascular remodeling. Depending on the disease
application, this approach allows for enhanced MB accumulation at the desired tissue site, permitting
improved delivery of drugs and genes to promote angiogenesis or arteriogenesis.
5. Activation of Implanted Biomaterials with Ultrasound to Elicit Vascular Remodeling
One interesting new therapeutic application of ultrasound has been the advent of acoustically
responsive biomaterials. For the past two decades, the principle of acoustic droplet vaporization (ADV)
has been utilized to develop phase shift droplet emulsions, sub-micron-sized liquid droplets that
vaporize into gas bubbles when exposed to sufficient acoustic pressure [140,141]. The general principle
is to stabilize a perfluorocarbon with a relatively low natural boiling point (below body temperature,
for example) in a superheated state using a surfactant, trapping the perfluorocarbon within the droplet,
and preventing rapid aggregation. The speed of sound in the perfluorocarbon is substantially different
than in the plasma surrounding the droplets in the bloodstream, permitting the use of the droplets as
both contrast agents in an imaging setting as well as a therapeutic delivery mechanism [142]. Exposure
to pressures above a particular threshold can induce the nucleation and growth of gas pockets within
the droplets. The droplets then rapidly expand into gas bubbles considerably larger than their initial
size [141,143–145], and can release payloads or oscillate like standard microbubbles. Emulsions of
such droplets have since been engineered to encapsulate and deliver drugs in a targeted manner for a
variety of disease applications [146–150].
Recently, these droplet emulsions have been utilized in a new application, droplet-hydrogel
composite materials, where a hydrogel matrix is doped with a perfluorocarbon emulsion containing a
therapeutic drug or molecule. This approach allows for both spatial and temporal control of the release
of the therapeutic. In a 2013 in vitro study, a fibrin matrix containing perfluorocarbon droplets loaded
with bFGF was activated with US, and the releasate from the hydrogel was applied to endothelial
cells in culture. The bFGF-containing releasate did indeed stimulate metabolic activity in the cultured
endothelial cells, demonstrating that the growth factor maintains functional bioactivity throughout
the encapsulation and release processes. Increases in metabolic activity were also observed when
endothelial cells were already seeded within the hydrogel at the time of US application [151]. These
acoustically-responsive scaffolds (ARS) have also been shown to respond similarly to US in terms of
payload release in vivo [152]. A bFGF-loaded ARS was injected subcutaneously into the dorsal region
of mice, and later activated with US to release the growth factor. The mice that received the ARS and
US demonstrated significantly enhanced perfusion relative to mice that received the ARS without US
or a control fibrin hydrogel (with or without free bFGF). Additionally, the ARS + US group showed a
significant upregulation in capillary density, indicating the growth factor-loaded ARS approach can be
used to stimulate therapeutic angiogenesis [153].
6. Outlook
As reviewed here, over the past 15 years, numerous pre-clinical studies have demonstrated the
potential of US to induce revascularization responses through the oscillation and/or destruction
of gas-filled MBs, the delivery of therapeutic genes, proteins, or cells, or the activation of
acoustically-responsive biomaterials. These approaches present opportunities for novel non-invasive
and spatially-targeted treatments for diseases caused or characterized by insufficient or aberrant
vasculature, replacing traditional interventions associated with invasive or high-risk procedures
(surgery) or off-target effects (systemic delivery). In particular, we believe that US-mediated
revascularization has immense potential for treating central nervous system disorders, where the
blood–brain barrier poses a significant challenge to many treatment modalities as well as tissue
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engineering and biomaterials where the ability to non-invasively activate an implanted material would
allow for highly tunable and versatile therapies that could be easily adapted to meet the needs of
individual patients.
Nonetheless, it is also true that, despite this abundance of pre-clinical investigation,
ultrasound-mediated approaches for revascularization have not been successfully translated to the
clinic. While this is discouraging, the past few years have seen a handful of ultrasound-mediated drug
delivery approaches enter into clinical trials, and we submit that these trials have the potential to open
doors for many new applications going forward. This includes the use of ultrasound for stimulating
revascularization. Indeed, in combination with i.v. microbubbles, ultrasound has now been used to
safely open the blood–brain barrier in Alzheimer’s disease patients [154] and to deliver chemotherapy
to patients with primary brain tumors [155,156]. Moreover, more trials utilizing focused ultrasound
and microbubbles for the blood–brain barrier opening are just now getting underway, signaling an
acceleration of clinical activity in this space. Meanwhile, ultrasound-microbubble-mediated drug
delivery has also entered clinical trials for an application outside of the CNS, with the targeted delivery
of gemcitabine having been performed in patients with pancreatic cancer [157]. With these trials serving
as the foundation, we are hopeful that the knowledge gained regarding the safety and relative efficacy
of ultrasound-microbubble-mediated treatments will facilitate the adoption of similar approaches for
therapeutic revascularization. Overall, we argue that US-based methods of promoting angiogenesis
and arteriogenesis still have potential to make an important positive impact on how we treat many
vascular pathologies in the future.
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Abstract: Exercise is a treatment option in peripheral artery disease (PAD) patients to improve their
clinical trajectory, at least in part induced by collateral growth. The ligation of the femoral artery (FAL)
in mice is an established model to induce arteriogenesis. We intended to develop an animal model to
stimulate collateral growth in mice through exercise. The training intensity assessment consisted
of comparing two different training regimens in C57BL/6 mice, a treadmill implementing forced
exercise and a free-to-access voluntary running wheel. The mice in the latter group covered a much
greater distance than the former pre- and postoperatively. C57BL/6 mice and hypercholesterolemic
ApoE-deficient (ApoE−/−) mice were subjected to FAL and had either access to a running wheel
or were kept in motion-restricting cages (control) and hind limb perfusion was measured pre- and
postoperatively at various times. Perfusion recovery in C57BL/6 mice was similar between the
groups. In contrast, ApoE−/− mice showed significant differences between training and control
7 d postoperatively with a significant increase in pericollateral macrophages while the collateral
diameter did not differ between training and control groups 21 d after surgery. ApoE−/− mice with
running wheel training is a suitable model to simulate exercise induced collateral growth in PAD.
This experimental set-up may provide a model for investigating molecular training effects.
Keywords: arteriogenesis; exercise training; mouse model; femoral artery ligation; running wheel;
voluntary training; peripheral artery disease
1. Introduction
Patients with peripheral arterial disease (PAD) often suffer from intermittent claudication, leading
to a significant walking impairment. According to the 2017 guidelines of the European Society
of Vascular Surgery (ESVS), supervised exercise training is a Class I, Level A recommendation in
patients presenting intermittent claudication, whereas unsupervised training is a Class I, Level C
recommendation. Walking has thus been shown to be a safe and effective treatment for patients with
PAD [1,2]. In particular, walking performance, cardiovascular parameters, and quality of life can be
improved by exercise.
Some potential exercise effects and scheduling modifiers are still unclear, in particular, risk factors
such as smoking, dyslipidemia, diabetes mellitus, obesity, and arterial hypertension as major
comorbidities of PAD are only considered infrequently [3–6]. Physical activity has suppressive effects
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on inflammation [7] and proinflammatory immune cells [8,9], as well as beneficial effects on endothelial
function [10]. Additionally, physical training has the potential to promote an additional vascularization
in hypoxic/ischemic tissues, such as the myocardium or peripheral limb [11]. Arteriogenesis, can be
induced by exercise in human [12–14] and in animal studies [15]. The driving force of arteriogenesis is
altered fluid shear stress (FSS) in the preformed collateral arteries due to increased blood flow [16].
The increased blood flow initiates vascular remodeling and diameter growth [17] and alters the miRNA
profile [18].
Nevertheless, the physiological pathways of how exercise affects collateral growth at the molecular
level are still not finally delineated.
Arteriogenesis is the process that results in growth of pre-existing collateral arterioles into
functional collateral arteries, triggered by a hemodynamically relevant stenosis of supplying blood
vessels. These bypassing vessels can sometimes be remarkably efficient and nearly completely
replace the occluded arteries [19]. This formation is stimulated by an increase of shear stress on the
endothelium [20]. An increase of blood flow can be achieved by a high demand and walking exercise
gives the best possibility to maximize the flow physiologically [6].
In past decades various models have been developed that help in understanding the mechanisms of
arteriogenesis. The ligation of the femoral artery (FAL) in mammals, especially the mouse, has become
a well-established model for the induction of arteriogenesis [3,21,22]. Exercise stress tests are widely
used for a variety of training protocols [23–25]. In most of the mice models, the training is voluntary
(treadmill or running wheel), only a minor share of the protocols is forced. As exercise characteristics
like frequency, intensity, type, and time cannot be controlled, a forced protocol may be appropriate.
On the other hand, forced exercise is, unlike voluntary exercise, affected by distress [25–27].
The aim of this study was to find a suitable mouse model for simulating PAD as well as to
establish a training protocol that would be accepted by cardiovascular-diseased animals and stimulate
arteriogenesis. Such a protocol could provide the basis to methodically investigate effects of training
on PAD at the molecular level in an experimental setup.
2. Results
2.1. Evaluation of a Training Regime in C57BL/6
In order to maximize training intensity, we compared two training regimens: A treadmill to
implement forced exercise and a free-to-access voluntary running wheel. During the treadmill protocol
the mice were trained using an incremental protocol: initial running speed was 0.2 m/s, increased
daily to the maximal speed of 0.3 m/s at day 7. The training frequency was twice per day, and each
training lasted 30 min. A maximum distance of 1.08 km was covered each day. Distances traveled and
running wheel speeds were recorded continuously. After an adaptation period a running distance
of 4.36 ± 0.41 km/d with an average speed of 0.5 m/s of was recorded. We observed increased speed
and distance values for the voluntary exercise mice when compared to those forced to exercise in
a treadmill throughout the observation period (Figure 1a,b).
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Figure 1. Daily running distance (a) and daily average speed (b) of C57BL/6 mice over time, during
7 days of adaptation in a treadmill receiving forced exercise (filled circles) or in a voluntary running
wheel (open circles). Data are displayed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.005.
2.2. Acceptance of Voluntary Training in ApoE−/− Mice after HFD and Post-Surgery
To further increase a similarity to patients presenting PAD we included ApoE−/− mice fed with
a high fat diet (HFD; 21% butter fat, 1.5% cholesterol) to the exercise study. These mice showed
numerous plaques throughout the whole arterial system including the femoral artery and the aortic
root as well as fat deposition in the collateral arterioles (Figure 2a–c).
Given the health constraints of ApoE−/− mice following 12 weeks of HFD, we intended to evaluate
whether they were able to cover the same distance as healthy C57BL/6 mice pre- and post-FAL. During
the adaptation the mean distance covered was 3.93 ± 0.28 km/d which was not significantly different
to C57BL/6 mice (p = 0.36). Post-FAL the re-adjustment period was similar to C57BL/6 mice, with no
significant difference, as visualized in the equal progression of running performance (Figure 2d).
Both strains, before and after surgery, recovered quickly to their initial distance when they had access
to a voluntary running wheel.
2.3. Reperfusion Recovery after FAL in C57BL/6 and ApoE−/− Mice with and without Training
In order to evaluate training effects on reperfusion recovery, 18-week-old ApoE−/− mice that had
been fed with an HFD for 12 weeks and 12-week-old healthy C57BL/6 mice were subjected to the
experimental protocols shown in Figure 3a,b. Both mouse strains were randomly subdivided into
training or control groups. The control group was housed in motion-restricting cages. The training
group was held in single cages containing a free-to-access running wheel starting 7 days prior surgery.
FAL was performed on day 0 and perfusion of the hind-limb was measured by LDPI pre- and
postoperatively and on postoperative days, d3, d7, and d14. Adductor muscle tissue was harvested
from ApoE−/− mice at different time points following FAL. The ratio of hind-limb perfusion in the
operated leg to that in the non-operated leg dropped to 10% on average in C57BL/6 mice (training:
11 ± 4%, n = 12, control: mean 8 ± 1%, n = 16; p > 0.05), whereas perfusion recovery increased similarly
within 14 days in the control (69 ± 10%) and training group (69 ± 4%) (Figure 3c).
In contrast, exercising ApoE−/− mice showed a significantly faster approximation of perfusion
with training (n = 19). A maximum of 78 ± 8% perfusion of the hind limbs could be reached within
7 days postoperatively, compared with the control group (n = 21) averaging 53 ± 3% (p = 0.012)
(Figure 3d,e). Interestingly, immediately postoperatively ApoE−/− mice showed a baseline perfusion
119
Int. J. Mol. Sci. 2019, 20, 3956
of 25% independent of a training adaptation that was significantly higher than that of C57BL/6 mice
(p = 0.001) (Figure 3f).
Figure 2. Plaque development in (a) the femoral artery, (b) the aortic root, and (c) the collateral artery
of ApoE−/− mice following 12 weeks of high fat diet, as visualized by Oil-red-O staining. (d) Daily
running distances of C57BL/6 mice (BL6, circles) compared to ApoE−/− mice (ApoE, squares) over time,
pre- and post-ligation of the femoral artery (FAL). Arrows indicate short term running breaks due to
anesthesia during perfusion measurements.
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Figure 3. Functional effects on hind limb perfusion in response to training. (a) Schematic of experimental
setup in C57BL/6, (b) schematic of experimental setup in ApoE−/−, and (c,d) laser Doppler perfusion
imaging in C57BL/6 and ApoE−/− as indicated. Data are expressed as ratio of the operated leg to the
non-operated leg and represent mean± SEM. Open symbols show the data of the training group whereas
filled symbols represent the control group. As a statistical test, the unpaired t-test was used; * p < 0.05.
(e) Representative laser Doppler perfusion images indicate the effect of training in the operated hind
limb when compared to the control group. (f) Postoperative perfusion ratio (R/L). Open symbols show
the data of the training group whereas filled symbols represent the control group. As a statistical test,
the one-way ANOVA was used; * p < 0.05; ** p < 0.01; *** p < 0.005; n.s. not significant.
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2.4. Increased Accumulation of Macrophages after Training in ApoE−/− Mice
In order to investigate the beneficial influence of exercise training on the vascular remodeling
process in ApoE−/− mice, adductor muscle tissue was harvested from these mice 21 days following FAL.
Early perfusion benefits were not reflected by morphometric examination at the end of the experimental
period. There was no difference of the size of the wall area between training and control groups on day
21 post-surgery (2.15 ± 0.53 mm2 and 2.46 ± 0.53 mm2, respectively; p > 0.05; Figure 4a,b).
In the initial phase, collateral growth is critically driven by pericollateral macrophage assembly.
Therefore, adductor muscle tissue was harvested from ApoE−/− mice 3 or 7 days following FAL and the
macrophage number was quantified in the vascular nerve sheath of the collateral vessels. Seven days
after FAL the number of macrophages in close proximity of growing collaterals was significantly higher
in the training group with an average of 3.9 ± 0.8 compared to the control group with an average of
2.3 ± 0.4 (p = 0.042; Figure 4c,d).
Figure 4. Histological evaluation of collateral growth in cross sections of the adductor muscles
of ApoE−/− mice in response to training. (a) Representative micrographs of collateral arteries for
morphometry. Scale bar: 200μm. (b) Quantification of wall area 21 days after FAL of the training
and control group. (c) Immunostaining to determine macrophage accumulation around collaterals
7 d after FAL of the training and control groups. Representative images of CD68 (green) and αSMA
(red) immunostaining. Blue staining indicates nuclei and scale bars are 25 μm. (d) Quantification of
macrophage number. Data are expressed as mean ± SEM of three collateral cross-sections per mouse of
at least three mice per group (n ≥ 3). As a statistical test, the unpaired t-test was used; * p < 0.05.
3. Discussion
Arteriogenesis is the natural compensation mechanism through which collateral circulation
develops. This formation is stimulated by an increase of shear stress on the endothelium [20].
An increase of blood flow can be achieved by a high demand and walking exercise is the best possibility
to maximize the flow physiologically [6]. Therefore, the aim of the study was to establish a training
protocol in a murine model of PAD that increases arteriogenesis through exercise. Our results suggest
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that a FAL surgery in ApoE−/− mice having free access to a voluntary running wheel serves best for
future studies of exercise-induced arteriogenesis.
To increase physiologic shear stress on the arterioles it is preferable to develop an exercise program
that maximizes intensity.
Initially we compared activity of healthy young C57BL/6 mice trained either with forced exercise
by treadmill twice daily or with a 24 h accessible running wheel. Forced exercise is controlled and
reproducible, but usually depends on a negative impulse. In models with forced exercise regimens,
increased distress values, depressive behavior, inflammation reactions, and elevated corticosterone
levels have been shown [26,28–30]. Distress, for example, may limit physiological remodeling normally
associated with exercise training in humans [31,32]. The transferability of forced exercise models into
humans may thus be limited. In contrast, similar structural and functional cardiac changes occurred in
forced and voluntary exercise regimens [33]. The pros and cons of a forced versus a voluntary exercise
model are thus not finally delineated.
We further showed that voluntary training leads to a much greater distance covered than forced
exercise. Furthermore, voluntary running resulted in a higher running speed. Resulting from this
higher exercise dose, a higher training effect response of voluntary running than of forced treadmill
walking would be expected. Free-to-access running wheels are an easy way to record and store activity
data without disturbing the habitual behavior. Likewise, voluntary access to running wheels permits
reasonable adaptation to exercise after surgery and provides an excellent tool to monitor the behavior
of mice. We could show that mice do tolerate this voluntary training much better with an increase of
the distance travelled compared to forced exercise. For the reasons given above we continued our
studies with voluntary training knowing well that this cannot be directly translated to the human
situation. There is a discrepancy in intrinsic exercise capacity and response to exercise training between
mice and humans. Mice do have a natural drive for running. Humans with sedentary behavior do
not push their maximum limit. The focus of our study was to establish a protocol in mice which was
adapted to their natural behavior and allowed for future investigations on collateral growth.
Since in PAD a stenosis is progressing over time and involves the whole arterial system, there is
an uncertainty if healthy animals can be used to simulate the human patient’s illness [3,23,34,35].
An acute occlusion in healthy participants by e.g., arterial emboli or trauma demands an instant
intervention. The sudden tissue hypoxia can lead to an acute inflammatory–angiogenic–myogenic
response which could result in massive loss of tissue. Patients suffering from PAD usually better
tolerate an acute occlusion [36].
In order to increase the similarity to patients presenting PAD we used ApoE−/− mice fed with
a HFD, that show numerous plaques throughout the whole arterial system [21,23,24,37] including fat
deposition in collaterals.
It was expected that different mouse strains don’t have similar responses to voluntary
training [27,38]. Our findings showed that C57BL/6 and ApoE−/− animals accepted the voluntary
training without a notable difference between the two strains. In this study we showed that there was
just a short postoperative readjustment period of 10 days needed to get mice back to the initial distance.
Whether this delay was due to the surgical intervention alone (opening and closing of the skin) cannot
be fully excluded, because a sham treatment group without FAL was not investigated.
Next, the voluntary training protocol (running wheel) was tested in both strains to evaluate the
reperfusion recovery after FAL.
The LDPI data acquired showed a significant higher perfusion immediately after the occlusion in
ApoE−/−mice. This could be explained due to an increased collateral growth as a result of arteriosclerotic
plaques in the major arteries [21]. C57BL/6 as well as ApoE−/− mice presented a maximum re-perfusion
up to 69% and 77% with no significant difference in between the two strains.
It could be shown that having training possibility allowed ApoE−/− mice to reach the maximum
reperfusion alignment one week post-FAL.
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In order to correlate the increased perfusion to arteriogenesis we performed histological analyses
of collateral tissue of ApoE−/− mice with and without exercise training. It is well accepted that
mechanical, cellular, and molecular factors influence collateral growth [39]. Macrophages accumulate
around the growing collaterals and cytokine secretion improves that process [40,41]. After training,
ApoE−/− mice show a higher accumulation of CD68+ macrophages in the vascular nerve sheath of the
collateral vessels than without training.
The presented experimental setup involves atherosclerotic ApoE−/− mice subjected to an acute
FAL. Functional as well as histological findings implicate an improvement of arteriogenesis after
exercise training in the proposed model.
4. Materials and Methods
4.1. Ethics Statement
Animal handling and all experimental procedures carried out were in full compliance with the
Directive 2010/63/EU of the European Parliament on protection of animals used for scientific purposes.
Approval was given by the responsible local authority, the Darmstadt governmental council for animal
protection and handling (permit reference numbers V54-19c20/15-B2/360, permit date: 30 October
2013). Throughout this study all mice had access to water and food ad libitum.
4.2. Femoral Artery Ligation (FAL)
Twenty-eight male C57BL/6 mice (Charles River, Sulzfeld, Germany) and 40 male ApoE−/− mice
were subjected to FAL as described [22]. The contralateral leg served as the reference. During the
surgical procedure mice were kept on a heating plate with a temperature of 38 ◦C. Anesthesia was
applied using ketamine (120 mg/kg BW) and xylazine (16 mg/kg BW) i.p.. For postoperative analgesia
carprofen (5 mg/kg BW) was injected s.c.. After termination of experiments the mice were euthanized
by an anesthetic overdose.
4.3. Forced Exercise on Treadmill
Mice were first accustomed by using a treadmill (Exer 3/6, Columbus Instruments, Columbus,
OH, USA) with a motivation grid for 15 min/day. This applied small amounts of electric shock for
conditioning when the mice stopped running.
After being conditioned, the mice started training at a light intensity with a preset speed of 0.2 m/s
leading up to a maximum of 0.3 m/s with no further resistance. Training frequency was 2 times per day.
Training was terminated at exhaustions. Exhaustion was defined as pause of more than 5 s at a time,
or three times for two or more seconds on the shock pad without trying to get back on the treadmill.
4.4. Voluntary Running Wheels
To evaluate voluntary training each animal was individually housed in a cage equipped with
a free-to-access running wheel. The running wheels were connected to a computer equipped with
TSE PhenoMaster V5.1.6 (2014-4115) (TSE Systems GmbH, Bad Homburg, Germany). This setup gave
accurate data on each animal, recording time and traveled distances and it allowed evaluation of
activity patterns during an adaptation period as well as identifing post-surgery effects.
4.5. Restraining Cages
For simulating inactivity, mice were kept as a reference (control) group in smaller cages without
the possibility to climb in order to minimize movement.
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4.6. Laser Doppler Perfusion Imaging (LDPI)
Perfusion of the paws was recorded using the laser Doppler imaging device PIM3 (Perimed
Instruments, Järfälla, Sweden; Software: LDPIwin for PIM3 3.1.3), on a heating plate at 38 ◦C, before
FAL (d0 pre), immediately after FAL (d0 post), as well as at d3, d7, and d14 after FAL.
The mean perfusion was shown as the ratio of the ligated hind limb to the contralateral,
non-ischemic hind limb.
4.7. Histology
Mice were perfused with 10 mL vasodilation buffer (100 μg adenosine, 1 μg sodium nitroprusside,
0.05% BSA in PBS, pH7.4) followed by 10 mL 4% PFA post mortem. Adductor muscles from ligated
or sham-operated mice were harvested and placed in 15% sucrose in PBS for 4 h and overnight at
4 ◦C in 30% sucrose in PBS. Tissue was cryopreserved in Tissue-Tek O.C.T. (Sakura, Alphen aan den
Rijn, The Netherlands) and cut in 8 μm cryosections. Morphometric analyses were performed using
a hematoxylin-eosin stain to evaluate the dimensions of collateral arteries.
4.8. Immunohistochemistry
Cryosections were stained with blue-fluorescent DNA stain DAPI
(4′,6-Diaminidino-2-phenyllindole-dilactate; Thermo Fisher Scientific, Waltham, MA, USA)
and counterstained for αSMA-Cy3 (C6198, Sigma-Aldrich GmbH, Taufkirchen, Germany) or
αSMA-FITC (F3777, Sigma-Aldrich GmbH, Taufkirchen, Germany) and CD68 (MCA1957A448T,
AbD Serotec, BioRad, Feldkirchen, Germany).
4.9. Statistical Analysis
All statistical analyses were supported by GraphPad software PRISM5 for Mac (GraphPad
Software, La Jolla, CA, USA), JMP for Mac (Version 9.0.12010 SAS Institute Inc., Heidelberg, Germany),
Image J (National Institutes of Health, Bethesda, Maryland, USA) and Microsoft Excel for Mac
(Version16.15, Microsoft, Redmond, Washington, USA). Comparisons between groups were based on
unpaired student’s t-test. One-way or two-way ANOVA were used to determine differences between
the means of three or more independent groups as indicated. Data were reported as standard error of
mean (SEM). Data deviations were considered to be statistically significant differences at p < 0.05.
5. Conclusions
Femoral artery ligated ApoE−/− mice on HFD with running wheel training is a suitable model
to simulate exercise induced collateral growth. This experimental set-up may provide a model for
investigating molecular training effects on arteriogenesis.
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Abbreviations
PAD Peripheral artery disease
CVD Cardiovascular disease
ApoE−/− Apolipoprotein E knockout
FAL Femoral artery ligation
HFD High fat diet
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Abstract: Background: The effects of blood flow restriction (training) may serve as a model of
peripheral artery disease. In both conditions, circulating micro RNAs (miRNAs) are suggested to
play a crucial role during exercise-induced arteriogenesis. We aimed to determine whether the profile
of circulating miRNAs is altered after acute resistance training during blood flow restriction (BFR)
as compared with unrestricted low- and high-volume training, and we hypothesized that miRNA
that are relevant for arteriogenesis are affected after resistance training. Methods: Eighteen healthy
volunteers (aged 25 ± 2 years) were enrolled in this three-arm, randomized-balanced crossover
study. The arms were single bouts of leg flexion/extension resistance training at (1) 70% of the
individual single-repetition maximum (1RM), (2) at 30% of the 1RM, and (3) at 30% of the 1RM
with BFR (artificially applied by a cuff at 300 mm Hg). Before the first exercise intervention, the
individual 1RM (N) and the blood flow velocity (m/s) used to validate the BFR application were
determined. During each training intervention, load-associated outcomes (fatigue, heart rate, and
exhaustion) were monitored. Acute effects (circulating miRNAs, lactate) were determined using
pre-and post-intervention measurements. Results: All training interventions increased lactate
concentration and heart rate (p < 0.001). The high-intensity intervention (HI) resulted in a higher
lactate concentration than both lower-intensity training protocols with BFR (LI-BFR) and without
(LI) (LI, p = 0.003; 30% LI-BFR, p = 0.008). The level of miR-143-3p was down-regulated by
LI-BFR, and miR-139-5p, miR-143-3p, miR-195-5p, miR-197-3p, miR-30a-5p, and miR-10b-5p were
up-regulated after HI. The lactate concentration and miR-143-3p expression showed a significant
positive linear correlation (p = 0.009, r = 0.52). A partial correlation (intervention partialized) showed
a systematic impact of the type of training (LI-BFR vs. HI) on the association (r = 0.35 remaining
after partialization of training type). Conclusions: The strong effects of LI-BFR and HI on lactate-
and arteriogenesis-associated miRNA-143-3p in young and healthy athletes are consistent with an
important role of this particular miRNA in metabolic processes during (here) artificial blood flow
restriction. BFR may be able to mimic the occlusion of a larger artery which leads to increased
collateral flow, and it may therefore serve as an external stimulus of arteriogenesis.
Int. J. Mol. Sci. 2019, 20, 3249; doi:10.3390/ijms20133249 www.mdpi.com/journal/ijms129
Int. J. Mol. Sci. 2019, 20, 3249
Keywords: circulating miRNA; miR-143-3p; blood flow restriction; peripheral artery disease;
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1. Introduction
Arteriogenesis is defined as the growth of functional collateral arteries from pre-existing arterio-
arteriolar anastomoses [1,2]. An initial trigger is the occlusion of a main artery, which occurs during
peripheral artery disease (PAD). Such an occlusion redirects the blood flow to the pre-formed collateral
arteries and thereby alters the fluid shear stress (FSS) [3]. The increased blood flow initiates vascular
remodeling and diameter growth [4]. Several mechano-sensors and transducers that convey the FSS
message during collateral remodeling have been proposed, including ion channels [5], the glycocalyx
layer of endothelial cells (ECs) [6], nitric oxide (NO) [7], and microRNAs (miRNAs) [8].
These small, non-coding ribonucleic acids have been shown to play a decisive role in processes
such as heart development, vascular regeneration, and tissue repair [9–12]. miRNAs are involved in
post-transcriptional gene regulation by binding to mRNAs, causing the repression of translation and
mRNA degradation, thus fine-tuning protein expression. Several miRNAs have been shown to control
the response of vascular cells to hemodynamic stress [8]. In addition, miRNAs can be secreted and can
thereby contribute to intercellular communication [13] or serve as circulating biomarkers [14].
Arteriogenesis can be amplified by exercise, as documented in human trials [15–17] and animal
studies [18]. Therefore, according to international guidelines, PAD patients in Fontaine stage I or IIA/B
(Rutherford 1–3) should be recommended for exercise training [19,20]. Mechanisms involved in the
exercise-mediated benefits of treating PAD are thought to be the suppression of inflammation [1],
expression of pro-inflammatory immune cells [21,22], and the improvement of endothelial function [23].
Beyond that, physical training has the potential to promote additional vascularization [24,25].
Comparable mechanisms have been discussed for the training effects of blood flow restriction
exercises: Blood flow restriction training (BFR) is a resistance training method in which blood flow
is reduced artificially. The decreased blood flow is usually caused by applying a blood pressure cuff
at the origin of the extremity (arms or legs) to be trained. The mechanisms of BFR are thought to
involve ischemic hypoxia and the increased expression of vascular endothelial growth factors [26].
The hemodynamic stimuli amplified by BFR (e.g., shear stress at the endothelium) lead to an increased
release of the endothelial NO synthase, among other responses [27].
To achieve systematic effects during BFR, a lower resistance load is used than in classic resistance
training without BFR: An intensity of 20% of the single repetition maximum (1RM) and a reduced
training time of about 4–8 weeks have been demonstrated to have effects on muscle hypertrophy and
muscular strength [28–30]. BFR training with a lower load in a shorter time can lead to the same results
as resistance training with significantly higher loads (at 65% 1RM). In particular, increases in muscle
thickness and strength are comparable between these strategies [31,32]. Due to the comparable effects
and lower loads, BFR is of great relevance for training persons with physical limitations (e.g., patients
with injuries, patients with cardiovascular diseases, or elderly persons) [33,34].
Despite the promising results derived from BFR as a method to mimic exercise effects under
different occlusion conditions like PAD and the potential role of miRNAs as effectors after hemodynamic
stress or FSS, nothing is known about the acute effects of strength training during BFR on miRNA
levels. Therefore, this study was designed to determine whether the profile of circulating miRNAs
is altered after resistance training during BFR, as compared with low- and high-volume training
protocols with no BFR. Our hypotheses were: (1) Blood flow restriction leads to a reduced blood
flow velocity; (2) low-intensity blood flow restriction training leads to metabolic responses that are
similar to those of high-intensity strength training without blood flow restriction; (3) low-intensity
blood flow restriction training and training without blood flow restriction lead to different expression
characteristics of miRNAs.
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2. Results
2.1. Sample
None of the participants withdrew their consent, and none had to be excluded. Eighteen healthy
adults (females = 11; mean age 25 ± standard deviation (SD) 2 years; body mass index 22.1 ± 1.8 kg/m2)
were included.
2.2. Blood Flow Velocity
The blood flow velocity in the A. poplitea was significantly reduced by wearing the BFR cuff
(compared to unrestricted, p = 0.002; mean intraindividual difference: −7.6 cm/s, −14%, Figure 1).
Figure 1. Blood flow velocity in the A. poplitea: (a,b) Representative original Doppler sonography
blood flow profiles at rest: The upper images show the region of interest of the A.poplitea; the lower
diagrams show the time course on the x-axis and the blood flow velocity heartbeat by heartbeat on
the y-axis. (a) Blood flow velocity without wearing a cuff. (b) Blood flow velocity while wearing the
cuff (occlusion pressure 300 mm Hg). (c) Boxplots of the grouped pre-post differences in blood flow
velocity with and without cuff. Data are displayed as median and inter-quartile ranges plus range
(whisker bars).
2.3. Basic Resistance Training Outcomes
2.3.1. Objective Outcomes of the Training Interventions
Lactate concentration and heart rate were increased after all training interventions (p < 0.001)
(Figure 2a,b). The lactate concentration was different between the groups: The high-intensity (HI)
intervention resulted in a higher lactate concentration than both lower-intensity (LI) training protocols
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(LI, p = 0.003; LI-BFR, p = 0.008). In the HI group, the mechanical pain threshold increased from before
to after training (p < 0.05) (Figure 2c).
Figure 2. Objective outcomes of training interventions. Data are displayed as mean and 95% confidence
intervals. Bpm, beats per minute; LI-BFR, low-intensity training with blood flow restriction; LI,
low-intensity training; HI, high-intensity training. (a) Differences in blood lactate concentration
pre- and post-training, (b) maximal heart rate, and (c) differences in mechanical pain threshold pre-
and post-training.
2.3.2. Participant-Reported Outcomes
The perceived exertion was greater during the HI intervention than in the LI interventions (LI,
p = 0.005; LI-BFR, p = 0.028). The HI group scored a lower value than the LI group in the feeling scale
(p < 0.05). Participants in the LI group reported lower values on the fatigue scale than the LI-BFR
group (p = 0.028) and the HI group (p = 0.004). The corresponding values are displayed in Figure 3.
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Figure 3. Participant-reported outcomes of training interventions. Data are displayed as mean and 95%
confidence intervals. (a) Maximal exertion. (b) Maximal fatigue. (c) Maximal discomfort. NRS, numeric
rating scale; LI-BFR, low-intensity training with blood flow restriction; LI, low-intensity training; HI,
high-intensity training.
2.4. Profiling of Circulating miRNAs
2.4.1. Capillary Blood for miRNA Isolation, Expression Analysis, and Quantification
A single capillary blood draw resulted in ≥50 μL plasma, and, in comparison to venous blood
sampling, the average degree of hemolysis differed significantly (p < 0.05) as determined by OD414
in a pilot study (Figure 4a,b). Only 50 μL of plasma were sufficient to isolate total RNA and
to reverse-transcribe miRNAs for real-time PCR-based quantification. In order to identify stably
expressed reference genes for normalization, five candidate miRNAs (hsa-miR-30e-5p, hsa-miR-148b-3p,
hsa-miR-222-3p, hsa-miR-425-5p, hsa-miR-484) were tested for stable expression over the entire range
of samples being investigated. Except for hsa-miR-222-3p, all miRNAs were suitable for normalization
(Figure 4c).
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Figure 4. (a) Example of an OD scan from 200 to 700 nm with a distinct absorbance peak at 414 nm to
assess hemolysis. Different lines depict different plasma samples. (b) OD414 values in plasma samples
after venous or capillary blood draw (* p < 0.05). (c) Differences in miRNA abundance of typically
detected miRNAs in plasma to determine stable expression pre- and post-training intervention.
2.4.2. Screening of Expression Changes in Circulating miRNAs before and after BFR Training
Based on the assumption that the LI-BFR reduces blood flow to the periphery in a way that is
comparable to that of a PAD, eight plasma samples of four participants pre- (control) and post-training
were selected and subjected to the human serum/plasma focus panel consisting of 179 miRNA assays
targeting human plasma-relevant miRNAs, reference miRNAs, and spike-in controls. A global CT
mean of expressed miRNAs was used for normalization, and cel-miR-39-3p was included as an
internal amplification control. In each sample, more than 80% of miRNAs surpassed the lower limit
of detection of a Ct < 35 (Figure 5a). Significant miRNA expression changes were visualized in the
volcano plot (Figure 5b). A total of 11 miRNAs were selected for further validation due to their
markedly altered expression or previous association with collateral growth (Table 1). Interestingly,
among the differentially expressed miRNAs identified, three arteriogenesis-associated, previously
detected miRNAs were recovered: miR-143-3p, miR-195-5p, and miR-126-5p.
134
Int. J. Mol. Sci. 2019, 20, 3249
Figure 5. qPCR-based serum/plasma focus panel of circulating miRNAs (a) Distribution of Ct values for
the processed data of each plasma sample. (b) Volcano plot of differentially expressed miRNAs pre- and
post-LI-BFR training. Data points outside the two dashed lines are up-regulated (red) or down-regulated
(green) more than x-fold. Data points above the solid horizontal line have p-values less than 0.05.
Table 1. Over-expressed miRNAs (fold regulation values greater than 1.5) and under-expressed miRNAs
(fold regulation values less than−1.5) detected in the screen and analyzed in the three different training groups.
miRNA ID Fold Change Screen p-Value HI LI-BFR LI
hsa-miR-197-3p 1.56 0.094
hsa-miR-326 1.65 0.002 **
hsa-miR-136-3p 1.57 0.063
hsa-miR-143-3p −1.7 0.170 up * down *
hsa-miR-30a-5p −1.59 0.003 ** up **
hsa-miR-139-5p −1.97 0.027 * up *
hsa-miR-125a-5p −2.63 0.026 *
hsa-miR-375 −1.59 0.492
hsa-miR-99a-5p −1.58 0.171
hsa-miR-126-5p −1.57 0.006 **
hsa-miR-10b-5p −2.4 0.030 * up **
hsa-miR-195-5p −2.92 0.017 * up *




* p-value < 0.05, ** p-value < 0.01, HI: High intensity training, LI-BFR: Low intensity training with blood flow
restriction, LI: Low intensity training. Bold text shows the miRNAs that have been previously associated with
collateral growth.
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2.4.3. Analysis of miRNAs in Different Training Intervention Groups
The abundance of these 11 differentially expressed miRNAs was analyzed in each training group
in individual assays in a larger cohort of 12 participants. Only miR-143-3p was confirmed to be
down-regulated after LI-BFR. In contrast to the initial screening results, miR-139-5p, miR-143-3p,
miR-195-5p, miR-197-3p, miR-30a-5p, and miR-10b-5p were up-regulated after HI. There was no
differential expression after LI. (Figure 6, Table 1)
Figure 6. Differences in miRNA expression pre- and post-training. Data are displayed as mean
and 95% confidence intervals. (a) LI-BFR, low-intensity training with blood flow restriction. (b) HI;
high-intensity training. (c) LI, low-intensity training.
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2.5. Associations between Training Outcomes and Circulating miRNAs
The pre-to-post changes in lactate concentration and miR-143-3p expression showed a significant
linear positive correlation (intervention partialized) of r = 0.34 (p = 0.048). This correlation is visualized
in Figure 7. Without considering the group as a partializing co-variate, lactate and miRNA-143-3p
differences were associated with a coefficient of r = 0.305; however, this correlation lacks statistical
significance (p = 0.075). No other systematic correlation between lactate concentration and miRNA
expressions occurred.
Figure 7. Scatterplot diagram of miR-143-3p and lactate concentration with a correlation line (including
confidence intervals); LI-BFR, low-intensity training with blood flow restriction; HI, high-intensity
training, LI, low-intensity training.
3. Discussion
In this three-armed crossover study, we investigated the miRNA profiles in young, healthy athletes
before and after various resistance training interventions (HI and LI). In addition, we employed
peripheral blood flow restriction (LI-BFR) that was achieved by applying an external cuff during the
resistance training at LI. We assumed that BFR can mimic the occlusion of a larger artery, leading to an
increased collateral flow, and would therefore serve as an external stimulus of arteriogenesis.
The BFR application led to a decreased blood flow velocity in the popliteal artery, confirming our
first hypothesis. The HI intervention showed the largest effects on lactate, and all interventions led to a
comparable heart rate response. The LI intervention resulted in the smallest pre to post differences.
Hypothesis 2 was thus partially verified (depending on the outcome). Our results further suggest that
miRNA profiles were acutely affected by HI training and LI-BFR training but not by LI training alone.
In particular, miR-143-3p expression correlated with training intensity, which verifies Hypothesis 3.
The fact that BFR application led to a decrease in the blood flow velocity (Hypothesis 1) confirms
the validity of BFR. The reduction of 7.6 cm/s is far beyond the standard error of measurement found
in inter-rater reliability analyses [35] and can thus be considered as clinically relevant. The mean blood
flow velocity in the popliteal artery in PAD patients was recently found to be 41 ± 17 (SD) cm/s [36],
which is considerably lower than the velocity we found in the no-cuff condition and is comparable to
the one we found in the blood flow-restricted condition. Consequently, one may consider our model
valid in terms of blood flow restriction and velocity, although the study population does not fully
mimic the PAD caused by atherosclerosis.
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All interventions induced increases in lactate and heart rate; the largest effects on lactate occurred
after the HI intervention, whereas all interventions led to a comparable heart rate response. The LI
intervention resulted in the smallest differences in pre- and post-intervention values in objective and
participant-reported outcomes. The finding of a BFR-induced increase in lactate concentration is in
accordance with previous reports [23]. The metabolic response thus varies with varying training
intensity. If BFR training effects comparable to those of 70% 1RM sessions without BFR are to be
reached, the current literature recommends BFR training at 30% of the individual 1RM [18]. Though
we followed this recommendation, BFR elicited lower values/effects in some of the outcomes than
during/after HI training; this is in contrast to our second hypothesis, which was only partially verified.
One possible reason may be due to our sample. The majority of current studies adopting BFR training
or interventions at 30% of the 1RM refer to an elderly or untrained population [18]. For a trained
study population, a minority of studies in the literature suggest that 50% of the 1RM should be used to
achieve a sufficient metabolic response [24].
We further analyzed the profiles of circulating miRNAs before and after resistance training.
Our results of the quantification in each intervention group suggest that the profile of circulating
miRNAs is altered as an acute effect of resistance training. In particular, we identified six miRNAs
(miR-139-5p, miR-143-3p, miR-195-5p, miR-197-3p, miR-30a-5p, and miR-10b-5p) that are up-regulated
after HI training. Only miR-143 was found to be down-regulated after LI-BFR training. The LI training,
in contrast, had no systematic effect of either miRNA. Other studies also demonstrated both acute
effects of intensive stimuli (miRNA-21, miRNA-146a, miRNA-221, and miRNA-222) and training
effects (miRNA-146a, miRNA-222, and miRNA-20a) [37]. Consequently, we conclude that increased
training intensity leads to increased miR-143-3p. The correlation of the lactate difference (BFR-LI, LI,
and HI) and miR-143-3p abundance further indicates a decisive role depending on training intensity.
In detail, 3.5 mmol/L of pre-to-post lactate difference was determined as a potential threshold from
miR-143-3p down-regulation to its up-regulation. Consequently, a major share, but not only the lactate
concentration (or the intensity of the training), is decisive for miRNA expression—as is (to a minor
share) the type of training. More concretely, BFR seems not only to lead to lower lactate increases
but also tendentiously leads to a down-regulation of miRNA-143-3p, whereas LI seems to be able
to increase lactate concentration but does not affect miRNA-143-3p expression. The HI, in contrast,
seemed to be able to both up-regulate lactate and miRNA-143-3p. Whether the differences between the
conditions are due to the lower intensity or the type of training may be finally delineated by using the
intensity increase up to 50% during BFR, as described above.
We have previously shown an association of miR-195-5p and miR-143-3p with collateral growth [38].
Both of these species were found to be highly up-regulated in the vascular tissue itself, and miR-143-3p
was identified as an essential factor for proper collateral formation following femoral artery ligation in
mice. The acute and local blockade of miR-143-3p in these mice completely abrogated arteriogenesis.
In blood vessels, miR-143 is one of the most-studied miRNAs expressed by vascular smooth muscle
cells, and, together with miR-145, this miRNA is thought to play a pivotal role in smooth muscle cell
differentiation and vascular disease [8,13,39]. Furthermore, circulating miR-143-3p has been associated
with cardiovascular disease [40] and is considered to be a predictor of aging and the acute adaptive
response to resistance exercise [41].
Small volumes of capillary blood are routinely used for lactate diagnostics. We aimed to
establish this routinely used, less invasive method of fingertip blood drawing for obtaining cell-free,
non-hemolytic plasma samples suitable for the isolation and quantification of circulating miRNAs.
Indeed, this method was successful in yielding plasma samples reproducible in quality and volume.
All miRNAs identified, with the exception of miR-10b-5p, were validated in terms of independency
of hemolytic score. For miRNA profiling, we included plasma samples of four participants with an
OD414 < 0.3 and an increased lactate concentration after training intervention, a maximal heart rate
during training of at least 60% of maximal calculated heart rate, and a participant-reported “very hard”
intensity on the Borg scale of at least 16 points (data not shown).
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Our results are in line with the proposed epigenetic potential of lifestyle interventions that may
alter gene expression [42,43]. Therefore, we postulate that in order to maximize the beneficial role of
miR-143-3p in collateral growth, training intensity will have to be adjusted. For symptomatic PAD
patients, controlled training is an efficient, conservative therapy that is a good alternative to invasive
therapies. The formation of collaterals and compensatory blood flow is the goal of conservative
treatment. However, since the success of training varies, responders and non-responders must be
identified. Thus, future studies are needed to (1) confirm our findings in PAD patients, (2) delineate the
mechanisms of how miRNA-143-3p may be decisive in response or non-response to resistance training,
and (3) determine how a pre-intervention screening of miRNA-143-3p or other microRNAs can be used
to stratify responders and non-responders for the individualization of intervention/training goals.
4. Materials and Methods
4.1. Ethical Standard and Study Design
The study had a randomized-balanced crossover design. Ethical approval was obtained from the
local institutional review board (protocol number 2018-16, 17.06.2018, Ethics Committee Department 5
Psychology and Sports Sciences Goethe-University Frankfurt). The trial was conducted in accordance
with the ethical standards set down by the declaration of Helsinki (World medical Association)
Declaration of Helsinki–Ethical Principles for Medical Research Involving Human Subjects) with
its recent modification of 2013 (Fortaleza). All participants gave written informed consent prior to
study enrollment.
4.2. Sample
Participants were considered eligible if they fulfilled the following criteria: (1) Healthy and (2)
aged 18 to 30 years. Exclusion criteria comprised (1) severe psychiatric, neurological, or cardiovascular
diseases; (2) acute orthopedic disorders; (3) pregnancy; (4) muscle soreness; and (5) intake of painkillers,
analgesics, or muscle relaxants within the previous 48 hours.
4.3. Experimental Design
The experimental design incorporated three arms. Each participant performed each of the
three conditions once (on three different days with a washout of at least 7 days in between) in a
randomized, balanced sequence. Before the first exercise intervention, blood flow velocity to validate
the BFR application and the individual 1RM from the knee extensor and knee flexor were determined.
During each training intervention, loading-associated outcomes were monitored. Acute effects were
determined using pre- and post-intervention measurements.
4.4. Blood Flow Velocity Measurement
The arterial blood flow velocity in the popliteal artery was measured in one leg (side randomly
chosen, in the prone position) with and without external blood flow restriction caused/provoked by
the BFR cuff (7 cm wide; nylon pneumatic cuff) at 300 mm Hg. Doppler sonography (Siemens Acuson
X300, Munich, Germany) was used with spectral analysis, and data were gathered about components
of the flow profile. The procedure is reliable [35].
4.5. RM Determination
Prior to the 1RM determination, participants warmed up by cycling for 5 min on a stationary
bicycle. After a one-minute rest, an individualized starting load (~80% of estimated the 1RM, estimation
based on sex, weight, and strength training experience) was moved through the full range of motion in
sagittal plane (knee extension and flexion). After each successful performance, the weight increased
until an attempt failed. One-minute rests were given between each attempt, and the 1RM was attained
within a maximum of 5 attempts.
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4.6. Intervention
The three training conditions were (1) resistance training during BFR at 30% of the 1RM, (2)
resistance training without BFR at 30% of the 1RM, and (3) resistance training without BFR at 70% of
the 1RM. The possible sequences of the conditions to be performed were randomly assigned to the
participants in a balanced frequency. Resistance training comprised knee extensors and flexors on a
combination training device (Schnell M3 Diagnosis, Peutenhausen, Germany). In conditions (1) and (2),
resistance training with 30% of 1RM was adopted, and each exercise period consisted of 75 repetitions
divided into 4 sets with a rest period of 90 s. In contrast, in condition (3), the resistance training
was performed at 70% of the 1RM; here, 30 repetitions divided into 3 sets with a break of 90 seconds
between sets. During condition (1), blood pressure cuffs inflated to 300 mm Hg were applied to both
legs. The exercise protocols have been used previously in other studies and have been classified as low
risk [44]. The washout phase between test days was at least 7 days. On each test day, a standardized
control condition (“do-nothing” phase) was performed for 20 min before the test condition.
4.7. Assessments
4.7.1. Laboratory Analytic Outcomes
Blood Lactate Concentration
Before and directly after each intervention, capillary blood was taken by pricking the earlobe
with a safety lancet. The sample was applied directly to a test strip to determine lactate concentration
(mmol/l) by means of a portable, hand-held unit (Lactate Scout, SensLab GmbH, Leipzig, Germany).
Heart Rate
During the intervention, a chest belt (Polar H7) and heart rate receiver (Polar M 430) continuously
measured heart rate (beats/min). The maximum heart rate was selected for further analyses.
Mechanical Pain Threshold
Before and directly after each intervention, the mechanical pain threshold (N/cm2) was determined.
Participants reclined supine on a bench with their legs extended. With an algometer (FPK, Wagner
Instruments, Greenwich, CT, USA) pressure was applied on the skin (1 cm2). Three measurements
were taken in the middle of both mm. recti femoris. The average of the three measurements was
selected for further analyses.
Blood Sampling and Plasma Preparation for miRNA Profiling
In order to minimize pre-analytical variables that might influence the miRNA expression
profile, care was taken in the collection of blood and the preparation of plasma to prevent blood
cell contamination and hemolysis. Before and after each intervention, fingertip capillary blood
samples (≥200 μL) were collected in microvettes (system for capillary blood collection) containing
Ethylenediaminetetraacetic acid (EDTA). Blood samples were centrifuged for 10 min at 3000 rpm and
4 ◦C. After the first centrifugation step, the upper plasma phase was transferred to a new tube without
disturbing the intermediate buffy coat layer. The plasma samples were centrifuged a second time for
10 min at 15,000 rpm and 4 ◦C. The cleared supernatant was carefully transferred to a new tube and
frozen at −80 ◦C.
Determination of Hemolysis
To assess hemolysis, oxyhemoglobin absorbance was measured at 414 nm in plasma samples
using NanoDrop (peqlab Biotechnologie GmbH; Erlangen, Germany).
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miRNA Isolation
Sample amounts were standardized by volume: The same volume of plasma was used for each
RNA isolation, and the same volume of purified RNA was used for all further analyses. The miRNAs
were isolated from 50 μL (qRT-PCR) or 200 μL (PANEL screen) of plasma using a column-based protocol
(miRNeasy Serum/Plasma Advanced Kit, (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. cel-miR-39 from Caenorhabditis elegans (1 nM) was spiked in. In the final step, total RNA
(>18 nucleotides) was eluted using 20 μL of RNase-free water.
Reverse Transcription and miRNA Profiling
For reverse transcription, the miRCURY LNA RT Kit (Qiagen, Hilden, Germany) was used.
Undiluted complementary DNA (cDNA, 20 μL) was used for miRCURY LNA miRNA Focus Panel
Human Serum/Plasma (YAHS-106Y) in the 2 × 96-well plate format. The Human Serum/Plasma Focus
Panel includes 179 miRNA assays targeting relevant miRNAs, reference miRNAs, and spike-in controls.
Reverse Transcription and qRT-PCR
Following reverse transcription as described above, quantitative real-time PCR was performed
using miRCURY LNA miRNA PCR assays (Appendix A) in a 10-μL reaction containing 3 μL of cDNA
(1:30) and a CFX real-time PCR detection system (BioRad, Munich, Germany). Assays were performed
in triplicate. The amount of the respective miRNA was normalized to miR-425-3p and cel-miR-39.
For the miRCURY miRNA PCR analysis, v1.0 raw Ct data from real-time PCR were
up-loaded at (https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-
page). Cel-miR-39-3p was used as an internal spike-in amplification control. A Ct cut-off of 35 was set
as the lower limit of detection. A global Ct mean of expressed miRNAs was used for normalization,
and the fold change was calculated as (2−ΔΔCt), which represents the average normalized miRNA
expression (2−ΔΔCt) of the samples in the test group divided by the average normalized miRNA
expression (2−ΔΔCt) of the samples in the control group.
4.7.2. Self-Reported Outcomes
Self-reported outcomes consisted of rates of perceived exertion (RPE-Borg; Likert 6 to 20 point
scale) [45], current well-being assessments (feeling scale: (+5 to −5, 10 point Likert scale)), and fatigue
reporting (numeric rating scale NRS: 0 to 10 points). All self-reported parameters were assessed once
after each intervention. The participants were asked to refer to the highest intensity during (RPE and
feeling scale) or at the end (fatigue) of each intervention.
4.8. Data Analyses and Statistics
For all outcomes assessed before and after each intervention, real values and absolute pre-to-post
differences were used for further analysis. Continuously assessed variables were processed in their
real values.
After the following plausibility control, all analyses were performed based on the results of
the initial checking for relevant underlying assumptions to test for parametric or nonparametric
characteristics (data, distribution of the variances and variance homogeneity). Between-group
differences and pre-to-post changes were assessed using omnibus and follow-up post-hoc testing. SPSS
23 (SPSS Inc., Chicago, IL, USA) and GraphPad software PRISM5 for Mac (GraphPad Software, La
Jolla, CA, USA) were used to conduct all statistical calculations and create figures. An alpha-error level
of 5% was considered to be a relevant cut-off value for significance testing, with p-values below 0.05
indicating significant differences.
Friedman tests were performed for omnibus between-group comparisons for all resistance
training outcomes (or the a priori calculated differences). For significant omnibus testing, post-hoc
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comparisons using post-hoc Bonferroni–Holm tests and alpha-error-adjusted Mann–Whitney-U-tests
were performed. For pre-to-post significance testing, Wilcoxon tests were performed.
To identify significant miRNA expression changes between conditions, a fold regulation was
calculated, and a fold-change threshold of 1.5 was defined. Significant miRNA expression changes
were visualized using the volcano plot. For each miRNA showing a significant expression change,
a pairwise group comparison (Student’s t-test) was made based on the 2−ΔΔCt value of the replicate
samples. The p-value calculation was based on a parametric, two-sample, equal variance, unpaired,
and two-tailed distribution.
The potential associations between the kinematic (treatment) effects of the miRNA and lactate
were analyzed using partial linear regression with the covariate group allocation.
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Abstract: Cardiovascular disease remains the leading global cause of death, and the number of
patients with coronary artery disease (CAD) and exhausted therapeutic options (i.e., percutaneous
coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical treatment) is on
the rise. Therefore, the evaluation of new therapeutic approaches to offer an alternative treatment
strategy for these patients is necessary. A promising research field is the promotion of the coronary
collateral circulation, an arterio-arterial network able to prevent or reduce myocardial ischemia in
CAD. This review summarizes the basic principles of the human coronary collateral circulation, its
extracardiac anastomoses as well as the different therapeutic approaches, especially that of stimulating
the extracardiac collateral circulation via permanent occlusion of the internal mammary arteries.
Keywords: human coronary collateral circulation; extracardiac anastomoses; collateral flow index;
collateral artery growth in man; permanent internal mammary artery occlusion
1. Introduction
According to the American Heart Association, “cardiovascular disease is the leading global cause
of death”, accounting for more than 17.6 million deaths in 2016, a number that is expected to grow to
more than 23.6 million by 2030 [1] In the event of acute coronary syndrome, percutaneous coronary
intervention (PCI) has been shown to be beneficial on outcome [2]. The beneficial effect of PCI on the
course of chronic stable coronary artery disease (CAD) has, so far, not been proven yet [3]. A recently
published randomized controlled trial among patients with stable, single-vessel CAD, the so called
ORBITA trial (e.g., Objective Randomised Blinded Investigation With Optimal Medical Therapy of
Angioplasty in Stable Angina) [4], found that PCI of the stenotic lesion did not prolong exercise time
by more than the effect of a sham procedure during the short observation period of six weeks. The new
aspect of the ORBITA trial was a methodological one, that is, the use of a sham control group of
patients undergoing the invasive coronary procedure, but not the actual PCI. The importance of a sham
control group in interventional procedures is pivotal, especially in a population with a high level of
suffering [5,6]. After all, it is known that the placebo effect can cause significant clinical improvements
(e.g., an increased exercise duration of >90 s [7]). Coronary artery bypass grafting (CABG), on the other
hand, has been found superior to PCI with respect to all-cause or cardiovascular mortality [8].
The number of patients with incomplete revascularization as well as so-called “no-option”-patients
(i.e., patients without options for PCI or CABG still suffering from symptoms of CAD despite optimal
medical therapy) is on the rise. It is estimated, that 30,000–50,000 new patients are affected in continental
Europe per year [9] and Williams et al. reported a prevalence of 25.8% of incomplete revascularization
in patients with CAD [10]. Apart from the limited quality of life, these patients also have a higher
mortality at three years than patients with complete revascularization [10].
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Accordingly, new therapeutic approaches are required. Because of the known survival benefit
of patients with a well-developed coronary collateral circulation [11,12], interventions aiming at
the promotion of coronary collaterals are a promising strategy. Coronary collaterals represent
pre-existing inter-arterial anastomoses and as such are the natural counterpart of surgically created
bypasses. To this end, biochemical (e.g., intracoronary vascular-endothelial growth factor or
intravenous granulocyte-macrophage colony-stimulating factor) as well as biophysical (e.g., external
counterpulsation) approaches have been evaluated for the promotion of those collaterals.
The aim of this review is to describe basic principles of the coronary collateral circulation, its
extracardiac anastomoses as well as different therapeutic approaches, especially that of stimulating
extracardiac coronary supply via permanent occlusion of the internal mammary arteries.
2. Basic Principles of the Human Coronary Collateral Circulation
2.1. Coronary Collateral Circulation
The development of the cardiovascular system during embryogenesis occurs by vasculogenesis,
a process defined as “the de novo formation of blood vessels from endothelial precursor cells” [13].
Directed by the concentration of local messenger substance, endothelial precursor cells sprout out
and start forming a dense vascular network with multiple anastomoses. The density of this network
is at its peak in neonates and declines subsequently by physiological regression, a process called
pruning [14–16].
Nevertheless, it has been hypothesized early on and tested that the coronary anastomoses of the
neonate do not vanish completely but some collaterals rather recede in calibre. This concept has been
decisively advanced by the findings of the Scottish pathologist W.F. Fulton, who found “numerous
anastomoses in all normal hearts” by using a vascular overlay detecting technique with radiographic
contrast medium containing uniform particles sized 0.5–2.0 μm to visualize even small arteries [17].
Interestingly, with changing vascular pressure- and resistance conditions, it is possible to recruit
these receded arterial anastomoses. This process is often seen during the course of CAD with
development of a pressure gradient across a stenotic lesion, which itself induces augmented flow
in preformed arterial anastomoses and finally, structural augmentation of these collateral arteries
(arteriogenesis). Accordingly, the prevalence of functional coronary anastomoses depends on the
presence of CAD and is highest in chronic total coronary occlusions [16].
Coronary collaterals in patients without coronary atherosclerosis range in calibre between 10–200
μm; collateral arteries of patients with CAD are approximately four times bigger (100–800 μm) [17].
This observation is in accordance with an experimental rabbit model, where occlusion of the femoral
artery increased the lumen diameter of pre-existent arterioles four- to fivefold [18]. “At the same time,
the growth in structural size goes along with a decreasing number of collateral arteries, a process
called pruning. Pathophysiologically and in the sense of the Hagen Poiseuille law, pruning may be
interpreted as a way of effectively reducing vascular resistance to collateral flow” [13].
2.2. Extracardiac Coronary Supply
Apart from inter-coronary arterial anastomoses, the human coronary arterial circulation is
supplied by several extracardiac anastomoses, also called the non-coronary collateral myocardial blood
flow (NCCMBF) [19]. Hence, the heart receives additional blood from the arteries of surrounding
structures [20–24]. Most of the extracardiac anastomoses originate from arteries, which supply the
pericardium [21] and these arteries are typically located at the sites of pericardial reflections (e.g.,
the entry of the caval veins or the exit of the great arteries) [22]. Thus, a well-known extracardiac
anastomosis connects the right internal mammary artery (IMA, also called internal thoracic artery) to
the right coronary artery via the pericardiacophrenic branch and the sinus node artery [25] (Figure 1).
This extracardiac coronary supply can also develop after coronary bypass surgery as shown exemplary
in Figure 2 [22].
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Figure 1. Angiographic demonstration of extracardiac coronary supply. (A) Posterior-anterior projection
of the right internal mammary artery (IMA, marked by *) and its connection to the right coronary
artery via the pericardiacophrenic branch (marked by +). (B) Lateral projection using the same markers.
Noteworthy, additional branches of the IMA (marked by #) heading towards the heart.
Figure 2. Angiographic demonstration of extracardiac coronary supply after coronary artery bypass
surgery. (A) Posterior-anterior projection of the left internal mammary artery bypass (marked by a
*) on the left anterior descending coronary artery (LAD, marked by a #). Upstream of the bypass
anastomosis, retrograde filling of the LAD is incomplete revealing coronary occlusion, which triggered
the arteriogenesis of the pericardiacophrenic branch (marked by a +) (B) Lateral projection using the
same markers revealing the connection of the pericardiacophrenic branch with the third diagonal
branch (marked by III).
Most commonly, NCCMBF originates from the bronchial or the internal mammary arteries [22].
Bjork et al. showed a prevalence for bronchial-coronary-anastomoses of more than 20% by reviewing
200 coronary angiographies [26]. According to this observation, most of the anastomoses connect to
the left circumflex artery (LCX) and demonstrate poor blood flow. However, blood flow within an
anastomosis between two arterial beds depends on the respective vascular resistances. Thus, a constant
decrease of vascular resistance in one arterial bed causes an increased blood flow to it with associated
arteriogenesis. Consequently and depending on the underlying pathology, bronchial-to-coronary (e.g.,
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in the case of a chronic occluded coronary artery [27]) as well as coronary-to-bronchial anastomoses
(e.g., during chronic pulmonary diseases [28]) have been described.
Additional evidence for extracardiac anastomoses comes from the work of Hudson et al., who, by
injecting ink into the coronary arteries, demonstrated anastomoses with anterior mediastinal, phrenic
and intercostal arteries as well as with esophageal arterial branches of the aorta [21].
NCCMBF has also been increasingly recognized by cardiac surgeons as they discovered that
anastomotic blood flow can dilute, and thus, be a potential hazard to cardioplegia [23]. To quantify
this phenomenon, several studies have been conducted with reported values of anastomotic perfusion
ranging between 3.4 to 14 mL/100 g/min [29,30] during cardiopulmonary bypass with cross-clamping
of the aorta.
2.3. Quantitative Evaluation of the Coronary Collateral Circulation
The first in vivo functional coronary collateral measurements were conducted in the 1970s,
showing a direct relation between “angiographic appearance and functional performance of coronary
collaterals during bypass surgery” [31]. Rentrop et al. proposed a transluminal coronary angioplasty
approach, which divided the appearance of coronary collaterals in four groups (0 = no collateral filling
from the contralateral vessel to 3 = “complete filling of the epicardial segment of the artery”) [32].
Unfortunately, the method is only qualitative and evaluation of extracardiac collaterals is not feasible.
Thereafter a method for quantitative coronary collateral function assessment based on coronary
occlusive pressure measurements was introduced. The so called collateral flow index (CFI) [33,34]
“is the ratio between mean coronary occlusive and aortic pressure both subtracted by central venous
pressure as obtained during a 1-min proximal coronary balloon occlusion” [33] (Figure 3). The method
is accepted as the reference method for functional collateral assessment in patients with chronic stable
CAD [35,36]. In terms of sufficient collateral blood supply, it has been demonstrated that a CFI of
>0.20–0.25 is related to absent signs of ischemia on the intracoronary electrocardiogram (i.c.ECG)
during this 1-min coronary artery balloon occlusion [37,38].
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CFI has also been determined in patients with angiographically normal coronary arteries, revealing
functional collateral arteries “to the extent, that one fifth to one quarter of them (i.e., the patients without
coronary stenoses) do not show signs of myocardial ischemia during the brief vascular occlusions” [39].
Those findings of functional sufficient collaterals even in the absence of CAD support the above
mentioned pathoanatomic observations [17], that coronary anastomoses calibre remain functional to a
considerable degree.
3. Angiogenesis and Arteriogenesis
To understand the different therapeutic approaches for promoting the coronary collateral
circulation, it is crucial to differentiate between two basic physiologic principles, that is, angiogenesis
and arteriogenesis.
3.1. Angiogenesis
The formation of capillaries from pre-existing vessels to expand the microvascular system
by increasing the capillary density is called angiogenesis. Driven by several growth factors such
as hypoxia-inducible factor 1α, vascular endothelial growth factor (VEGF) [40] and inflammatory
mediators as well as inflammatory cells (mainly monocytes [41]), a local milieu is formed [42] which
promotes the proliferation and migration of endothelial cells, pericytes and smooth muscle cells.
Thereby, “the amplification of the vascular network occurs within a short time due to either abluminal
outgrowth (sprouting) or intraluminal division (intussusceptive growth) of capillaries” [43]. In contrast
to arteriogenesis, angiogenesis is mostly driven by metabolic demands (i.e., hypoxemia) [44]
3.2. Arteriogenesis
“Although capillary sprouting may deliver some relief to the underperfused territory, only true
collateral arteries are principally capable of providing large enough amounts of blood flow to the
ischemic area at risk for necrosis or loss of function.” [41] Hence, arteriogenesis is the process of outward
remodelling [44] (i.e., growth in diameter and length) of pre-existing anastomoses [45], resulting in an
increased flow capacity of the artery.
Fluid shear stress, “the product of spatial flow velocity changes during the cardiac cycle and
blood viscosity” [46] “is the primary and strongest arteriogenic stimulus” [47]. It leads to the
expression of nitric oxide (NO), VEGF and monocyte chemoattractant protein-1 (MCP-1), resulting in
the attraction and activation of monocytes [41,44,48–51]. Those inflammatory cells conduct the process
of arteriogenesis with induction of cell proliferation as well as preparation of the extracellular matrix
to enable cell migration [48].
Arteriogenesis is a common phenomenon that interventional cardiologists encounter on a daily
basis as it appears (e.g., in the course of hypertensive heart disease with concentric left ventricular
hypertrophy and augmented myocardial mass). Due to the direct and curvilinear relationship
between myocardial mass and coronary arterial cross-sectional area [52], structural remodelling (i.e.,
arteriogenesis of the epicardial coronary arteries) occurs, resulting in large vascular calibres and,
because of undirected growth, also affecting vascular length. Thus, this leads to the typical corkscrew
pattern that is seen in this condition (Figure 4A).
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Figure 4. Angiographic presentation of two different pathophysiological etiologies of arteriogenesis. (A)
Arteriogenesis in the course of hypertensive heart disease with concentric left ventricular hypertrophy.
Enlarged myocardial mass is the driving force behind this arterial growth. (B) Arteriogenesis solely
initiated by constant elevation of fluid shear stress. Iatrogenic drainage of the left anterior descending
artery (LAD) into the right ventricular cavity after myocardial biopsy significantly increased coronary
blood flow and consequently vascular size.
Importantly and in contrast to the previously outlined process of angiogenesis, myocardial ischemia
is unrelated to this process [53,54]. Arteriogenesis depends solely on physical pressure gradients
across pre-formed anastomoses between different arterial territories with consequent augmentation of
endothelial fluid shear stress [47,53,55]. Figure 4B illustrates this concept: After myocardial biopsy
with perforation of the LAD and consecutive drainage into the (low resistance) right ventricular cavity,
blood flow in the LAD increased due to the abrupt decrease in “vascular” resistance. As a consequence,
abundant growth of the LAD, both in cross-sectional area and length, could be observed [56].
4. Therapeutic Promotion of the Coronary Collateral Circulation
The following chapter summarizes the most promising therapeutic approaches of coronary
collateral promotion divided according to the basic concept of biochemical or biophysical methods.
4.1. Biochemical Concepts
In general, biochemical concepts are “prone to potentially harmful effects, since arteriogenesis
shares many common mechanisms with inflammatory diseases, such as atherosclerosis” [44].
Accordingly, Epstein et al. coined (biochemical) collateral promotion a “Janus Phenomenon”, that is,
“whatever intervention enhances collaterals increases atherogenesis and vice versa” [57].
With the rapid development of angiogenic growth factors and the growing understanding of
their mechanisms of action, multiple trials testing collateral growth promotion have been initiated.
Because of the known pivotal role of monocytes in orchestrating the different processes of angio- and
arteriogenesis [50], most of the projects focused on the activation or the recruitment of this cell line.
Growth factors most extensively studied have been granulocyte-macrophage colony-stimulating factor
(GM-CSF) [58–62], granulocyte colony-stimulating factor (G-CSF) [63–66] or monocyte chemoattractant
protein-1 (MCP-1) [41]. Besides, also different fibroblast growth factors (FGF) [67–69] and VEGF [70]
have been clinically tested. Altogether, this study showed that angiogenesis is less efficient than
arteriogenesis [71] for promoting bulk collateral blood flow, since it only promotes microvascular
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density. Consequently, clinical trials evaluating the effect of angiogenetic factors such as FGF or VEGF
have failed to demonstrate a therapeutic effect that exceeds the effect of placebo treatment [67,68,70].
Colony-stimulating factors, on the other hand, have been found to promote the formation of
large interconnecting arterioles (arteriogenesis), which are required for the salvage of myocardium
in the presence of occlusive CAD [58]. Buschmann et al. [61] found that a continuous infusion of
GM-CSF into the stump of the acutely occluded femoral artery of rabbits enhanced blood flow to
the hind limb five-fold. The mechanism of action in that study has been found to be the prolonged
survival of monocytes, “known to play a decisive role in arteriogenesis” [61]. In two small but
randomized and placebo-controlled clinical trials with 35 patients in total, GM-CSF has been shown to
be efficacious in a short-term subcutaneous administration protocol of two weeks [58,59]. Both studies
have demonstrated a significant increase in CFI (from 0.116 to 0.159; p = 0.028 respectively from 0.21 to
0.31; p < 0.05). Of note, this beneficial effect of GM-CSF in the promotion of coronary collateral growth
could not be transferred to the clinical setting of peripheral vascular disease, where it failed to improve
the walking time [60]. Further, one of the clinical trials using GM-CSF for arteriogenesis had to be
stopped prematurely for safety concerns in the context of two patients with acute coronary syndrome
in the treatment group [59].
G-CSF has been reported in meta-analyses to be safe in terms of major adverse cardiovascular
events (cardiovascular death, recurrent myocardial infarction and in-stent restenosis) and toleration of
the treatment injections [72–74]. These findings and promising animal test results [75] have led to a
randomized, placebo-controlled clinical trial in humans, in which subcutaneous G-CSF was shown to
increase CFI from 0.121 to 0.166 (p < 0.0001) when administered every other day for two weeks [63].
Despite the above meta-analyses, one study assessing the outcomes and risks of G-CSF in patients with
CAD has reported an increased frequency of adverse outcomes (i.e., acute coronary syndrome) [64].
In conclusion, despite the promising results of small clinical trials or animal models using
biochemical concepts to therapeutically promote the coronary collateral circulation, none of the
approaches evaluated so far could be successfully translated into clinical practice. Besides the above
mentioned limitations such as inefficient collateral formation (i.e., angiogenesis) or potentially harmful
propagation of atherogenesis (i.e., the “Janus Phenomenon” [57]), a number of additional unresolved
issues remains. These include questions relating to the dosage, the application route and the timing of
administration of growth factors [44]. Importantly, considering that “no-option” patients with extensive
CAD are the most likely candidates for coronary arteriogenesis, safety of any collateral-promoting
substance is crucial [59].
4.2. Biophysical Concepts
The biophysical concept of arteriogenesis is to increase tangential vascular shear stress in
preformed coronary anastomoses. One of the natural ways of increasing vascular shear stress is
physical exercise [76]. However, because of different comorbidities it is often not feasible for patients
with CAD to perform physical exercise training sufficiently. Thus, several other biophysical approaches
have been introduced and will be described subsequently.
4.2.1. Physical Exercise
The positive effects of physical exercise on the cardiovascular system have been known for a long
time [77]. For instance, it was concluded in 1958 by Morris and Crawford that physically active people
are less prone to develop stable CAD in comparison with sedentary people [78]. Physical exercise
has a positive effect on several cardiovascular aspects such as vascular remodelling, increase of the
maximal coronary blood flow (i.e., coronary flow reserve; CFR) as well as a decrease of coronary
artherogenesis [79,80].
Concerning the effect of training on coronary collateral function, Scheel et al. observed an
arteriogenetic effect of physical exercise in dogs with a constricted coronary artery whereas this effect
was not observed in dogs without coronary stenosis [81]. In the groups with artificial coronary occlusion,
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exercise stress doubled the collateral growth and hence, the coronary flow reserve when compared to
none exercised dogs. In humans, Zbinden et al. documented an increase of the quantitative parameter
CFI in a proof-of-concept study [82]. They evaluated CFI, CFR and other cardiac parameters before
and immediately after exercise training of a healthy marathon runner and demonstrated an increase of
CFI from 0.23 to 0.37. Two small, non-randomized clinical trials have supported the positive effect
of physical exercise on coronary collateral function, the increase in coronary cross-sectional area [83]
as well as dose-dependent relation between training and increase in CFI [84]. Those results are in
agreement with several other studies [80,85–89], which showed augmented perfusion by collateral
vessels in response to exercise training. Besides, there have been other clinical trials failing to show
a beneficial effect on the collateral circulation by exercise as assessed by angiographic imaging, but
not by functional measurements [90]. However, the authors mention the limited validity of the
angiographic approach and despite the negative outcome on coronary collateral formation, the exercise
group had a significant better clinical outcome concerning the frequency of cardiac symptoms and the
physical performance.
Recently, the first randomized clinical trial on the effect of physical exercise on coronary collateral
function has been published [91]. Möbius-Winkler et al. randomly assigned 60 patients to two training
groups (moderate- and high-intensity exercise with 10 h of training per week in each group) and one
control group (usual care with encouragement to perform regular physical activity according to current
recommendations). After four weeks, both exercise groups showed a significant increase in CFI (from
0.142 to 0.198, p = 0.005 respectively from 0.143 to 0.202, p = 0.004) without a statistically relevant
difference between the training modalities whereas CFI in the control group remained unchanged
(from 0.149 to 0.150, p = n.s.).
In conclusion, the positive effect of physical exercise on the human coronary collateral circulation
has been repeatedly demonstrated. However, there remain important questions concerning the type
and extent of physical exercise for optimal promotion as well as the implementation for patients with
limited physical possibilities.
4.2.2. External Counterpulsation (ECP)
“External counterpulsation therapy was first developed as a resuscitative tool to support the
failing heart and was based on the hemodynamic principles of the intra-aortic balloon pump”, which
is the augmentation of diastolic blood flow with consecutive improvement of coronary perfusion as
well as ventricular afterload reduction [92]. ECP uses three pairs of pneumatic cuffs wrapped around
each of the lower extremities. Those cuffs are sequentially inflated from distal to proximal triggered by
the ECG. Besides augmenting diastolic blood flow and reducing ventricular afterload, ECP increases
tangential endothelial shear stress triggering arteriogenesis. Used as a safe, effective and low-cost
second line treatment in refractory angina pectoris, ECP has been shown to be efficacious in reducing
CAD symptoms as well as improving exercise time [92–96]. Of note, the positive effect appears to
outlast the actual, conventional seven week period of treatment [97].
The effects of ECP on the coronary collateral circulation have been evaluated in two invasive
clinical trials. Buschmann et al. demonstrated in a non-randomized study a significant increase in
CFI. Other invasive parameters obtained in that study as the index of microvascular resistance (IMR)
or quantitative coronary angiography (QCA) remained unchanged and hence, the increase of CFI
reflected a “true” improvement of the myocardial blood flow [98]. These results have been confirmed in
a randomized, sham-controlled clinical trial with an increase in CFI from 0.125 to 0.174 at a four-week
follow-up exam (p = 0.006) in the experimental, but not in the placebo group (CFI changed from 0.129
to 0.111, p = 0.14) [46].
Recently, the principle of external counterpulsation has been individualized in order to alleviate
the side effects of ECP (i.e., the cumbersome procedure with high pressure levels), thus increasing its
acceptance. The so called individual shear rate therapy (ISRT) adjusts the used treatment pressures of
the pneumatic cuffs according to individually adapted intra-arterial shear rates to achieve the same
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effect with reduced pressure values [99]. The calculation is based on Doppler-flow parameters in the
common carotid artery at different treatment pressure values. Due to this procedure, the individually
calculated treatment pressure ranged between 160 to 220 mmHg instead of the regular treatment
pressure of 250 to 300 mmHg.
4.2.3. Coronary Sinus Reducer
The biophysical concept of the coronary sinus reducer is based on a perioperative approach
during heart surgery with artificially narrowed coronary sinus for augmented retro-perfusion [100].
The exact pathophysiologic principle for a beneficial effect remains unclear [101]. One proposed
mechanism assumes that the venous back pressure as applied in the coronary sinus is regionally
balanced in the venous, but not in the vascular bed upstream of the microcirculation [102]. Based on
the two regionally counteracting responses of the microcirculation during myocardial ischemia, that
is maximal vasodilatation and increased myocardial compressive forces (i.e., augmented ventricular
wall stress due to diminished myocardial thickness), regional imbalance in microvascular resistance
with higher resistance in the ischemic area arises. Thus, augmented venous back pressure is able to
reach the non-ischaemic microcirculation more easily than the ischaemic one, thereby increasing the
microcirculatory resistance in the non-ischaemic zone. This leads to a flow diversion of arterialised
blood to the ischaemic area at risk under the necessary condition of functional collateral connections
originating from the non-ischaemic area [102].
Due to advances in percutaneous coronary intervention, and at the same time, increasing number
of patients with refractory angina pectoris, several investigators have picked up this approach by using
balloon-expandable, hourglass-shaped devices to physically narrow the coronary sinus [103–105]. In a
first-in-man study, this device has demonstrated relief of angina pectoris in 12 out of 14 patients without
options for coronary revascularization [103]. Subsequently, Verheye et al. performed a randomized,
sham-controlled clinical trial in 104 patients, which confirmed the results of the first study [101].
They showed an improvement in Canadian Cardiovascular Society (CCS) score as well as quality of
life. Nevertheless, exercise time and mean change in the wall motion index as assessed by means of
dobutamine stress echocardiography remained unchanged [101]. Subsequently and to evaluate the role
of this device in future clinical practice, a post marketing study is currently enrolling selected patients
without revascularization options (called Reducer-I-study; NCT02710435). They plan to recruit over
400 patients and assess the clinical efficacy as well as the long-term outcome with follow-ups up to five
years after implantation [104].
4.2.4. Pharmacologic Biophysical Arteriogenesis
Ivabradine, a specific inhibitor of the If-channel mainly expressed in sinoatrial nodal cells [106],
specifically decreases the heart rate without affecting cardiac contractility, afterload or vasomotion as it
occurs with beta-blockers [107,108]. Based on the biophysical rationale of diastolic prolongation by
ivabradine with extension of diastolic vascular shear stress, a small randomized placebo-controlled trial
has demonstrated a significant increase in CFI by ivabradine (from 0.107 to 0.152, p = 0.0461) [109]. This
result is in accordance with several other trials, which have shown an arteriogenic effect on coronary
arteries by initiating bradycardia [110–112]). However, despite the promotion of coronary collateral
supply, ivabradine has not been shown to be efficacious with respect to cardiovascular outcomes
(composite of death from cardiovascular causes or nonfatal myocardial infarction) in patients with
stable CAD [106] in bigger randomized trials such as the BEAUTIFUL [113] and SIGNIFY trials [114].
5. Therapeutic Promotion of Extracardiac Coronary Supply
The anatomical connection between the IMAs and the coronary arteries via their most proximal
branch (i.e., the pericardiacophrenic artery departing at the first or second intercostal space) is well
documented [21,22,25] (Figures 1 and 2). Additionally, due to the connection of the IMAs with the iliac
external arteries via the superior and inferior epigastric arteries, collateral supply from the caudal side
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amounts to approximately two thirds of the flow during IMA patency [102]. This dual blood supply
along with the direct anatomical connection to the coronary circulation provided the rationale for the
IMA ligation method as a surgical treatment for angina pectoris. Using a small incision between the
second and third rib under local anesthesia, transthoracic surgical access and ligation of the IMAs
was first performed by D. Fieschi in 1939 (i.e., before the advent of modern cardiac surgery with
cardioplegia and heart-lung-bypass) [115]. Later on, the approach was tested by a series of trials carried
out in the late 1950s [116–122]. The primary end point of those clinical trials was angina pectoris
and, inconsistently, ECG signs of myocardial ischemia. Battezzati et al. [116], after identifying anew a
connection between both IMAs and the myocardium, reported consistent improvement in terms of
cardiac symptoms in a uncontrolled trial among 304 CAD patients in 1959. Notable, this improvement
was sustained during a follow-up of up to four years after the surgical intervention. In a further
uncontrolled trial among 50 CAD patients, Kitchell et al. [123] reported similarly favorable results with
symptomatic relief in 68% of the patients undergoing bilateral IMA ligation.
The following sham-controlled trials of bilateral IMA ligation in 35 CAD patients coined the phrase
“surgery as placebo” in the context of their negative results [124–126]. Although the introduction
of a sham-control study design in the context of surgical trials was seminal [127], the conclusion
drawn from the negative results of the IMA ligation trials at hand is questionable. In the trial by
Cobb et al. [125], angina pectoris relief was found in five of eight patients (63%) after IMA ligation
and in five of seven patients (71%) after IMA sham ligation. Dimond et al. [126] reported nine of 13
patients in the verum and five of five patients in the sham-operation group, respectively. Thus, the
abrupt stop of bilateral transthoracic IMA ligation was mainly caused by the advent of modern cardiac
surgery with bypass grafting rather than by the slim evidence against IMA ligation claimed by the
controlled trials. Especially because the soft study end point of angina pectoris would have required
patient numbers at one order of magnitude higher than those recruited for the sham-controlled IMA
ligation trials [125,126].
Because of the slim evidence against IMA ligation and the promising surgical results in terms
of symptomatic relief, this therapeutic concept was revived 75 years after the first attempt using
percutaneous interventional techniques. In the context of soft study endpoints, the first observational
interventional study on the function of coronary supply by the IMAs has predefined intracoronary ECG
(i.c.ECG) ST-segment elevation during coronary occlusion, not angina pectoris, as the first end point for
ischemia [128]. In this trial, myocardial ischemia has been induced twice with and without simultaneous
IMA occlusion by proximal coronary balloon occlusion in the process of CFI measurement. Further, to
eliminate the effect of coronary collateral recruitment or ischemic preconditioning occurring during the
second (but not the first) occlusion on the collateral circulation, CFI measurement with simultaneous
IMA occlusion was performed before the control measurement without IMA occlusion. Despite
this conservative study design, the approach showed a consistently reduced i.c.ECG ST-segment
elevation during ipsilateral IMA with RCA or LAD occlusion as an expression of reduced ischemia.
Further, CFI has been found higher in the presence versus the absence of IMA occlusion in 68% of the
measurements, and overall, this difference amounted to +0.025 compared with the absence of IMA
occlusion (p < 0.0001) [128]. However, contralateral IMA occlusion did not cause an effect indicating
the necessity of anatomic vicinity. In this trial, functional connection between the coronary arteries and
the IMAs was slightly less frequent in case of LAD with left IMA occlusion (25 of 30 measurements)
than in the case of RCA with right IMA occlusion (28 of 30 measurements).
Based on those functional findings, an anti-ischemic therapeutic approach consisting in distal
IMA occlusion by interventional techniques could be a promising therapeutic alternative to IMA
bypass grafting. In an open-label proof-of-concept study, Stoller et al. investigated a catheter-based
permanent IMA occlusion in the setting of the less frequently grafted right IMA among patients with
ischemia in the RCA territory [129]. In this study, 50 patients with chronic stable CAD underwent
permanent device occlusion of the distal right IMA. CFI of the RCA measured immediately before
and six weeks after the IMA-occlusion showed a consistent increase from 0.071 at baseline to 0.132
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(p < 0.0001). Further, this augmented coronary blood supply was reflected by the i.c.ECG as a direct
measure of myocardial physiology revealing a decreased ischemia during RCA occlusion from baseline
to follow-up examination (p = 0.0015). Figure 5 illustrates this increased collateral function along with
decreased myocardial ischemia during coronary occlusion as outlined by an absent ST-deprivation in
the ECG of the follow-up intervention.
(A)                                (B) 
Figure 5. Collateral flow index (CFI) measurements of the right coronary artery (RCA) with
corresponding electrocardiograms (ECG) after a one-minute proximal coronary balloon occlusion. (A)
CFI measured immediately before permanent right internal mammary artery occlusion showing a
collateral blood supply of 0.100 and marked ST-deprivations in the ECG as a sign of ischemia (marked
with an arrow). (B) Six weeks after the permanent occlusion, CFI increased to 0.250 (+0.150). This
augmented coronary blood supply is reflected by the ECG revealing a decreased ischemia without
ST-deprivations (marked with an arrow).
To conclude, augmentation of extracardiac coronary supply by permanent right IMA device
occlusion is effective and feasible. However, if and how this increased collateral blood flow
improves clinical outcome parameters is subject of current research. For this reason, a randomized,
sham-controlled and double-blind clinical trial is currently enrolling patients (NCT03710070). It aims
to include 250 patients in order to assess the clinical efficacy (measured as treadmill exercise time
increment) in the next few years.
6. Conclusions
Based on the growing problem of patients with coronary artery disease and incomplete
revascularization, several promising therapeutic alternatives for myocardial revascularization have
been examined. Because of the known survival benefit of patients with a functional coronary collateral
circulation, its promotion is a promising concept. However, until now, none of the evaluated concept
could be implemented in daily clinical practice despite appealing results in clinical trials.
Biochemical concepts of angio- or arteriogenesis by growth factors seem to be prone to potentially
harmful effects, since arteriogenesis shares many common mechanisms with inflammatory diseases,
such as atherosclerosis. Thus, the risk benefit ratio is inappropriate and further research using growth
factors was discontinued.
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Biophysical concepts are based on increasing arteriogenesis via elevated tangential vascular
fluid shear stress. Physical exercise training or external counterpulsation have been documented to
positively affect clinical symptoms as well as coronary blood flow. The effect of both physical arteriogenic
procedures is, however, transient (i.e., vanishes after its termination) and the time-consuming procedure
of several hours per week limits the use to selected, highly motivated patients.
Alternative techniques such as coronary sinus reduction or promotion of extracardiac coronary
supply by permanent occlusion of the distal internal mammary artery are promising approaches, since
they have a permanent effect and ought to be efficacious in reducing myocardial ischemia to the effect
that it is clinically relevant. Both approaches are being currently studied in ongoing clinical trials
(NCT0271043 respectively NCT03710070) and the results of these investigations will clarify the clinical
potential of those new therapeutic methods.
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CABG Coronary Artery Bypass Grafting
CAD Coronary Artery Disease
CCS Canadian Cardiovascular Society-Score
CFI Collateral Flow Index




G-CSF Granulocyte Colony-Stimulating Factor
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor
IMA Internal Mammary Artery
IMR Index of Microvascular Resistance
ISRT Individual Shear Rate Therapy
LAD Left Anterior Descending (Artery)
LCX Left Circumflex Artery
MCP-1 Monocyte Chemoattractant Protein-1
NCCMBF Noncoronary Collateral Myocardial Blood Flow
NO Nitric oxide
PCI Percutaneous Coronary Intervention
QCA Quantitative Coronary Angiography
RCA Right Coronary Artery
VEGF Vascular Endothelial Growth-Factor
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